TITLE	O
:	O
Infectious	O
bronchitis	O
virus	O
E	O
protein	O
is	O
targeted	O
to	O
the	O
Golgi	O
complex	O
and	O
directs	O
release	B-PATH
of	O
virus	O
-	O
like	O
particles	O
.	O

Vascular	O
studies	O
showed	O
the	O
presence	O
of	O
IgG	O
-	O
IgM	O
polyclonal	O
positive	O
cryoglobulins	O
and	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
showed	O
hepatitis	B-PATH
C	I-PATH
virus	O
to	O
be	O
present	O
.	O

ABSTRACT	O
:	O
Mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
is	O
a	O
31	O
-	O
kb	O
positive	O
-	O
strand	O
RNA	O
virus	O
that	O
is	O
replicated	O
in	O
the	O
cytoplasm	O
of	O
infected	O
cells	O
by	O
a	O
viral	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
,	O
termed	O
the	O
replicase	O
.	O

The	O
persistent	O
presence	O
of	O
viruses	O
in	O
the	O
upper	O
respiratory	O
tract	O
of	O
asthmatic	O
children	O
shows	O
a	O
possible	O
connection	O
between	O
viral	O
infections	O
and	O
asthma	B-PATH
.	O

CONCLUSIONS	O
:	O
Tuberculosis	B-PATH
can	O
be	O
a	O
life	O
-	O
threatening	O
infection	O
.	O

Oral	O
contraceptives	O
may	O
produce	O
asthma	B-PATH
exacerbation	O
,	O
while	O
long	O
term	O
use	O
and	O
/	O
or	O
high	O
doses	O
of	O
postmenopausal	O
hormone	O
replacement	O
therapy	O
increase	O
the	O
risk	O
of	O
asthma	B-PATH
.	O

Onset	O
of	O
melon	O
-	O
induced	O
allergic	O
symptoms	O
occurred	O
from	O
6	O
to	O
45	O
years	O
(	O
median	O
,	O
20	O
years	O
),	O
preceded	O
by	O
seasonal	O
rhinitis	O
,	O
asthma	B-PATH
,	O
or	O
both	O
in	O
88	O
%	O
(	O
15	O
/	O
17	O
).	O

TITLE	O
:	O
[	O
A	O
case	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
induced	O
by	O
fulminant	O
influenza	B-PATH
A	I-PATH
(	O
H3	O
N2	O
)	O
pneumonia	O
].	O

TITLE	O
:	O
Inhibition	O
of	O
hepatitis	B-PATH
C	I-PATH
virus	O
NS3	O
protease	O
activity	O
by	O
product	O
-	O
based	O
peptides	O
is	O
dependent	O
on	O
helicase	O
domain	O
.	O

Heroin	O
inhalation	O
can	O
induce	O
severe	O
and	O
even	O
fatal	O
exacerbations	O
of	O
asthma	B-PATH
.	O

In	O
developing	O
countries	O
,	O
early	O
and	O
adequate	O
treatment	O
of	O
uncomplicated	O
disease	O
using	O
cheap	O
alternatives	O
to	O
classical	O
compounds	O
should	O
contribute	O
to	O
""""	O
roll	O
back	O
""""	O
malaria	B-PATH
,	O
particularly	O
in	O
sub	O
-	O
Saharan	O
Africa	O
.	O

Addition	O
of	O
the	O
general	O
caspase	O
inhibitor	O
z	O
-	O
VAD	O
-	O
FMK	O
to	O
the	O
culture	O
media	O
showed	O
inhibition	O
of	O
the	O
hallmarks	O
of	O
apoptosis	B-PATH
and	O
increase	O
of	O
the	O
release	B-PATH
of	O
virus	O
to	O
the	O
culture	O
media	O
at	O
16	O
h	O
postinfection	O
.	O

This	O
study	O
adds	O
one	O
more	O
example	O
to	O
the	O
growing	O
list	O
of	O
animal	O
viruses	O
that	O
induce	O
apoptosis	B-PATH
during	O
their	O
replication	O
cycles	O
.	O

The	O
intergenic	O
sequence	O
is	O
the	O
presumed	O
crossover	O
region	O
(	O
fusion	O
site	O
)	O
for	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
during	O
discontinuous	O
transcription	O
,	O
a	O
process	O
leading	O
to	O
sgmRNAs	O
that	O
are	O
both	O
5	O
'	O
and	O
3	O
'	O
coterminal	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
is	O
to	O
determine	O
whether	O
airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
APRV	O
)	O
can	O
safely	O
enhance	O
hemodynamics	O
in	O
patients	O
with	O
acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
/	O
or	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
relative	O
to	O
pressure	O
control	O
ventilation	O
(	O
PCV	O
).	O

ABSTRACT	O
:	O
Toxic	O
epidermal	O
necrolysis	O
(	O
TEN	O
)	O
is	O
a	O
rare	O
severe	O
acute	O
exfoliative	O
drug	O
-	O
induced	O
skin	O
disorder	O
which	O
has	O
recently	O
been	O
ascribed	O
to	O
alterations	O
in	O
the	O
control	O
of	O
keratinocyte	O
apoptosis	B-PATH
,	O
mediated	O
by	O
an	O
interaction	O
between	O
the	O
cell	O
surface	O
death	O
receptor	O
Fas	O
and	O
its	O
respective	O
ligand	O
.	O

Four	O
rhinovirus	O
,	O
four	O
coronavirus	O
,	O
three	O
RSV	O
,	O
one	O
Mycoplasma	O
pneumoniae	O
,	O
and	O
one	O
influenza	B-PATH
A	I-PATH
/	O
enterovirus	O
double	O
infection	O
were	O
confirmed	O
.	O

Besides	O
these	O
specific	O
conditions	O
,	O
infection	O
is	O
a	O
major	O
problem	O
in	O
drug	O
abusers	O
,	O
irrespective	O
of	O
the	O
drug	O
:	O
bacterial	O
pneumonia	O
,	O
tuberculosis	B-PATH
,	O
HIV	B-PATH
infection	I-PATH
are	O
much	O
more	O
frequent	O
in	O
this	O
high	O
-	O
risk	O
group	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
between	O
these	O
viruses	O
in	O
the	O
potential	O
to	O
induce	O
apoptosis	B-PATH
in	O
cultured	O
cells	O
.	O

Concomitant	O
release	B-PATH
of	O
reactive	O
oxygen	O
and	O
nitrogen	O
species	O
subsequently	O
modulates	O
endothelial	O
function	O
.	O

ABSTRACT	O
:	O
The	O
pulmonary	O
endothelium	O
synthesizes	O
many	O
bioactive	O
compounds	O
and	O
their	O
activation	O
or	O
injury	O
may	O
cause	O
release	B-PATH
these	O
substances	O
into	O
the	O
blood	O
.	O

Seven	O
hundred	O
and	O
twenty	O
patients	O
were	O
selected	O
on	O
the	O
basis	O
of	O
seasonal	O
or	O
perennial	O
rhinitis	O
,	O
or	O
asthma	B-PATH
,	O
or	O
both	O
.	O

Nasopharyngeal	O
secretion	O
obtained	O
at	O
onset	O
of	O
illness	O
was	O
cultured	O
for	O
bacterial	O
pathogens	O
of	O
otitis	O
media	O
using	O
selective	O
agars	O
and	O
tested	O
for	O
rhinovirus	O
,	O
coronavirus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
and	O
parainfluenza	O
1	O
-	O
3	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
technology	O
.	O

ABSTRACT	O
:	O
fgl2	O
prothrombinase	O
,	O
by	O
its	O
ability	O
to	O
generate	O
thrombin	O
,	O
has	O
been	O
shown	O
to	O
be	O
pivotal	O
to	O
the	O
pathogenesis	O
of	O
viral	O
-	O
induced	O
hepatitis	O
,	O
cytokine	O
-	O
induced	O
fetal	O
loss	O
syndrome	O
,	O
and	O
xeno	O
-	O
and	O
allograft	B-PATH
rejection	I-PATH
.	O

Our	O
findings	O
indicate	O
that	O
GM	O
-	O
CSF	O
plays	O
a	O
critical	O
role	O
in	O
coupling	O
pancreatitis	O
to	O
ALI	O
and	O
suggest	O
that	O
GM	O
-	O
CSF	O
may	O
act	O
indirectly	O
by	O
regulating	O
the	O
release	B-PATH
of	O
other	O
proinflammatory	O
factors	O
including	O
MIP	O
-	O
2	O
.	O

Because	O
enhanced	O
release	B-PATH
of	O
inflammatory	O
mediators	O
by	O
AMPhi	O
may	O
contribute	O
to	O
ARDS	O
after	O
severe	O
trauma	O
,	O
inhibition	O
of	O
intracellular	O
signaling	O
pathways	O
represents	O
a	O
target	O
to	O
attenuate	O
organ	O
injury	O
under	O
those	O
conditions	O
.	O

The	O
underlying	O
pathological	O
events	O
were	O
respectively	O
pulmonary	O
tuberculosis	B-PATH
and	O
upper	O
respiratory	O
infection	O
in	O
the	O
two	O
monophasic	O
cases	O
;	O
in	O
the	O
22	O
recurrent	O
ONM	O
patients	O
:	O
pulmonary	O
tuberculosis	B-PATH
(	O
3	O
),	O
neurocysticercosis	O
(	O
1	O
),	O
polyarteritis	O
nodosa	O
(	O
1	O
),	O
antinuclear	O
antibody	O
and	O
rheumatoid	O
factor	O
(	O
1	O
),	O
antiphospholipid	O
antibody	O
primary	O
syndrome	O
(	O
1	O
),	O
diabetes	O
mellitus	O
(	O
1	O
),	O
hypothyroidism	O
(	O
1	O
),	O
and	O
amenorrhea	O
-	O
galactorrhea	O
(	O
4	O
).	O

ABSTRACT	O
:	O
The	O
role	O
of	O
apoptosis	B-PATH
in	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
infection	O
is	O
still	O
controversial	O
.	O

To	O
better	O
assess	O
the	O
role	O
of	O
apoptosis	B-PATH
in	O
MHV	O
infection	O
,	O
we	O
used	O
three	O
different	O
biologic	O
phenotypes	O
of	O
MHV	O
to	O
examine	O
their	O
differential	O
effect	O
on	O
the	O
induction	O
of	O
apoptosis	B-PATH
.	O

We	O
detected	O
apoptosis	B-PATH
by	O
electronmicroscopy	O
in	O
olfactory	O
neurons	O
during	O
acute	O
infection	O
with	O
MHV	O
-	O
A59	O
.	O

The	O
presence	O
of	O
TUNEL	O
staining	O
in	O
oligodendrocytes	O
suggests	O
that	O
apoptosis	B-PATH
may	O
play	O
an	O
important	O
role	O
in	O
MHV	O
-	O
induced	O
demyelination	O
.	O

The	O
surfactant	O
preparation	O
used	O
reduced	O
baseline	O
TNF	O
production	O
by	O
murine	O
alveolar	O
macrophages	O
,	O
indicating	O
that	O
the	O
exaggeration	O
of	O
ventilation	O
-	O
induced	O
TNF	O
release	B-PATH
cannot	O
be	O
explained	O
by	O
a	O
direct	O
effect	O
of	O
surfactant	O
on	O
these	O
cells	O
.	O

Neurofilament	O
immunostaining	O
of	O
spinal	O
cord	O
sections	O
demonstrates	O
that	O
axonal	O
injury	O
with	O
oligodendrocyte	O
apoptosis	B-PATH
also	O
precedes	O
demyelination	O
in	O
an	O
animal	O
model	O
for	O
MS	O
,	O
Theiler	O
'	O
s	O
murine	O
encephalomyelitis	O
virus	O
infection	O
.	O

We	O
included	O
children	O
aged	O
2	O
-	O
16	O
years	O
with	O
active	O
asthma	B-PATH
,	O
defined	O
as	O
three	O
or	O
more	O
recurrent	O
episodes	O
of	O
reversible	O
wheezing	O
.	O

There	O
was	O
no	O
correlation	O
between	O
severity	O
of	O
chronic	O
asthma	B-PATH
or	O
asthmatic	O
exacerbations	O
and	O
the	O
diagnosis	O
of	O
infection	O
.	O

As	O
single	O
viral	O
findings	O
,	O
rhinoviruses	O
were	O
associated	O
with	O
the	O
development	O
of	O
asthma	B-PATH
(	O
P	O
=.	O
047	O
;	O
odds	O
ratio	O
,	O
4	O
.	O
14	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
02	O
-	O
16	O
.	O
77	O
versus	O
rhinovirus	O
-	O
negative	O
cases	O
[	O
by	O
logistic	O
regression	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
and	O
atopic	O
dermatitis	O
on	O
entry	O
)].	O

Subsequently	O
,	O
the	O
adrenal	O
glands	O
release	B-PATH
cortisol	O
,	O
a	O
hormone	O
which	O
will	O
likely	O
counteract	O
the	O
inflammatory	O
process	O
and	O
restore	O
cardiovascular	O
homeostasis	O
.	O

Airway	O
neutrophilia	O
,	O
and	O
activation	O
of	O
neutrophilis	O
with	O
release	B-PATH
of	O
their	O
granules	O
into	O
the	O
airway	O
is	O
a	O
precursor	O
of	O
progressive	O
BO	O
.	O

Mature	O
RCV	O
particles	O
were	O
distributed	O
around	O
the	O
ER	O
pools	O
,	O
cytoplasm	O
,	O
and	O
intercellular	O
space	O
,	O
and	O
the	O
RCVs	O
in	O
the	O
endosome	O
/	O
lysosome	B-PATH
were	O
devoid	O
of	O
the	O
envelop	O
and	O
nuclear	O
capsid	O
.	O

The	O
pathogenesis	O
of	O
these	O
lung	O
diseases	O
is	O
characterized	O
by	O
a	O
neutrophil	O
-	O
predominant	O
inflammation	O
associated	O
with	O
excessive	O
release	B-PATH
of	O
neutrophil	O
proteases	O
,	O
including	O
neutrophil	O
elastase	O
(	O
NE	O
),	O
a	O
terminal	O
pulmonary	O
tissue	O
destroyer	O
.	O

IBV	O
M	O
proteins	O
that	O
are	O
missing	O
portions	O
of	O
their	O
cytoplasmic	O
tails	O
or	O
transmembrane	O
regions	O
were	O
not	O
able	O
to	O
support	O
VLP	O
formation	O
,	O
regardless	O
of	O
their	O
ability	O
to	O
be	O
crosslinked	O
to	O
IBV	O
E	O
.	O
Interactions	O
between	O
the	O
E	O
and	O
M	O
proteins	O
and	O
the	O
membrane	O
bilayer	O
are	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
VLP	O
formation	O
and	O
virus	O
budding	B-PATH
.	O

Klenow	O
-	O
FragELTM	O
DNA	O
Fragmentation	O
Detection	O
Kit	O
and	O
immunohistochemical	O
alkaline	O
phosphatase	O
detection	O
reagent	O
kit	O
were	O
used	O
to	O
detect	O
cell	O
apoptosis	B-PATH
and	O
expressions	O
of	O
CD68	O
,	O
CD20	O
,	O
CD4	O
,	O
CD8	O
and	O
CD45RA	O
in	O
the	O
pathological	O
tissues	O
of	O
SARS	O
patients	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
represents	O
a	O
medical	O
emergency	O
because	O
it	O
may	O
rapidly	O
progress	O
to	O
complications	O
and	O
death	O
without	O
prompt	O
and	O
appropriate	O
treatment	O
.	O

TITLE	O
:	O
Increased	O
expression	O
of	O
19	O
-	O
kD	O
interacting	O
protein	O
-	O
3	O
-	O
like	O
protein	O
and	O
the	O
relationship	O
to	O
apoptosis	B-PATH
in	O
the	O
lung	O
of	O
rats	O
with	O
severe	O
acute	O
pancreatitis	O
.	O

Churg	O
-	O
Strauss	O
syndrome	O
was	O
diagnosed	O
based	O
on	O
her	O
history	O
of	O
asthma	B-PATH
,	O
evidence	O
of	O
peripheral	O
eosinophilia	O
and	O
results	O
of	O
endomycardial	O
biopsy	O
.	O

Although	O
initial	O
clinical	O
trials	O
in	O
cystic	O
fibrosis	O
and	O
non	B-PATH
-	I-PATH
small	I-PATH
cell	I-PATH
lung	I-PATH
cancer	I-PATH
have	O
shown	O
promise	O
the	O
results	O
have	O
not	O
been	O
as	O
good	O
as	O
might	O
have	O
been	O
anticipated	O
.	O

ABSTRACT	O
:	O
While	O
the	O
risks	O
of	O
transfusion	O
-	O
transmitted	O
human	O
immunodeficiency	O
virus	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
and	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
I	O
/	O
II	O
continue	O
to	O
decrease	O
,	O
additional	O
threats	O
to	O
transfusion	O
safety	O
are	O
posed	O
by	O
emerging	O
""""	O
new	O
""""	O
infectious	O
diseases	O
.	O

ABSTRACT	O
:	O
To	O
discuss	O
the	O
false	O
-	O
positive	O
of	O
serological	O
diagnostic	O
testing	O
for	O
coronavirus	O
antibody	O
in	O
patients	O
with	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
(	O
SLE	O
),	O
66	O
normal	O
individual	O
and	O
31	O
SLE	O
with	O
non	O
-	O
SARS	O
patients	O
were	O
detected	O
for	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
antibody	O
and	O
RNA	O
by	O
enzymelinked	O
immunosorbent	O
assays	O
(	O
ELISA	O
)	O
and	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

ABSTRACT	O
:	O
The	O
persistent	O
airway	O
neutrophilia	O
observed	O
in	O
chronic	O
lung	O
disease	O
of	O
prematurity	O
(	O
CLD	O
)	O
may	O
reflect	O
inappropriate	O
suppression	O
of	O
neutrophil	O
apoptosis	B-PATH
.	O

Neutrophil	O
apoptosis	B-PATH
was	O
increased	O
in	O
the	O
RDS	O
group	O
(	O
mean	O
(	O
SEM	O
)	O
neutrophil	O
apoptosis	B-PATH
on	O
day	O
7	O
BAL	O
:	O
RDS	O
17	O
.	O
0	O
(	O
8	O
.	O
6	O
)%	O
v	O
CLD	O
0	O
.	O
7	O
(	O
0	O
.	O
2	O
)%	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

There	O
were	O
similar	O
findings	O
in	O
the	O
ECMO	O
group	O
:	O
survivors	O
had	O
proapoptotic	O
BAL	O
fluid	O
compared	O
with	O
non	O
-	O
survivors	O
(	O
apoptosis	B-PATH
ratio	O
day	O
1	O
,	O
survivors	O
7	O
.	O
9	O
(	O
2	O
.	O
1	O
)	O
v	O
non	O
-	O
survivors	O
2	O
.	O
1	O
(	O
0	O
.	O
7	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)).	O

Virus	O
entered	O
cells	O
by	O
endocytosis	B-PATH
or	O
membrane	O
fusion	O
and	O
was	O
released	O
through	O
a	O
budding	B-PATH
process	O
.	O

Virus	O
entered	O
cells	O
by	O
endocytosis	B-PATH
or	O
membrane	O
fusion	O
and	O
was	O
released	O
through	O
a	O
budding	B-PATH
process	O
.	O

Influenza	B-PATH
A	I-PATH
viruses	O
of	O
subtype	O
H5N1	O
also	O
caused	O
severe	O
respiratory	O
disease	O
in	O
humans	O
in	O
Hong	O
Kong	O
in	O
1997	O
and	O
2003	O
,	O
including	O
at	O
least	O
seven	O
fatal	O
cases	O
,	O
posing	O
a	O
serious	O
human	O
pandemic	O
threat	O
.	O

Its	O
R	O
value	O
(	O
the	O
average	O
number	O
of	O
secondary	O
cases	O
infected	O
by	O
a	O
primary	O
case	O
)	O
is	O
lower	O
than	O
that	O
for	O
measles	B-PATH
,	O
human	O
parvovirus	O
,	O
chickenpox	O
,	O
mumps	O
,	O
rubella	O
,	O
and	O
poliomyelitis	O
;	O
only	O
the	O
value	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
is	O
lower	O
.	O

After	O
introduction	O
of	O
chloroquine	O
in	O
the	O
1950s	O
world	O
-	O
wide	O
for	O
prophylactic	O
use	O
,	O
chloroquine	O
-	O
resistant	O
malaria	B-PATH
emerged	O
.	O

The	O
use	O
of	O
the	O
picornavirus	O
encephalomyocarditis	O
virus	O
(	O
EMCV	O
)	O
internal	O
ribosome	B-PATH
entry	O
site	O
(	O
IRES	O
)	O
sequence	O
to	O
initiate	O
gene	O
translation	O
was	O
investigated	O
as	O
an	O
alternative	O
method	O
to	O
the	O
coronavirus	O
-	O
mediated	O
TAS	O
-	O
controlled	O
heterologous	O
gene	O
expression	O
system	O
.	O

Human	O
metapneumovirus	O
was	O
studied	O
by	O
polymerase	O
chain	O
reaction	O
on	O
negative	O
samples	O
for	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
virus	O
,	O
parainfluenza	O
(	O
1	O
,	O
2	O
and	O
3	O
)	O
virus	O
,	O
adenovirus	O
,	O
coronavirus	O
and	O
rhinovirus	O
.	O

Rhinovirus	O
was	O
not	O
associated	O
with	O
wheezing	O
and	O
did	O
not	O
appear	O
to	O
be	O
a	O
trigger	O
for	O
asthma	B-PATH
exacerbations	O
.	O

Peroxisome	B-PATH
proliferator	O
-	O
activated	O
receptor	O
-	O
gamma	O
(	O
PPAR	O
-	O
gamma	O
)	O
belongs	O
to	O
the	O
nuclear	O
receptor	O
superfamily	O
and	O
has	O
an	O
anti	O
-	O
inflammatory	O
effect	O
by	O
preventing	O
the	O
activation	O
of	O
transcription	O
factors	O
such	O
as	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
).	O

Prevention	O
of	O
Mycobacterium	O
tuberculosis	B-PATH
transmission	O
also	O
requires	O
effective	O
infection	O
control	O
in	O
health	O
-	O
care	O
facilities	O
.	O

We	O
report	O
a	O
woman	O
with	O
HIV	B-PATH
infection	I-PATH
,	O
who	O
developed	O
hypocomplementemic	O
acute	O
nephritic	O
syndrome	O
10	O
days	O
after	O
an	O
upper	O
respiratory	O
infection	O
.	O

It	O
is	O
known	O
for	O
some	O
viruses	O
(	O
including	O
members	O
of	O
family	O
Coronaviridae	O
)	O
that	O
CPE	O
can	O
be	O
caused	O
either	O
by	O
virus	O
-	O
induced	O
apoptosis	B-PATH
(	O
active	O
death	O
)	O
or	O
cell	O
necrosis	O
(	O
passive	O
death	O
).	O

Here	O
,	O
we	O
provide	O
evidences	O
that	O
RNAi	O
targeting	O
at	O
coronavirus	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RDRP	B-PATH
)	O
using	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
expression	O
plasmids	O
can	O
specifically	O
inhibit	O
expression	O
of	O
extraneous	O
coronavirus	O
RDRP	B-PATH
in	O
293	O
and	O
HeLa	O
cells	O
.	O

Several	O
putative	O
functional	O
domains	O
such	O
as	O
a	O
papain	O
-	O
like	O
proteinase	O
(	O
PL	O
(	O
pro	O
)),	O
main	O
protease	O
(	O
M	O
(	O
pro	O
)),	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
and	O
RNA	O
helicase	O
encoded	O
by	O
the	O
replicase	O
gene	O
are	O
important	O
for	O
virus	O
replication	O
.	O

ABSTRACT	O
:	O
In	O
California	O
,	O
molecular	O
testing	O
was	O
useful	O
in	O
decreasing	O
suspicion	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
by	O
detecting	O
common	O
respiratory	O
pathogens	O
(	O
influenza	B-PATH
A	I-PATH
/	O
B	O
,	O
human	O
metapneumovirus	O
,	O
picornavirus	O
,	O
Mycoplasma	O
pneumoniae	O
,	O
Chlamydia	O
spp	O
.,	O
parainfluenza	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
and	O
adenovirus	O
)	O
in	O
23	O
(	O
45	O
%)	O
of	O
51	O
patients	O
with	O
suspected	O
SARS	O
and	O
9	O
(	O
47	O
%)	O
of	O
19	O
patients	O
with	O
probable	O
SARS	O
.	O

Finally	O
,	O
in	O
the	O
51	O
acute	O
pneumonias	O
hospitalised	O
with	O
respiratory	O
distress	O
syndrome	O
,	O
a	O
virus	O
was	O
identified	O
in	O
17	O
(	O
33	O
.	O
3	O
%)	O
cases	O
,	O
including	O
3	O
(	O
5	O
.	O
5	O
%)	O
RSV	O
,	O
6	O
influenza	B-PATH
A	I-PATH
,	O
3	O
rhinovirus	O
,	O
2	O
adenovirus	O
,	O
2	O
herpes	O
simplex	O
virus	O
and	O
1	O
cytomegalovirus	O
.	O

Our	O
predictions	O
against	O
experimental	O
data	O
from	O
four	O
melanoma	B-PATH
-	O
related	O
proteins	O
showed	O
that	O
MULTIPRED	O
ANN	O
and	O
HMM	O
models	O
could	O
predict	O
T	O
-	O
cell	O
epitopes	O
with	O
high	O
accuracy	O
.	O

We	O
were	O
,	O
and	O
are	O
,	O
expecting	O
a	O
new	O
influenza	B-PATH
A	I-PATH
pandemic	O
,	O
but	O
no	O
one	O
predicted	O
the	O
emergence	O
of	O
an	O
unknown	O
coronavirus	O
(	O
CoV	O
)	O
as	O
a	O
deadly	O
human	O
pathogen	O
.	O

In	O
light	O
of	O
observations	O
that	O
three	O
Chinese	O
herbal	O
formulations	O
recommended	O
for	O
treatment	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
specifically	O
inhibited	O
the	O
release	B-PATH
of	O
HMGB1	O
from	O
innate	O
immune	O
cells	O
,	O
we	O
hypothesize	O
that	O
HMGB1	O
might	O
occupy	O
a	O
pathogenic	O
role	O
in	O
SARS	O
by	O
mediating	O
an	O
injurious	O
pulmonary	O
inflammatory	O
response	O
.	O

The	O
analysis	O
of	O
morbidity	O
in	O
tuberculosis	B-PATH
,	O
measles	B-PATH
,	O
HIV	B-PATH
infection	I-PATH
,	O
viral	O
hepatitis	O
A	O
,	O
typhoid	O
fever	O
,	O
cholera	O
and	O
quarantine	O
infections	O
,	O
Crimean	O
hemorrhagic	O
fever	O
,	O
West	O
Nile	O
fever	O
,	O
rabies	O
,	O
malaria	B-PATH
has	O
been	O
carried	O
out	O
.	O

Clinical	O
samples	O
tested	O
negative	O
for	O
IgM	O
antibodies	O
to	O
Japanese	O
encephalitis	O
,	O
West	O
Nile	O
,	O
dengue	O
,	O
and	O
measles	B-PATH
viruses	O
,	O
and	O
for	O
RNA	O
of	O
coronavirus	O
,	O
paramyxovirus	O
,	O
enterovirus	O
,	O
and	O
influenza	O
viruses	O
.	O

Influenza	B-PATH
infection	I-PATH
was	O
confirmed	O
in	O
172	O
volunteers	O
(	O
11	O
.	O
1	O
%)	O
presenting	O
with	O
influenza	O
-	O
like	O
illness	O
.	O

ABSTRACT	O
:	O
Occupational	O
asthma	B-PATH
(	O
OA	O
)	O
is	O
a	O
frequent	O
work	O
-	O
related	O
disease	O
in	O
industrialised	O
countries	O
.	O

The	O
two	O
-	O
step	O
screening	O
method	O
described	O
here	O
yielded	O
several	O
small	O
molecules	O
that	O
can	O
be	O
used	O
for	O
developing	O
new	O
classes	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
drugs	O
and	O
is	O
potentially	O
useful	O
for	O
the	O
high	O
-	O
throughput	O
screening	O
of	O
drugs	O
inhibiting	O
the	O
entry	O
of	O
HIV	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
and	O
other	O
insidious	O
viruses	O
into	O
their	O
host	O
cells	O
.	O

When	O
the	O
host	O
produces	O
antibodies	O
against	O
these	O
viral	O
antigens	O
,	O
the	O
antibodies	O
also	O
bind	O
to	O
the	O
host	O
'	O
s	O
own	O
ACTH	O
,	O
which	O
limits	O
the	O
host	O
'	O
s	O
stress	B-PATH
response	I-PATH
by	O
interfering	O
with	O
ACTH	O
'	O
s	O
ability	O
to	O
stimulate	O
the	O
secretion	O
of	O
corticosteroids	O
.	O

When	O
the	O
cDNA	O
encoding	O
CD209L	O
from	O
clone	O
2	O
.	O
27	O
was	O
cloned	O
and	O
transfected	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
,	O
the	O
cells	O
expressed	O
human	O
CD209L	O
glycoprotein	O
and	O
became	O
susceptible	O
to	O
infection	O
with	O
SARS	O
-	O
CoV	O
.	O
Immunohistochemistry	O
showed	O
that	O
CD209L	O
is	O
expressed	O
in	O
human	O
lung	O
in	O
type	O
II	O
alveolar	O
cells	O
and	O
endothelial	O
cells	O
,	O
both	O
potential	O
targets	O
for	O
SARS	O
-	O
CoV	O
.	O
Several	O
other	O
enveloped	O
viruses	O
including	O
Ebola	O
and	O
Sindbis	O
also	O
use	O
CD209L	O
as	O
a	O
portal	O
of	O
entry	O
,	O
and	O
HIV	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
can	O
bind	O
to	O
CD209L	O
on	O
cell	O
membranes	O
but	O
do	O
not	O
use	O
it	O
to	O
mediate	O
virus	O
entry	O
.	O

ABSTRACT	O
:	O
To	O
promote	O
viral	O
entry	O
,	O
replication	O
,	O
release	B-PATH
,	O
and	O
spread	O
to	O
neighboring	O
cells	O
,	O
many	O
cytolytic	O
animal	O
viruses	O
encode	O
proteins	O
responsible	O
for	O
modification	O
of	O
host	O
cell	O
membrane	O
permeability	O
and	O
for	O
formation	O
of	O
ion	O
channels	O
in	O
host	O
cell	O
membranes	O
during	O
their	O
life	O
cycles	O
.	O

In	O
addition	O
,	O
weak	O
activation	O
of	O
Akt	O
cannot	O
prevent	O
SARS	O
-	O
CoV	O
infection	O
-	O
induced	O
apoptosis	B-PATH
in	O
Vero	O
E6	O
cells	O
.	O

ABSTRACT	O
:	O
A	O
88	O
year	O
old	O
female	O
with	O
active	O
rheumatoid	B-PATH
arthritis	I-PATH
treated	O
by	O
low	O
dose	O
of	O
prednisolone	O
and	O
methotrexate	O
was	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
severe	O
bilateral	O
pulmonary	O
infiltration	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
The	O
cell	B-PATH
cycle	I-PATH
and	O
virus	O
infection	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
different	O
viruses	O
interact	O
with	O
the	O
cell	B-PATH
cycle	I-PATH
in	O
order	O
to	O
subvert	O
host	O
-	O
cell	O
function	O
and	O
increase	O
the	O
efficiency	O
of	O
virus	O
replication	O
;	O
examples	O
can	O
be	O
found	O
from	O
DNA	O
,	O
retro	O
,	O
and	O
RNA	O
viruses	O
.	O

Although	O
cell	B-PATH
cycle	I-PATH
control	O
is	O
fairly	O
well	O
characterized	O
in	O
terms	O
of	O
checkpoints	O
and	O
control	O
molecules	O
(	O
e	O
.	O
g	O
.,	O
cyclins	O
),	O
in	O
recent	O
years	O
several	O
researchers	O
have	O
demonstrated	O
that	O
the	O
nucleolus	O
is	O
also	O
involved	O
in	O
cell	B-PATH
cycle	I-PATH
control	O
.	O

In	O
order	O
to	O
study	O
the	O
interactions	O
between	O
a	O
virus	O
and	O
the	O
cell	B-PATH
cycle	I-PATH
and	O
vice	O
versa	O
we	O
have	O
developed	O
and	O
adapted	O
a	O
number	O
of	O
different	O
approaches	O
and	O
strategies	O
.	O

About	O
30	O
new	O
diseases	O
have	O
been	O
identified	O
,	O
including	O
Legionnaires	O
'	O
disease	O
,	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)/	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
),	O
hepatitis	B-PATH
C	I-PATH
,	O
bovine	O
spongiform	O
encephalopathy	O
(	O
BSE	O
)/	O
variant	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
(	O
vCJD	O
),	O
Nipah	O
virus	O
,	O
several	O
viral	O
hemorrhagic	O
fevers	O
and	O
,	O
most	O
recently	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
avian	O
influenza	O
.	O

TITLE	O
:	O
Induction	O
of	O
IL	O
-	O
8	O
release	B-PATH
in	O
lung	O
cells	O
via	O
activator	O
protein	O
-	O
1	O
by	O
recombinant	O
baculovirus	O
displaying	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
spike	O
proteins	O
:	O
identification	O
of	O
two	O
functional	O
regions	O
.	O

IL	O
-	O
8	O
release	B-PATH
was	O
effectively	O
induced	O
by	O
vAtEpGS688	O
,	O
a	O
baculovirus	O
exhibiting	O
the	O
aa	O
17	O
-	O
688	O
fragment	O
of	O
S	O
protein	O
,	O
and	O
this	O
induction	O
was	O
attenuated	O
by	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
Ab	O
.	O

These	O
results	O
suggested	O
that	O
the	O
S	O
protein	O
of	O
SARS	O
-	O
CoV	O
could	O
induce	O
release	B-PATH
of	O
IL	O
-	O
8	O
in	O
the	O
lung	O
cells	O
via	O
activations	O
of	O
MAPKs	O
and	O
AP	O
-	O
1	O
.	O

All	O
patients	O
,	O
more	O
than	O
15	O
years	O
-	O
old	O
with	O
falciparum	O
malaria	B-PATH
who	O
were	O
admitted	O
to	O
intensive	O
care	O
units	O
between	O
October	O
1997	O
and	O
April	O
2004	O
were	O
included	O
.	O

Severe	O
imported	O
malaria	B-PATH
remains	O
associated	O
with	O
a	O
bad	O
outcome	O
.	O

Besides	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
,	O
RNA	O
helicase	O
,	O
and	O
protease	O
activities	O
,	O
which	O
are	O
common	O
to	O
RNA	O
viruses	O
,	O
the	O
coronavirus	O
replicase	O
was	O
recently	O
predicted	O
to	O
employ	O
a	O
variety	O
of	O
RNA	O
processing	O
enzymes	O
that	O
are	O
not	O
(	O
or	O
extremely	O
rarely	O
)	O
found	O
in	O
other	O
RNA	O
viruses	O
and	O
include	O
putative	O
sequence	O
-	O
specific	O
endoribonuclease	O
,	O
3	O
'-	O
to	O
-	O
5	O
'	O
exoribonuclease	O
,	O
2	O
'-	O
O	O
-	O
ribose	O
methyltransferase	O
,	O
ADP	O
ribose	O
1	O
"""-"	O
phosphatase	O
and	O
,	O
in	O
a	O
subset	O
of	O
group	O
2	O
coronaviruses	O
,	O
cyclic	O
phosphodiesterase	O
activities	O
.	O

This	O
chapter	O
reviews	O
(	O
1	O
)	O
the	O
organization	O
of	O
the	O
coronavirus	O
replicase	O
gene	O
,	O
(	O
2	O
)	O
the	O
proteolytic	O
processing	O
of	O
the	O
replicase	O
by	O
viral	O
proteases	O
,	O
(	O
3	O
)	O
the	O
available	O
functional	O
and	O
structural	O
information	O
on	O
individual	O
subunits	O
of	O
the	O
replicase	O
,	O
such	O
as	O
proteases	O
,	O
RNA	O
helicase	O
,	O
and	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
,	O
and	O
(	O
4	O
)	O
the	O
subcellular	O
localization	O
of	O
coronavirus	O
proteins	O
involved	O
in	O
RNA	O
synthesis	O
.	O

These	O
proteins	O
include	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
RNA	O
helicase	O
,	O
proteases	O
,	O
metal	O
-	O
binding	O
proteins	O
,	O
and	O
a	O
number	O
of	O
other	O
proteins	O
of	O
unknown	O
function	O
.	O

Mechanical	O
ventilation	O
with	O
airway	O
pressure	O
release	B-PATH
ventilation	O
permits	O
spontaneous	O
breathing	O
throughout	O
the	O
entire	O
respiratory	O
cycle	O
,	O
improves	O
patient	O
comfort	O
,	O
reduces	O
the	O
use	O
of	O
sedation	O
,	O
and	O
may	O
reduce	O
ventilator	O
days	O
.	O

The	O
distribution	O
of	O
the	O
segregating	O
sites	O
is	O
not	O
steady	O
,	O
the	O
most	O
variable	O
region	O
appears	O
in	O
S1	O
protein	O
,	O
and	O
the	O
nucleotide	O
sequence	O
of	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
has	O
very	O
few	O
mutation	O
sites	O
.	O

TITLE	O
:	O
Systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
complicated	O
by	O
HELLP	O
syndrome	O
.	O

However	O
,	O
opinions	O
were	O
equally	O
divided	O
regarding	O
its	O
use	O
when	O
treating	O
patients	O
with	O
pulmonary	O
tuberculosis	B-PATH
;	O
with	O
51	O
%	O
being	O
in	O
favour	O
.	O

Some	O
examples	O
of	O
pathogens	O
with	O
this	O
pattern	O
of	O
transmission	O
are	O
human	O
immunodeficiency	O
virus	O
/	O
acquired	O
immune	O
deficiency	O
syndrome	O
,	O
influenza	B-PATH
A	I-PATH
,	O
Ebola	O
virus	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

TITLE	O
:	O
Fatal	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
in	O
a	O
child	O
presenting	O
with	O
diarrhea	O
followed	O
by	O
coma	O
.	O

TITLE	O
:	O
Tuberculosis	B-PATH
in	O
a	O
SARS	O
outbreak	O
.	O

ABSTRACT	O
:	O
Preoccupied	O
with	O
the	O
diagnosis	O
of	O
SARS	O
(	O
severe	O
acute	O
respiratory	O
syndrome	O
)	O
in	O
a	O
SARS	O
outbreak	O
,	O
doctors	O
tend	O
to	O
overlook	O
other	O
endemic	O
diseases	O
,	O
such	O
as	O
tuberculosis	B-PATH
.	O

More	O
basic	O
research	O
into	O
virus	O
ecology	O
and	O
evolution	O
and	O
development	O
of	O
effective	O
vaccines	O
and	O
antiviral	O
strategies	O
are	O
required	O
to	O
limit	O
the	O
impact	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
zoonoses	O
and	O
the	O
threat	O
of	O
an	O
influenza	O
pandemic	O
.	O

ABSTRACT	O
:	O
Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
and	O
Mycobacterium	O
tuberculosis	B-PATH
annually	O
cause	O
3	O
million	O
and	O
2	O
million	O
deaths	O
,	O
respectively	O
.	O

Although	O
the	O
perceived	O
threats	O
of	O
new	O
infections	O
such	O
as	O
SARS	O
,	O
new	O
variant	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
and	O
anthrax	O
are	O
real	O
,	O
these	O
outbreaks	O
have	O
caused	O
less	O
than	O
1	O
,	O
000	O
deaths	O
globally	O
,	O
a	O
death	O
toll	O
AIDS	O
and	O
tuberculosis	B-PATH
exact	O
every	O
2	O
h	O
.	O
In	O
2003	O
,	O
40	O
million	O
people	O
were	O
infected	O
with	O
HIV	O
,	O
2	O
billion	O
with	O
M	O
.	O
tuberculosis	B-PATH
,	O
and	O
15	O
million	O
with	O
both	O
.	O

This	O
report	O
describes	O
the	O
response	O
model	O
of	O
the	O
Istituto	O
Nazionale	O
per	O
le	O
Malattie	O
Infettive	O
Lazzaro	O
Spallanzani	O
(	O
INMI	O
),	O
Rome	O
,	O
Italy	O
for	O
managing	O
patients	O
suspected	O
of	O
or	O
affected	O
by	O
smallpox	O
or	O
viral	O
haemorrhagic	O
fever	O
(	O
VHF	O
)	O
either	O
in	O
the	O
context	O
of	O
an	O
intentional	O
release	B-PATH
or	O
natural	O
occurrence	O
.	O

Real	O
-	O
time	O
qRT	O
-	O
PCR	O
was	O
used	O
to	O
confirm	O
the	O
regulated	O
expression	O
of	O
genes	O
related	O
to	O
several	O
functional	O
classes	O
including	O
kinases	O
,	O
interferon	O
induced	O
genes	O
,	O
chemokines	O
and	O
adhesion	O
molecules	O
,	O
vesicular	O
trafficking	O
and	O
fusion	O
protein	O
genes	O
,	O
extracellular	O
matrix	O
protein	O
genes	O
,	O
cell	B-PATH
cycle	I-PATH
,	O
metabolism	O
,	O
cell	O
physiology	O
and	O
development	O
,	O
translation	O
,	O
RNA	O
binding	O
,	O
lysosomal	O
,	O
protein	O
degradation	O
and	O
ubiquitination	O
related	O
genes	O
.	O

Besides	O
the	O
upregulation	O
of	O
genes	O
associated	O
with	O
apoptosis	B-PATH
,	O
which	O
was	O
exactly	O
opposite	O
to	O
the	O
previously	O
reported	O
effect	O
of	O
SARS	O
-	O
CoV	O
in	O
a	O
colonic	O
carcinoma	O
cell	O
line	O
,	O
genes	O
related	O
to	O
inflammation	O
,	O
stress	B-PATH
response	I-PATH
,	O
and	O
procoagulation	O
were	O
also	O
upregulated	O
.	O

TITLE	O
:	O
A	O
throat	O
lozenge	O
containing	O
amyl	O
meta	O
cresol	O
and	O
dichlorobenzyl	O
alcohol	O
has	O
a	O
direct	O
virucidal	O
effect	O
on	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
and	O
SARS	O
-	O
CoV	O
.	O
ABSTRACT	O
:	O
A	O
potent	O
virucidal	O
mixture	O
containing	O
amyl	O
metacresol	O
and	O
dichlorobenzyl	O
alcohol	O
at	O
low	O
pH	O
inactivated	O
enveloped	O
respiratory	O
viruses	O
influenza	B-PATH
A	I-PATH
,	O
respiratory	O
synctial	O
virus	O
(	O
RSV	O
)	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
but	O
not	O
viruses	O
with	O
icosahedral	O
symmetry	O
,	O
such	O
as	O
adenoviruses	O
or	O
rhinoviruses	O
.	O

In	O
addition	O
to	O
causing	O
upper	O
respiratory	O
disease	O
,	O
we	O
found	O
that	O
HCoV	O
-	O
NL63	O
can	O
present	O
as	O
croup	O
,	O
asthma	B-PATH
exacerbation	O
,	O
febrile	O
seizures	O
,	O
and	O
high	O
fever	O
.	O

Furthermore	O
,	O
immature	O
but	O
not	O
mature	O
recombinant	O
Hsp60	O
induced	O
in	O
vitro	O
the	O
release	B-PATH
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
from	O
RAW	O
264	O
.	O
7	O
murine	O
macrophages	O
.	O

In	O
contrast	O
to	O
the	O
case	O
with	O
human	O
coronavirus	O
229E	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
there	O
was	O
little	O
or	O
no	O
induction	O
of	O
beta	O
interferon	O
(	O
IFN	O
-	O
beta	O
)	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
macrophages	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
requires	O
lipid	O
rafts	O
for	O
virus	O
entry	O
and	O
cell	O
-	O
cell	O
fusion	O
but	O
not	O
for	O
virus	O
release	B-PATH
.	O

These	O
trends	O
are	O
attributable	O
to	O
differences	O
in	O
monocyte	O
TNFR2	O
release	B-PATH
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
between	O
the	O
strains	O
since	O
sTNFR2	O
decreased	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
levels	O
of	O
NO	O
production	O
.	O

TITLE	O
:	O
Apoptosis	B-PATH
induced	O
by	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
in	O
Vero	O
cells	O
is	O
replication	O
-	O
dependent	O
and	O
involves	O
caspase	O
.	O

Although	O
there	O
is	O
a	O
positive	O
correlation	O
between	O
apoptosis	B-PATH
and	O
virus	O
replication	O
,	O
the	O
latter	O
is	O
not	O
significantly	O
blocked	O
by	O
treatment	O
with	O
the	O
caspase	O
inhibitor	O
z	O
-	O
DEVD	O
-	O
FMK	O
.	O

ABSTRACT	O
:	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
cause	O
of	O
the	O
life	O
-	O
threatening	O
atypical	O
pneumonia	O
,	O
infects	O
many	O
organs	O
,	O
such	O
as	O
lung	O
,	O
liver	O
and	O
immune	O
organ	O
,	O
and	O
induces	O
parenchyma	O
cells	O
apoptosis	B-PATH
and	O
necrosis	O
.	O

The	O
use	O
of	O
a	O
shell	O
vial	O
assay	O
and	O
PCR	O
identified	O
a	O
pathogen	O
in	O
103	O
(	O
39	O
%)	O
of	O
the	O
patients	O
,	O
including	O
influenza	B-PATH
A	I-PATH
or	O
B	O
in	O
54	O
,	O
picornavirus	O
in	O
28	O
(	O
including	O
rhinovirus	O
in	O
24	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
in	O
12	O
,	O
human	O
metapneumovirus	O
in	O
4	O
,	O
human	O
coronavirus	O
OC43	O
in	O
2	O
,	O
adenovirus	O
in	O
2	O
,	O
parainfluenza	O
virus	O
type	O
1	O
in	O
1	O
,	O
and	O
coinfection	O
with	O
influenza	O
and	O
parainfluenza	O
virus	O
type	O
1	O
in	O
2	O
.	O

The	O
use	O
of	O
a	O
shell	O
vial	O
assay	O
and	O
PCR	O
identified	O
a	O
pathogen	O
in	O
103	O
(	O
39	O
%)	O
of	O
the	O
patients	O
,	O
including	O
influenza	B-PATH
A	I-PATH
or	O
B	O
in	O
54	O
,	O
picornavirus	O
in	O
28	O
(	O
including	O
rhinovirus	O
in	O
24	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
in	O
12	O
,	O
human	O
metapneumovirus	O
in	O
4	O
,	O
human	O
coronavirus	O
OC43	O
in	O
2	O
,	O
adenovirus	O
in	O
2	O
,	O
parainfluenza	O
virus	O
type	O
1	O
in	O
1	O
,	O
and	O
coinfection	O
with	O
influenza	O
and	O
parainfluenza	O
virus	O
type	O
1	O
in	O
2	O
.	O

The	O
kinetic	O
study	O
of	O
the	O
replication	O
of	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
showed	O
that	O
there	O
were	O
infected	O
cells	O
in	O
HuH7	O
and	O
MDCK	O
lines	O
as	O
early	O
as	O
24	O
hr	O
post	O
-	O
infection	O
.	O

The	O
results	O
indicated	O
that	O
apart	O
from	O
the	O
two	O
subunits	O
of	O
cellular	O
RNA	B-PATH
polymerase	I-PATH
complex	O
,	O
BTF3	O
and	O
ATF5	O
,	O
this	O
nsp10	O
protein	O
was	O
also	O
able	O
to	O
interact	O
specifically	O
with	O
the	O
NADH	O
4L	O
subunit	O
and	O
cytochrome	O
oxidase	O
II	O
.	O

A	O
more	O
dramatic	O
phenotype	O
was	O
obtained	O
when	O
the	O
endocytosis	B-PATH
signal	O
was	O
mutated	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
endocytosis	B-PATH
signal	O
of	O
IBV	O
S	O
is	O
essential	O
for	O
productive	O
virus	O
infection	O
.	O

We	O
first	O
validate	O
this	O
method	O
on	O
the	O
human	O
influenza	B-PATH
A	I-PATH
viral	O
genomes	O
as	O
well	O
as	O
on	O
the	O
human	O
mitochondrial	O
DNA	O
database	O
.	O

Apoptosis	B-PATH
degree	O
of	O
blood	O
vessel	O
endothelium	O
was	O
increased	O
too	O
.	O

A	O
proteasome	B-PATH
inhibitor	O
stabilized	O
IBV	O
3b	O
in	O
mammalian	O
cells	O
,	O
but	O
had	O
little	O
effect	O
on	O
IBV	O
3b	O
in	O
avian	O
cells	O
,	O
suggesting	O
that	O
rapid	O
turnover	O
of	O
IBV	O
3b	O
in	O
mammalian	O
cells	O
is	O
proteasome	B-PATH
-	O
dependent	O
while	O
turnover	O
in	O
avian	O
cells	O
may	O
be	O
proteasome	B-PATH
-	O
independent	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
7a	O
protein	O
blocks	O
cell	B-PATH
cycle	I-PATH
progression	O
at	O
G0	O
/	O
G1	O
phase	O
via	O
the	O
cyclin	O
D3	O
/	O
pRb	O
pathway	O
.	O

Accumulation	O
of	O
hypo	O
-	O
or	O
non	O
-	O
phosphorylated	O
pRb	O
thus	O
prevents	O
cell	B-PATH
cycle	I-PATH
progression	O
at	O
G0	O
/	O
G1	O
phase	O
.	O

NO	O
release	B-PATH
and	O
eNOS	O
expression	O
were	O
determined	O
to	O
examine	O
the	O
effect	O
of	O
chronic	O
EtOH	O
stimulation	O
on	O
endothelial	O
NO	O
metabolism	O
.	O

Doxorubicin	O
induced	O
apoptosis	B-PATH
of	O
human	O
hepatocellular	O
carcinoma	O
(	O
HepG2	O
)	O
was	O
studied	O
using	O
the	O
integrated	O
microfluidic	O
device	O
with	O
concentration	O
generator	O
.	O

TITLE	O
:	O
Role	O
of	O
the	O
mitochondrial	O
signaling	O
pathway	O
in	O
murine	O
coronavirus	O
-	O
induced	O
oligodendrocyte	O
apoptosis	B-PATH
.	O

Analyses	O
of	O
cytochrome	O
c	O
release	B-PATH
further	O
revealed	O
an	O
activation	O
of	O
the	O
mitochondrial	O
apoptotic	O
pathway	O
.	O

Compared	O
with	O
cells	O
heterozygous	O
for	O
L	O
-	O
SIGN	O
,	O
cells	O
homozygous	O
for	O
L	O
-	O
SIGN	O
show	O
higher	O
binding	O
capacity	O
for	O
SARS	O
-	O
CoV	O
,	O
higher	O
proteasome	B-PATH
-	O
dependent	O
viral	O
degradation	O
and	O
a	O
lower	O
capacity	O
for	O
trans	O
infection	O
.	O

ABSTRACT	O
:	O
It	O
was	O
recently	O
shown	O
that	O
the	O
7a	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
induces	O
biochemical	O
changes	O
associated	O
with	O
apoptosis	B-PATH
.	O

In	O
this	O
study	O
,	O
the	O
mechanism	O
by	O
which	O
the	O
7a	O
protein	O
induces	O
apoptosis	B-PATH
was	O
examined	O
.	O

These	O
observations	O
concern	O
(	O
i	O
)	O
the	O
induction	O
of	O
interferon	O
by	O
synthetic	O
polyanions	O
such	O
as	O
polyacrylic	O
acid	O
and	O
polymethacrylic	O
acid	O
;	O
(	O
ii	O
)	O
the	O
prolonged	O
antiviral	O
activity	O
shown	O
by	O
polyacrylic	O
acid	O
in	O
vivo	O
;	O
(	O
iii	O
)	O
the	O
interferon	O
-	O
inducing	O
ability	O
of	O
double	O
-	O
stranded	O
RNAs	O
such	O
as	O
poly	O
(	O
I	O
)	O
x	O
poly	O
(	O
C	O
)	O
and	O
(	O
iv	O
)	O
mismatched	O
derivatives	O
thereof	O
(	O
i	O
.	O
e	O
.	O
ampligen	O
);	O
(	O
v	O
)	O
the	O
cloning	O
and	O
expression	O
of	O
interferon	O
-	O
beta	O
,	O
and	O
(	O
vi	O
)	O
its	O
usefulness	O
in	O
the	O
treatment	O
of	O
multiple	O
sclerosis	O
;	O
(	O
vii	O
)	O
the	O
potential	O
of	O
(	O
pegylated	O
)	O
interferon	O
-	O
alpha	O
in	O
the	O
treatment	O
of	O
hepatitis	B-PATH
C	I-PATH
and	O
(	O
viii	O
)	O
the	O
therapy	O
/	O
prophylaxis	O
of	O
SARS	O
;	O
(	O
ix	O
)	O
the	O
efficacy	O
of	O
interferon	O
(	O
inducers	O
)	O
in	O
the	O
experimental	O
treatment	O
of	O
flavivirus	O
encephalitis	O
and	O
enterovirus	O
myocarditis	O
;	O
and	O
,	O
finally	O
,	O
(	O
x	O
)	O
the	O
role	O
of	O
interferon	O
in	O
the	O
activity	O
shown	O
by	O
S	O
-	O
adenosylhomocysteine	O
inhibitors	O
such	O
as	O
3	O
-	O
deazaneplanocin	O
A	O
against	O
experimental	O
Ebola	O
virus	O
infections	O
in	O
mice	O
.	O

We	O
conclude	O
that	O
vivax	O
malaria	B-PATH
-	O
associated	O
ARDS	O
can	O
develop	O
before	O
anti	O
-	O
malarial	O
therapy	O
.	O

In	O
many	O
coronaviruses	O
,	O
the	O
nucleocapsid	O
protein	O
(	O
N	O
protein	O
)	O
has	O
been	O
shown	O
to	O
inhibit	O
cell	B-PATH
cycle	I-PATH
progression	O
although	O
the	O
mechanism	O
behind	O
this	O
is	O
poorly	O
understood	O
.	O

ABSTRACT	O
:	O
The	O
virally	O
encoded	O
integrase	O
protein	O
is	O
an	O
essential	O
enzyme	O
in	O
the	O
life	O
cycle	O
of	O
the	O
HIV	O
-	O
1	O
virus	O
and	O
represents	O
an	O
attractive	O
and	O
validated	O
target	O
in	O
the	O
development	O
of	O
therapeutics	O
against	O
HIV	B-PATH
infection	I-PATH
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
3C	O
-	O
like	O
protease	O
-	O
induced	O
apoptosis	B-PATH
.	O

The	O
possible	O
role	O
of	O
SARS	O
-	O
CoV	O
3C	O
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
in	O
virus	O
-	O
induced	O
apoptosis	B-PATH
is	O
characterized	O
in	O
this	O
study	O
.	O

TITLE	O
:	O
Comparison	O
of	O
two	O
rapid	O
influenza	B-PATH
A	I-PATH
/	O
B	O
test	O
kits	O
with	O
reference	O
methods	O
showing	O
high	O
specificity	O
and	O
sensitivity	O
for	O
influenza	B-PATH
A	I-PATH
infection	O
.	O

ABSTRACT	O
:	O
The	O
pathology	O
of	O
2	O
zoonotic	O
human	O
viral	O
infections	O
that	O
recently	O
emerged	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
due	O
to	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
and	O
avian	O
influenza	B-PATH
A	I-PATH
subtype	O
H5N1	O
,	O
is	O
reviewed	O
and	O
compared	O
based	O
on	O
the	O
literature	O
and	O
the	O
cases	O
examined	O
by	O
the	O
authors	O
.	O

Expression	O
of	O
recombinant	O
human	O
ALX	O
in	O
A549	O
airway	O
epithelial	O
cells	O
uncovered	O
ALX	O
-	O
dependent	O
inhibition	O
of	O
cytokine	O
release	B-PATH
by	O
LXA	O
(	O
4	O
).	O

ABSTRACT	O
:	O
As	O
influenza	B-PATH
A	I-PATH
/	O
H5N1	O
spreads	O
around	O
the	O
globe	O
the	O
risk	O
of	O
an	O
epidemic	O
increases	O
.	O

This	O
was	O
confirmed	O
using	O
a	O
pan	O
-	O
coronavirus	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
that	O
amplified	O
part	O
of	O
gene	O
1	O
that	O
encodes	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

In	O
comparison	O
with	O
Influenza	B-PATH
A	I-PATH
virus	O
and	O
Sendai	O
virus	O
,	O
IBV	O
was	O
most	O
sensitive	O
to	O
pre	O
-	O
treatment	O
of	O
cells	O
with	O
neuraminidase	O
.	O

ABSTRACT	O
:	O
Hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
is	O
believed	O
to	O
assemble	O
by	O
budding	B-PATH
into	O
membranes	O
of	O
the	O
early	O
secretory	O
pathway	O
,	O
consistent	O
with	O
the	O
membrane	O
location	O
where	O
the	O
viral	O
envelope	O
glycoproteins	O
E1	O
and	O
E2	O
accumulate	O
when	O
expressed	O
.	O

We	O
reported	O
previously	O
that	O
SARS	O
-	O
CoV	O
3b	O
is	O
predominantly	O
localized	O
in	O
the	O
nucleolus	O
,	O
and	O
induces	O
G0	O
/	O
G1	O
arrest	O
and	O
apoptosis	B-PATH
in	O
transfected	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
plasma	O
kallikrein	O
-	O
kinin	O
system	O
(	O
KKS	O
)	O
participates	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
reactions	O
involved	O
in	O
cellular	O
injury	O
,	O
coagulation	O
,	O
fibrinolysis	O
,	O
kinin	O
formation	O
,	O
complement	O
activation	O
,	O
cytokine	O
secretion	O
and	O
release	B-PATH
of	O
proteases	O
.	O

A	O
case	O
of	O
a	O
75	O
year	O
old	O
patient	O
with	O
intravesical	O
BCG	O
instillations	O
after	O
a	O
transurethral	O
resection	O
of	O
bladder	B-PATH
cancer	I-PATH
is	O
presented	O
.	O

These	O
two	O
genes	O
encode	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RDRP	O
)	O
and	O
envelope	O
E	O
protein	O
.	O

ABSTRACT	O
:	O
It	O
has	O
been	O
shown	O
that	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
3a	O
and	O
7a	O
proteins	O
,	O
but	O
not	O
membrane	O
(	O
M	O
)	O
protein	O
,	O
induce	O
apoptosis	B-PATH
in	O
mammalian	O
cells	O
.	O

ABSTRACT	O
:	O
The	O
nucleolus	O
is	O
a	O
dynamic	O
subnuclear	O
structure	O
involved	O
in	O
ribosome	B-PATH
subunit	O
biogenesis	O
,	O
cell	B-PATH
cycle	I-PATH
control	O
and	O
mediating	O
responses	O
to	O
cell	O
stress	O
,	O
among	O
other	O
functions	O
.	O

ABSTRACT	O
:	O
SARS	O
-	O
associated	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
induced	O
cell	O
apoptosis	B-PATH
and	O
its	O
structural	O
proteins	O
may	O
play	O
a	O
role	O
in	O
this	O
process	O
.	O

ABSTRACT	O
:	O
The	O
early	O
release	B-PATH
of	O
cytokines	O
by	O
cells	O
involved	O
in	O
innate	O
immunity	O
is	O
an	O
important	O
host	O
response	O
to	O
intracellular	O
pathogens	O
.	O

TITLE	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
induced	O
by	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
in	O
mice	O
.	O

Hepatitis	B-PATH
C	I-PATH
virus	O
causes	O
various	O
forms	O
of	O
glomerulonephritis	O
,	O
including	O
cryoglobulinemia	O
-	O
mediated	O
glomerulonephritis	O
.	O

TITLE	O
:	O
Communicable	O
respiratory	O
threats	O
in	O
the	O
ED	O
:	O
tuberculosis	B-PATH
,	O
influenza	O
,	O
SARS	O
,	O
and	O
other	O
aerosolized	O
infections	O
.	O

ABSTRACT	O
:	O
Recently	O
there	O
were	O
reports	O
from	O
all	O
over	O
India	O
about	O
changing	O
spectrum	O
of	O
clinical	O
presentation	O
of	O
severe	O
malaria	B-PATH
.	O

We	O
should	O
recognize	O
that	O
an	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
can	O
induce	O
hemophagocytic	O
syndrome	O
and	O
acute	O
respiratory	O
failure	O
as	O
the	O
initial	O
manifestations	O
of	O
multiple	O
organ	O
failure	O
.	O

She	O
had	O
a	O
history	O
of	O
close	O
contact	O
with	O
her	O
domestic	O
poultry	O
,	O
which	O
was	O
infected	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
).	O

Phylogenetic	O
trees	O
constructed	O
using	O
chymotrypsin	O
-	O
like	O
protease	O
,	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
,	O
helicase	O
,	O
spike	O
,	O
and	O
nucleocapsid	O
all	O
showed	O
that	O
the	O
group	O
2a	O
and	O
2b	O
and	O
putative	O
group	O
2c	O
and	O
2d	O
coronaviruses	O
are	O
more	O
closely	O
related	O
to	O
each	O
other	O
than	O
to	O
group	O
1	O
and	O
3	O
coronaviruses	O
.	O

The	O
following	O
clinical	O
presentations	O
were	O
noted	O
:	O
fever	O
(	O
100	O
%),	O
rhinitis	O
(	O
44	O
%),	O
acute	O
bronchiolitis	O
(	O
44	O
%),	O
viral	O
pneumonia	O
(	O
33	O
%),	O
viral	O
pneumonia	O
triggering	O
asthma	B-PATH
exacerbation	O
(	O
11	O
%)	O
as	O
well	O
as	O
viral	O
pneumonia	O
causing	O
BPD	O
exacerbation	O
(	O
11	O
%).	O

We	O
sought	O
to	O
determine	O
the	O
contribution	O
of	O
respiratory	O
viruses	O
to	O
asthma	B-PATH
exacerbations	O
in	O
children	O
with	O
a	O
panel	O
of	O
PCR	O
assays	O
for	O
common	O
and	O
newly	O
discovered	O
respiratory	O
viruses	O
.	O

Upper	O
airway	O
disturbances	O
with	O
an	O
allergic	O
or	O
irritative	O
aetiology	O
are	O
very	O
frequent	O
;	O
Asthma	B-PATH
and	O
Hypersensitivity	O
Pneumonitis	O
are	O
more	O
rarely	O
reported	O
but	O
may	O
become	O
severe	O
and	O
widespread	O
when	O
certain	O
environmental	O
conditions	O
prevail	O
.	O

Whilst	O
this	O
is	O
increasingly	O
being	O
recognized	O
in	O
malaria	B-PATH
-	O
endemic	O
countries	O
,	O
clinicians	O
in	O
temperate	O
zones	O
should	O
be	O
aware	O
that	O
malaria	B-PATH
may	O
be	O
a	O
possible	O
cause	O
of	O
'	O
pneumonia	O
'	O
in	O
a	O
visiting	O
or	O
returning	O
child	O
.	O

These	O
results	O
demonstrate	O
that	O
oligodendrocyte	O
apoptosis	B-PATH
is	O
triggered	O
by	O
MHV	O
infection	O
during	O
cell	O
entry	O
through	O
the	O
activation	O
of	O
the	O
Fas	O
signaling	O
pathway	O
.	O

In	O
contrast	O
,	O
cholesterol	O
depletion	O
at	O
the	O
post	O
-	O
entry	O
stage	O
(	O
3h	O
post	O
-	O
infection	O
)	O
caused	O
only	O
a	O
limited	O
effect	O
on	O
virus	O
particle	O
release	B-PATH
.	O

All	O
patients	O
had	O
acquired	O
falciparum	O
malaria	B-PATH
in	O
sub	O
-	O
Saharan	O
Africa	O
.	O

An	O
acute	O
attack	O
of	O
malaria	B-PATH
does	O
not	O
confer	O
protection	O
from	O
future	O
attacks	O
:	O
individuals	O
who	O
have	O
had	O
malaria	B-PATH
should	O
take	O
effective	O
anti	O
-	O
mosquito	O
precautions	O
and	O
chemoprophylaxis	O
during	O
future	O
visits	O
to	O
endemic	O
areas	O
.	O

TITLE	O
:	O
5	O
'-	O
proximal	O
hot	O
spot	O
for	O
an	O
inducible	O
positive	O
-	O
to	O
-	O
negative	O
-	O
strand	O
template	O
switch	O
by	O
coronavirus	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

ABSTRACT	O
:	O
Production	O
of	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
core	O
protein	O
requires	O
the	O
cleavages	O
of	O
polyprotein	O
by	O
signal	O
peptidase	O
and	O
signal	O
peptide	O
peptidase	O
(	O
SPP	O
).	O

TITLE	O
:	O
Effective	O
inhibition	O
of	O
porcine	O
transmissible	O
gastroenteritis	O
virus	O
replication	O
in	O
ST	O
cells	O
by	O
shRNAs	O
targeting	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
gene	O
.	O

According	O
to	O
the	O
criteria	O
set	O
by	O
the	O
WHO	O
(	O
5	O
),	O
malaria	B-PATH
was	O
classified	O
as	O
severe	O
in	O
36	O
cases	O
.	O

Indeed	O
,	O
G3139	O
has	O
been	O
shown	O
to	O
cause	O
apoptosis	B-PATH
in	O
EBV	O
-	O
infected	O
cells	O
leading	O
to	O
clearance	O
of	O
the	O
virus	O
.	O

We	O
found	O
that	O
PLP1	O
processes	O
cleavage	O
site	O
1	O
to	O
release	B-PATH
nsp1	O
,	O
whereas	O
PLP2	O
is	O
responsible	O
for	O
processing	O
both	O
cleavage	O
sites	O
2	O
and	O
3	O
to	O
release	B-PATH
nsp2	O
and	O
nsp3	O
.	O

Interestingly	O
,	O
heat	O
shock	O
cognate	O
71	O
-	O
kDa	O
protein	O
(	O
HSP70	O
),	O
which	O
antagonizes	O
apoptosis	B-PATH
-	O
inducing	O
factor	O
was	O
shown	O
to	O
down	O
-	O
regulate	O
and	O
had	O
a	O
5	O
.	O
29	O
-	O
fold	O
decrease	O
.	O

These	O
results	O
indicate	O
that	O
SARS	O
-	O
CoV	O
3a	O
protein	O
,	O
through	O
limiting	O
the	O
expression	O
of	O
cyclin	O
D3	O
,	O
may	O
inhibit	O
Rb	O
phosphorylation	O
,	O
which	O
in	O
turn	O
leads	O
to	O
a	O
block	O
in	O
the	O
G1	O
phase	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
and	O
an	O
inhibition	O
of	O
cell	O
proliferation	O
.	O

TITLE	O
:	O
The	O
critically	O
ill	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
patient	O
.	O

ABSTRACT	O
:	O
This	O
review	O
examines	O
perspectives	O
of	O
human	O
infection	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
H5N1	O
(	O
AI	O
H5N1	O
),	O
specifically	O
focusing	O
on	O
the	O
presentation	O
,	O
diagnosis	O
,	O
and	O
management	O
of	O
those	O
critically	O
ill	O
with	O
AI	O
H5N1	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
overexpression	O
of	O
Bcl	O
-	O
XL	O
,	O
a	O
prosurvival	O
member	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
,	O
blocks	O
7a	O
-	O
induced	O
apoptosis	B-PATH
,	O
suggesting	O
that	O
the	O
mechanism	O
for	O
apoptosis	B-PATH
induction	O
by	O
7a	O
is	O
at	O
the	O
level	O
of	O
or	O
upstream	O
from	O
the	O
Bcl	O
-	O
2	O
family	O
.	O

TITLE	O
:	O
Drug	O
-	O
resistant	O
genital	O
tuberculosis	B-PATH
of	O
the	O
penis	O
in	O
a	O
human	O
immunodeficiency	O
virus	O
non	O
-	O
reactive	O
individual	O
.	O

In	O
conclusion	O
,	O
SARS	O
coronavirus	O
N	O
protein	O
can	O
induce	O
apoptosis	B-PATH
of	O
COS	O
-	O
1	O
cells	O
by	O
activating	O
mitochondrial	O
pathway	O
.	O

This	O
downregulation	O
,	O
which	O
is	O
reminiscent	O
of	O
a	O
cellular	O
stress	B-PATH
response	I-PATH
,	O
was	O
dependent	O
on	O
viral	O
replication	O
and	O
caused	O
by	O
mRNA	O
decay	O
.	O

ABSTRACT	O
:	O
Manipulation	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
and	O
induction	O
of	O
apoptosis	B-PATH
are	O
two	O
common	O
strategies	O
used	O
by	O
many	O
viruses	O
to	O
regulate	O
their	O
infection	O
cycles	O
.	O

This	O
conclusion	O
was	O
drawn	O
based	O
on	O
the	O
observations	O
that	O
apoptosis	B-PATH
occurred	O
in	O
both	O
IBV	O
-	O
infected	O
H1299	O
and	O
Vero	O
cells	O
,	O
and	O
that	O
IBV	O
infection	O
did	O
not	O
affect	O
the	O
expression	O
of	O
p53	O
in	O
host	O
cells	O
.	O

For	O
instance	O
,	O
ACE	O
has	O
been	O
shown	O
to	O
work	O
not	O
only	O
by	O
generating	O
angiotensin	O
-	O
II	O
but	O
also	O
by	O
interacting	O
with	O
receptors	O
outside	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
.	O

We	O
found	O
that	O
direct	O
induction	O
of	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
alpha	O
release	B-PATH
in	O
the	O
supernatant	O
in	O
a	O
dose	O
-,	O
time	O
-	O
dependent	O
manner	O
and	O
highly	O
spike	O
protein	O
-	O
specific	O
,	O
but	O
no	O
induction	O
of	O
IL	O
-	O
8	O
was	O
detected	O
.	O

ABSTRACT	O
:	O
All	O
plus	O
-	O
strand	O
RNA	O
viruses	O
encode	O
an	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
that	O
functions	O
as	O
the	O
catalytic	O
subunit	O
of	O
the	O
viral	O
replication	O
/	O
transcription	O
complex	O
,	O
directing	O
viral	O
RNA	O
synthesis	O
in	O
concert	O
with	O
other	O
viral	O
proteins	O
and	O
,	O
sometimes	O
,	O
host	O
proteins	O
.	O

The	O
second	O
exemplar	O
involves	O
the	O
newly	O
appreciated	O
complexity	O
of	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
as	O
a	O
regulator	O
of	O
the	O
cardiovascular	O
system	O
.	O

Furthermore	O
,	O
the	O
new	O
method	O
has	O
been	O
successfully	O
applied	O
to	O
the	O
screening	O
of	O
inhibitors	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
and	O
SARS	O
coronavirus	O
,	O
as	O
well	O
as	O
the	O
construction	O
of	O
quartz	O
crystal	O
microbalance	O
(	O
QCM	O
)	O
biosensor	O
for	O
human	O
interferon	O
-	O
beta	O
.	O

ABSTRACT	O
:	O
Infection	O
by	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
strain	O
A59	O
(	O
MHV	O
-	O
A59	O
)	O
requires	O
the	O
release	B-PATH
of	O
the	O
viral	O
genome	O
by	O
fusion	O
with	O
the	O
respective	O
target	O
membrane	O
of	O
the	O
host	O
cell	O
.	O

Deletion	O
of	O
gene	O
7	O
had	O
no	O
effect	O
on	O
SARS	O
-	O
CoV	O
replication	O
in	O
transformed	O
cell	O
lines	O
,	O
nor	O
did	O
it	O
alter	O
the	O
induction	O
of	O
early	O
apoptosis	B-PATH
markers	O
such	O
as	O
annexin	O
V	O
binding	O
and	O
activation	O
of	O
caspase	O
3	O
.	O

The	O
data	O
indicate	O
that	O
open	O
reading	O
frames	O
7a	O
and	O
7b	O
contribute	O
to	O
but	O
are	O
not	O
solely	O
responsible	O
for	O
the	O
apoptosis	B-PATH
seen	O
in	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
.	O

These	O
results	O
demonstrate	O
that	O
parasite	O
components	O
can	O
alter	O
endothelial	O
barrier	O
function	O
and	O
thus	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
severe	O
falciparum	O
malaria	B-PATH
.	O

Internalization	O
in	O
monocytes	O
was	O
efficient	O
and	O
proceeded	O
via	O
endocytosis	B-PATH
.	O

ABSTRACT	O
:	O
Between	O
50	O
%	O
and	O
80	O
%	O
of	O
asthma	B-PATH
exacerbations	O
are	O
associated	O
with	O
viral	O
respiratory	O
tract	O
infections	O
(	O
RTIs	O
),	O
yet	O
the	O
influence	O
of	O
viral	O
pathogen	O
diversity	O
on	O
asthma	B-PATH
outcomes	O
is	O
poorly	O
understood	O
because	O
of	O
the	O
limited	O
scope	O
and	O
throughput	O
of	O
conventional	O
viral	O
detection	O
methods	O
.	O

Among	O
25	O
patients	O
who	O
underwent	O
virus	O
studies	O
,	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
(	O
n	O
=	O
7	O
)	O
was	O
the	O
most	O
frequently	O
identified	O
agent	O
.	O

Rather	O
,	O
PLpro	O
interacts	O
with	O
IRF	O
-	O
3	O
and	O
inhibits	O
the	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
IRF	O
-	O
3	O
,	O
thereby	O
disrupting	O
the	O
activation	O
of	O
type	O
I	O
IFN	O
responses	O
through	O
either	O
Toll	O
-	O
like	O
receptor	O
3	O
or	O
retinoic	O
acid	O
-	O
inducible	O
gene	O
I	O
/	O
melanoma	B-PATH
differentiation	O
-	O
associated	O
gene	O
5	O
pathways	O
.	O

TITLE	O
:	O
5	O
'-	O
O	O
-	O
masked	O
2	O
'-	O
deoxyadenosine	O
analogues	O
as	O
lead	O
compounds	O
for	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
therapeutic	O
agents	O
.	O

Topics	O
covered	O
in	O
invited	O
lectures	O
included	O
detection	O
of	O
novel	O
respiratory	O
viral	O
pathogens	O
and	O
viral	O
evolution	O
,	O
characterization	O
of	O
the	O
1918	O
pandemic	O
virus	O
,	O
human	O
metapneumovirus	O
infections	O
,	O
human	O
respiratory	O
epithelial	O
cultures	O
for	O
studying	O
viral	O
pathogenesis	O
,	O
the	O
role	O
of	O
respiratory	O
viruses	O
in	O
the	O
pathogenesis	O
of	O
asthma	B-PATH
,	O
influenza	O
-	O
bacterial	O
interactions	O
,	O
advances	O
in	O
generating	O
vaccine	O
candidates	O
against	O
global	O
respiratory	O
threats	O
like	O
avian	O
influenza	O
and	O
SARS	O
,	O
antiviral	O
resistance	O
surveillance	O
in	O
influenza	O
viruses	O
,	O
and	O
a	O
mini	O
-	O
symposium	O
on	O
advances	O
in	O
viral	O
diagnostics	O
.	O

In	O
alveolar	O
epithelial	O
cells	O
exposed	O
to	O
severe	O
hypoxia	O
,	O
we	O
have	O
reported	O
that	O
increased	O
production	O
of	O
mitochondrial	O
reactive	O
oxygen	O
species	O
leads	O
to	O
Na	O
,	O
K	O
-	O
ATPase	O
endocytosis	B-PATH
and	O
degradation	O
.	O

Bordetella	O
bronchiseptica	O
and	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
)	O
are	O
respiratory	O
pathogens	O
of	O
pigs	O
whose	O
relatives	O
,	O
B	O
.	O
pertussis	B-PATH
and	O
the	O
SARS	O
virus	O
,	O
cause	O
respiratory	O
disease	O
in	O
humans	O
.	O

Of	O
these	O
,	O
nine	O
were	O
for	O
viral	O
diseases	O
,	O
including	O
four	O
against	O
HIV	O
,	O
two	O
against	O
hepatitis	B-PATH
C	I-PATH
virus	O
and	O
one	O
each	O
against	O
respiratory	O
syncytial	O
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
coronavirus	O
)	O
and	O
a	O
variety	O
of	O
viruses	O
.	O

Since	O
more	O
30	O
years	O
rhinovirus	O
,	O
coronavirus	O
,	O
enterovirus	O
,	O
parainfluenza	O
virus	O
and	O
respiratory	O
syncytial	O
virus	O
were	O
added	O
to	O
influenza	O
,	O
adenovirus	O
and	O
measles	B-PATH
virus	O
as	O
causes	O
of	O
respiratory	O
tract	O
infections	O
.	O

ABSTRACT	O
:	O
The	O
common	O
respiratory	O
viruses	O
,	O
including	O
influenza	B-PATH
A	I-PATH
,	O
influenza	O
B	O
,	O
and	O
newly	O
emerging	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
viruses	O
,	O
may	O
cause	O
similar	O
clinical	O
symptoms	O
.	O

A	O
comparison	O
of	O
intracellular	O
and	O
extracellular	O
virus	O
yields	O
suggested	O
that	O
release	B-PATH
is	O
only	O
slightly	O
impaired	O
.	O

Neurological	O
conditions	O
most	O
likely	O
result	O
in	O
cardiopulmonary	O
sequelae	O
as	O
a	O
result	O
of	O
an	O
interplay	O
between	O
enhanced	O
sympathetic	O
tone	O
,	O
inflammatory	O
cytokine	O
release	B-PATH
and	O
other	O
factors	O
.	O

The	O
emergence	O
of	O
antimicrobial	O
drug	O
resistance	O
among	O
bacterial	O
pathogens	O
,	O
the	O
reemergence	O
of	O
tuberculosis	B-PATH
,	O
the	O
entrance	O
of	O
HIV	O
into	O
Arctic	O
communities	O
,	O
and	O
the	O
spectre	O
of	O
pandemic	O
influenza	O
or	O
the	O
sudden	O
emergence	O
and	O
introduction	O
of	O
new	O
viral	O
pathogens	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
are	O
of	O
increasing	O
concern	O
to	O
residents	O
,	O
governments	O
,	O
and	O
public	O
health	O
authorities	O
.	O

The	O
more	O
severe	O
the	O
disease	O
,	O
the	O
more	O
intense	O
is	O
endotoxemia	O
but	O
the	O
lower	O
is	O
the	O
capacity	O
of	O
mononuclear	O
cells	O
to	O
release	B-PATH
cytokines	O
(	O
tolerance	O
).	O

In	O
-	O
situ	O
labelling	O
was	O
employed	O
in	O
order	O
to	O
demonstrate	O
cellular	O
apoptosis	B-PATH
in	O
the	O
cerebrum	O
,	O
but	O
there	O
was	O
no	O
evidence	O
of	O
apoptosis	B-PATH
within	O
the	O
myocardium	O
.	O

Shell	O
vial	O
culture	O
for	O
RSV	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
,	O
adenovirus	O
and	O
parainfluenza	O
viruses	O
1	O
,	O
2	O
,	O
3	O
was	O
performed	O
on	O
every	O
5th	O
sample	O
.	O

We	O
also	O
find	O
respiratory	O
infections	O
with	O
triple	O
viral	O
etiology	O
:	O
RSV	B-PATH
+	I-PATH
Influenza	I-PATH
A	I-PATH
virus	O
+	O
Rhinovirus	O
.	O

Interestingly	O
,	O
a	O
novel	O
homologue	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
,	O
termed	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
),	O
has	O
been	O
identified	O
as	O
a	O
receptor	O
for	O
SARS	O
-	O
CoV	O
.	O
Angiotensin	O
-	O
converting	O
enzyme	O
and	O
ACE2	O
share	O
homology	O
in	O
their	O
catalytic	O
domain	O
and	O
provide	O
different	O
key	O
functions	O
in	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
(	O
RAS	O
).	O

Clinical	O
diagnoses	O
included	O
9	O
pneumonia	O
,	O
6	O
bronchiolitis	O
,	O
2	O
cold	O
,	O
1	O
asthma	B-PATH
exacerbation	O
for	O
rhinovirus	O
;	O
10	O
pneumonia	O
,	O
4	O
bronchiolitis	O
,	O
and	O
1	O
clinical	O
sepsis	O
for	O
hPMV	O
;	O
and	O
1	O
pneumonia	O
,	O
2	O
croup	O
,	O
and	O
1	O
cold	O
for	O
coronavirus	O
.	O

TITLE	O
:	O
Parasite	O
burden	O
and	O
CD36	O
-	O
mediated	O
sequestration	O
are	O
determinants	O
of	O
acute	O
lung	O
injury	O
in	O
an	O
experimental	O
malaria	B-PATH
model	O
.	O

About	O
85	O
%	O
of	O
RSV	O
,	O
influenza	B-PATH
A	I-PATH
and	O
adenovirus	O
detections	O
were	O
associated	O
with	O
a	O
CFLI	O
,	O
whereas	O
less	O
than	O
62	O
%	O
of	O
other	O
virus	O
detections	O
were	O
associated	O
with	O
CFLI	O
.	O

Interestingly	O
,	O
when	O
the	O
cells	O
transiently	O
overexpressed	O
a	O
dominant	O
-	O
negative	O
form	O
(	O
DIII	O
)	O
of	O
Eps15	O
,	O
which	O
is	O
thought	O
to	O
be	O
an	O
essential	O
component	O
of	O
the	O
clathrin	O
pathway	O
,	O
viral	O
gene	O
expression	O
and	O
infectivity	O
were	O
unaffected	O
,	O
although	O
DIII	O
expression	O
blocked	O
transferrin	O
uptake	O
and	O
vesicular	O
stomatitis	O
virus	O
infection	O
,	O
which	O
are	O
dependent	O
on	O
clathrin	O
-	O
mediated	O
endocytosis	B-PATH
.	O

ABSTRACT	O
:	O
DC	O
-	O
SIGN	O
,	O
a	O
C	O
-	O
type	O
lectin	O
receptor	O
expressed	O
in	O
dendritic	O
cells	O
(	O
DCs	O
),	O
has	O
been	O
identified	O
as	O
a	O
receptor	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
Ebola	O
virus	O
,	O
cytomegalovirus	O
,	O
dengue	O
virus	O
,	O
and	O
the	O
SARS	O
coronavirus	O
.	O

In	O
young	O
mice	O
,	O
genes	O
related	O
to	O
cellular	O
development	O
,	O
cell	O
growth	O
,	O
and	O
cell	B-PATH
cycle	I-PATH
were	O
downregulated	O
during	O
peak	O
viral	O
replication	O
,	O
and	O
these	O
transcripts	O
returned	O
to	O
basal	O
levels	O
as	O
virus	O
was	O
cleared	O
.	O

In	O
direct	O
Annexin	O
V	O
staining	O
assays	O
,	O
the	O
3a	O
protein	O
-	O
expressing	O
cells	O
showed	O
increased	O
apoptosis	B-PATH
that	O
was	O
attenuated	O
with	O
the	O
p38	O
MAPK	O
inhibitor	O
SB203580	O
.	O

TITLE	O
:	O
A	O
SARS	O
-	O
CoV	O
protein	O
,	O
ORF	O
-	O
6	O
,	O
induces	O
caspase	O
-	O
3	O
mediated	O
,	O
ER	O
stress	O
and	O
JNK	O
-	O
dependent	O
apoptosis	B-PATH
.	O

After	O
exclusion	O
of	O
other	O
possible	O
causes	O
of	O
death	O
,	O
the	O
results	O
indicated	O
that	O
viral	B-PATH
myocarditis	I-PATH
was	O
the	O
cause	O
of	O
death	O
in	O
patients	O
with	O
adenovirus	O
infection	O
.	O

Immunofluorescence	O
was	O
performed	O
to	O
detect	O
Respiratory	O
Syncytial	O
Virus	O
,	O
Adenovirus	O
,	O
Parainfluenza	O
1	O
,	O
2	O
,	O
3	O
and	O
Influenza	B-PATH
A	I-PATH
and	O
B	O
.	O
Polymerase	O
Chain	O
Reaction	O
was	O
used	O
to	O
detect	O
Rhinovirus	O
,	O
Enterovirus	O
,	O
Metapneumovirus	O
,	O
Bocavirus	O
,	O
Adenovirus	O
and	O
Coronavirus	O
.	O

Overall	O
,	O
the	O
prevalence	O
of	O
detected	O
respiratory	O
viruses	O
was	O
:	O
Respiratory	O
Syncytial	O
Virus	O
55	O
(	O
43	O
%);	O
Rhinovirus	O
30	O
(	O
23	O
%);	O
Metapneumovirus	O
13	O
(	O
10	O
%);	O
Influenza	B-PATH
A	I-PATH
8	O
(	O
6	O
%);	O
Enterovirus	O
6	O
(	O
5	O
%);	O
Bocavirus	O
6	O
(	O
5	O
%);	O
Adenovirus	O
4	O
(	O
3	O
%);	O
Coronavirus	O
3	O
(	O
2	O
%);	O
Parainfluenza	O
1	O
:	O
2	O
(	O
1	O
%);	O
Influenza	O
B	O
,	O
1	O
(	O
1	O
%)	O
and	O
Parainfluenza	O
3	O
:	O
1	O
(	O
1	O
%).	O

We	O
sought	O
to	O
assess	O
whether	O
coexistent	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
infection	O
potentiated	O
the	O
hepatotoxic	O
effects	O
of	O
acetaminophen	O
.	O

ABSTRACT	O
:	O
Apolipoprotein	O
D	O
(	O
apoD	O
)	O
is	O
a	O
lipocalin	O
upregulated	O
in	O
the	O
nervous	O
system	O
after	O
injury	O
or	O
pathologies	O
such	O
as	O
Alzheimer	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
,	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
,	O
and	O
multiple	O
sclerosis	O
.	O

Later	O
posttransplant	O
,	O
infection	O
with	O
viruses	O
circulating	O
in	O
the	O
community	O
can	O
occur	O
with	O
a	O
number	O
of	O
pathogens	O
,	O
including	O
some	O
vaccine	O
-	O
preventable	O
illnesses	O
such	O
as	O
measles	B-PATH
and	O
mumps	O
.	O

Protease	O
inhibitor	O
development	O
is	O
most	O
advanced	O
for	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
),	O
and	O
we	O
also	O
provide	O
a	O
review	O
of	O
HCV	O
NS3	O
/	O
4A	O
serine	O
protease	O
inhibitor	O
development	O
,	O
including	O
combination	O
therapy	O
and	O
resistance	O
.	O

Vaccinia	O
virus	O
as	O
a	O
vector	O
for	O
the	O
full	O
-	O
length	O
IBV	O
cDNA	O
has	O
the	O
advantage	O
that	O
modifications	O
can	O
be	O
introduced	O
into	O
the	O
IBV	O
cDNA	O
using	O
homologous	B-PATH
recombination	I-PATH
,	O
a	O
method	O
frequently	O
used	O
to	O
insert	O
and	O
delete	O
sequences	O
from	O
the	O
vaccinia	O
virus	O
genome	O
.	O

Infectious	O
recombinant	O
IBVs	O
are	O
generated	O
in	O
situ	O
following	O
the	O
transfection	O
of	O
vaccinia	O
virus	O
DNA	O
containing	O
the	O
modified	O
IBV	O
cDNA	O
into	O
cells	O
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
DNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

TITLE	O
:	O
Severe	O
Plasmodium	O
vivax	O
malaria	B-PATH
:	O
a	O
report	O
on	O
serial	O
cases	O
from	O
Bikaner	O
in	O
northwestern	O
India	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
M	O
protein	O
is	O
an	O
essential	O
component	O
of	O
virion	O
and	O
plays	O
pivotal	O
roles	O
in	O
virion	O
assembly	O
,	O
budding	B-PATH
and	O
maturation	O
.	O

TITLE	O
:	O
Acute	O
disseminated	O
encephalomyelitis	O
developed	O
after	O
Mycoplasma	O
pneumoniae	O
infection	O
complicating	O
subclinical	O
measles	B-PATH
infection	O
.	O

He	O
was	O
diagnosed	O
with	O
subclinical	O
measles	B-PATH
infection	O
since	O
no	O
anthema	O
was	O
observed	O
despite	O
the	O
fact	O
that	O
his	O
serum	O
and	O
cerebrospinal	O
fluid	O
samples	O
were	O
positive	O
for	O
measles	B-PATH
IgM	O
antibodies	O
.	O

ADEM	O
following	O
mixed	O
infection	O
with	O
measles	B-PATH
and	O
M	O
.	O
pneumoniae	O
is	O
rare	O
,	O
and	O
it	O
is	O
not	O
clear	O
whether	O
an	O
additional	O
infection	O
with	O
measles	B-PATH
influenced	O
the	O
onset	O
of	O
ADEM	O
after	O
M	O
.	O
pneumoniae	O
infection	O
.	O

This	O
includes	O
potential	O
mechanisms	O
of	O
presynaptic	O
feedback	O
which	O
may	O
reduce	O
acetylcholine	O
release	B-PATH
and	O
postsynaptic	O
receptor	O
desensitization	O
and	O
provides	O
some	O
explanation	O
for	O
the	O
time	O
course	O
of	O
IMS	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
9b	O
protein	O
is	O
translated	O
from	O
bicistronic	O
mRNA9	O
via	O
leaky	O
ribosome	B-PATH
scanning	O
and	O
it	O
is	O
incorporated	O
into	O
both	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
and	O
purified	O
SARS	O
-	O
CoV	O
virions	O
.	O

Among	O
the	O
different	O
functions	O
identified	O
,	O
3a	O
is	O
a	O
capable	O
of	O
inducing	O
apoptosis	B-PATH
.	O

We	O
previously	O
showed	O
that	O
caspase	O
pathways	O
are	O
involved	O
in	O
3a	O
-	O
induced	O
apoptosis	B-PATH
.	O

As	O
ion	O
channel	O
activity	O
has	O
been	O
reported	O
to	O
regulate	O
apoptosis	B-PATH
in	O
different	O
pathologic	O
conditions	O
,	O
finding	O
ways	O
to	O
modulate	O
the	O
ion	O
channel	O
activity	O
may	O
offer	O
a	O
new	O
direction	O
toward	O
the	O
inhibition	O
of	O
apoptosis	B-PATH
triggered	O
by	O
SARS	O
-	O
CoV	O
.	O

TITLE	O
:	O
MAVS	O
-	O
mediated	O
apoptosis	B-PATH
and	O
its	O
inhibition	O
by	O
viral	O
proteins	O
.	O

Here	O
,	O
we	O
present	O
an	O
overview	O
of	O
recently	O
identified	O
substances	O
that	O
inhibit	O
and	O
/	O
or	O
reverse	O
endothelial	O
barrier	O
disruption	O
and	O
permeability	O
or	O
alveolar	O
epithelial	O
dysfunction	O
:	O
(	O
1	O
)	O
zinc	O
chelators	O
,	O
which	O
were	O
shown	O
to	O
attenuate	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
the	O
pulmonary	O
endothelium	O
;	O
(	O
2	O
)	O
peroxisome	B-PATH
proliferator	O
activated	O
receptor	O
(	O
PPAR	O
)	O
ligands	O
,	O
which	O
have	O
been	O
shown	O
to	O
exert	O
anti	O
-	O
inflammatory	O
effects	O
,	O
by	O
decreasing	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
genes	O
;	O
(	O
3	O
)	O
extracellular	O
ATP	O
,	O
produced	O
during	O
inflammation	O
,	O
which	O
induces	O
a	O
rapid	O
and	O
dose	O
-	O
dependent	O
increase	O
in	O
transendothelial	O
electrical	O
resistance	O
(	O
TER	O
)	O
across	O
pulmonary	O
endothelial	O
cells	O
;	O
(	O
4	O
)	O
the	O
lectin	O
-	O
like	O
domain	O
of	O
TNF	O
,	O
which	O
is	O
spatially	O
distinct	O
from	O
the	O
receptor	O
binding	O
sites	O
and	O
which	O
protects	O
from	O
hydrostatic	O
and	O
permeability	O
edema	O
and	O
(	O
5	O
)	O
Hsp90	O
inhibitors	O
,	O
which	O
prevent	O
and	O
repair	O
toxin	O
-	O
induced	O
hyperpermeability	O
.	O

Taken	O
together	O
,	O
CC	O
/	O
Fr	O
.	O
2	O
contains	O
unknown	O
substances	O
,	O
that	O
could	O
inhibit	O
the	O
infection	O
,	O
probably	O
by	O
interfering	O
with	O
endocytosis	B-PATH
,	O
and	O
it	O
also	O
contains	O
procyanidins	O
that	O
did	O
not	O
inhibit	O
the	O
internalization	O
but	O
inhibited	O
the	O
infection	O
.	O

ABSTRACT	O
:	O
This	O
retrospective	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
incidence	O
of	O
various	O
complications	O
of	O
Plasmodium	O
vivax	O
malaria	B-PATH
based	O
on	O
review	O
of	O
case	O
records	O
.	O

Based	O
on	O
these	O
results	O
we	O
believe	O
that	O
this	O
molecular	O
test	O
can	O
perform	O
an	O
important	O
role	O
as	O
a	O
sentinel	O
test	O
to	O
detect	O
novel	O
non	O
-	O
seasonal	O
influenza	B-PATH
A	I-PATH
viruses	O
in	O
patients	O
presenting	O
with	O
influenza	O
-	O
like	O
illness	O
(	O
ILI	O
)	O
and	O
therefore	O
act	O
as	O
an	O
early	O
warning	O
system	O
for	O
the	O
detection	O
of	O
future	O
pandemic	O
influenza	O
threats	O
.	O

Though	O
viral	O
respiratory	O
tract	O
infections	O
are	O
reported	O
triggers	O
for	O
exacerbations	O
,	O
information	O
on	O
these	O
infections	O
with	O
asthma	B-PATH
is	O
sparse	O
in	O
Caribbean	O
territories	O
.	O

TITLE	O
:	O
Pneumonia	O
and	O
respiratory	O
failure	O
from	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Mexico	O
.	O

In	O
those	O
returning	O
from	O
the	O
tropics	O
malaria	B-PATH
must	O
always	O
be	O
excluded	O
,	O
and	O
HIV	O
considered	O
,	O
from	O
all	O
settings	O
.	O

ABSTRACT	O
:	O
In	O
April	O
2009	O
,	O
CDC	O
reported	O
the	O
first	O
two	O
cases	O
in	O
the	O
United	O
States	O
of	O
human	O
infection	O
with	O
a	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
.	O

The	O
RSV	O
assay	O
was	O
applied	O
to	O
100	O
samples	O
and	O
the	O
Influenza	B-PATH
A	I-PATH
and	O
B	O
assay	O
applied	O
to	O
96	O
samples	O
all	O
of	O
which	O
had	O
been	O
tested	O
previously	O
by	O
an	O
""""	O
in	O
-	O
house	O
""""	O
multiplex	O
real	O
-	O
time	O
PCR	O
assay	O
.	O

Following	O
PRCV	O
infection	O
,	O
more	O
severe	O
PRRSV	O
-	O
related	O
pulmonary	O
alveolar	O
macrophage	O
(	O
PAM	O
)	O
apoptosis	B-PATH
occurred	O
,	O
as	O
determined	O
by	O
an	O
in	O
situ	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
end	O
labelling	O
assay	O
,	O
suggesting	O
increased	O
PRRSV	O
replication	O
in	O
PAMs	O
.	O

On	O
the	O
basis	O
of	O
this	O
study	O
,	O
four	O
different	O
plasmids	O
were	O
constructed	O
:	O
(	O
i	O
)	O
DNA	O
encoding	O
the	O
unmodified	O
N	O
(	O
p	O
-	O
N	O
)	O
or	O
N	O
(	O
70	O
-	O
122	O
)	O
(	O
p	O
-	O
N	O
(	O
70	O
-	O
122	O
))	O
as	O
an	O
endogenous	O
cytoplasmic	O
protein	O
or	O
(	O
ii	O
)	O
DNA	O
encoding	O
a	O
lysosome	B-PATH
-	O
associated	O
membrane	O
protein	O
(	O
LAMP	O
)	O
chimera	O
with	O
N	O
(	O
p	O
-	O
LAMP	O
/	O
N	O
)	O
or	O
N	O
(	O
70	O
-	O
122	O
)	O
(	O
p	O
-	O
LAMP	O
/	O
N	O
(	O
70	O
-	O
122	O
)).	O

general	O
ward	O
:	O
110	O
patients	O
with	O
oxygen	O
saturation	O
<	O
96	O
%	O
and	O
/	O
or	O
risk	O
factors	O
(	O
65	O
.	O
5	O
%	O
had	O
asthma	B-PATH
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
obesity	O
,	O
pregnancy	O
or	O
other	O
)	O
were	O
admitted	O
(	O
5	O
times	O
more	O
than	O
in	O
1999	O
-	O
2006	O
).	O

ABSTRACT	O
:	O
A	O
previous	O
study	O
demonstrated	O
that	O
infection	O
of	O
a	O
canine	O
fibrosarcoma	O
cell	O
line	O
(	O
A	O
-	O
72	O
cells	O
)	O
by	O
canine	O
coronavirus	O
(	O
CCoV	O
)	O
resulted	O
in	O
apoptosis	B-PATH
(	O
Ruggieri	O
et	O
al	O
.,	O
2007	O
).	O

ABSTRACT	O
:	O
Between	O
March	O
and	O
July	O
2009	O
,	O
the	O
largest	O
number	O
of	O
confirmed	O
cases	O
of	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
occurred	O
in	O
North	O
America	O
.	O

Among	O
the	O
168	O
patients	O
with	O
confirmed	O
or	O
probable	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
),	O
the	O
mean	O
(	O
SD	O
)	O
age	O
was	O
32	O
.	O
3	O
(	O
21	O
.	O
4	O
)	O
years	O
;	O
113	O
were	O
female	O
(	O
67	O
.	O
3	O
%)	O
and	O
50	O
were	O
children	O
(	O
29	O
.	O
8	O
%).	O

RESULTS	O
:	O
Critical	O
illness	O
occurred	O
in	O
215	O
patients	O
with	O
confirmed	O
(	O
n	O
=	O
162	O
),	O
probable	O
(	O
n	O
=	O
6	O
),	O
or	O
suspected	O
(	O
n	O
=	O
47	O
)	O
community	O
-	O
acquired	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

CONCLUSIONS	O
:	O
Critical	O
illness	O
due	O
to	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
Canada	O
occurred	O
rapidly	O
after	O
hospital	O
admission	O
,	O
often	O
in	O
young	O
adults	O
,	O
and	O
was	O
associated	O
with	O
severe	O
hypoxemia	O
,	O
multisystem	O
organ	O
failure	O
,	O
a	O
requirement	O
for	O
prolonged	O
mechanical	O
ventilation	O
,	O
and	O
the	O
frequent	O
use	O
of	O
rescue	O
therapies	O
.	O

TITLE	O
:	O
Extracorporeal	O
Membrane	O
Oxygenation	O
for	O
2009	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O

To	O
describe	O
the	O
characteristics	O
of	O
all	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
associated	O
ARDS	O
treated	O
with	O
ECMO	O
and	O
to	O
report	O
incidence	O
,	O
resource	O
utilization	O
,	O
and	O
patient	O
outcomes	O
.	O

Sixty	O
-	O
eight	O
patients	O
with	O
severe	O
influenza	O
-	O
associated	O
ARDS	O
were	O
treated	O
with	O
ECMO	O
,	O
of	O
whom	O
61	O
had	O
either	O
confirmed	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
(	O
n	O
=	O
53	O
)	O
or	O
influenza	B-PATH
A	I-PATH
not	O
subtyped	O
(	O
n	O
=	O
8	O
),	O
representing	O
an	O
incidence	O
rate	O
of	O
2	O
.	O
6	O
ECMO	O
cases	O
per	O
million	O
population	O
.	O

An	O
additional	O
133	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
received	O
mechanical	O
ventilation	O
but	O
no	O
ECMO	O
in	O
the	O
same	O
ICUs	O
.	O

ABSTRACT	O
:	O
Benign	O
acute	O
childhood	O
myositis	O
(	O
BACM	O
)	O
is	O
a	O
rare	O
transient	O
condition	O
usually	O
occurring	O
at	O
the	O
early	O
convalescent	O
phase	O
of	O
a	O
viral	O
upper	O
respiratory	O
tract	O
illness	O
,	O
normally	O
influenza	B-PATH
A	I-PATH
,	O
and	O
,	O
more	O
frequently	O
,	O
influenza	O
B	O
infection	O
.	O

Nsp1	O
also	O
induced	O
RNA	O
cleavage	O
in	O
templates	O
carrying	O
the	O
internal	O
ribosome	B-PATH
entry	O
site	O
(	O
IRES	O
)	O
from	O
encephalomyocarditis	O
virus	O
,	O
but	O
not	O
in	O
those	O
carrying	O
IRES	O
elements	O
from	O
hepatitis	B-PATH
C	I-PATH
or	O
cricket	O
paralysis	O
viruses	O
,	O
demonstrating	O
that	O
the	O
nsp1	O
-	O
induced	O
RNA	O
modification	O
was	O
template	O
-	O
dependent	O
.	O

ABSTRACT	O
:	O
An	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
is	O
the	O
central	O
catalytic	O
subunit	O
of	O
the	O
RNA	O
-	O
synthesizing	O
machinery	O
of	O
all	O
positive	O
-	O
strand	O
RNA	O
viruses	O
.	O

TITLE	O
:	O
Plasmodium	O
vivax	O
malaria	B-PATH
:	O
an	O
unusual	O
presentation	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
42	O
-	O
year	O
-	O
old	O
male	O
living	O
in	O
a	O
malaria	B-PATH
-	O
endemic	O
area	O
who	O
presented	O
with	O
ARDS	O
and	O
was	O
diagnosed	O
as	O
having	O
Plasmodium	O
vivax	O
malaria	B-PATH
.	O

ABSTRACT	O
:	O
During	O
the	O
past	O
decade	O
,	O
the	O
global	O
public	O
health	O
community	O
has	O
been	O
challenged	O
by	O
the	O
emergence	O
and	O
rapid	O
worldwide	O
spread	O
of	O
novel	O
influenza	O
strains	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
chikungunya	O
virus	O
,	O
drug	O
-	O
resistant	O
tuberculosis	B-PATH
,	O
and	O
other	O
conditions	O
and	O
pathogens	O
.	O

ABSTRACT	O
:	O
During	O
the	O
2009	O
H1N1	O
influenza	B-PATH
A	I-PATH
virus	O
pandemic	O
,	O
a	O
minority	O
of	O
patients	O
developed	O
rapidly	O
progressive	O
pneumonia	O
leading	O
to	O
acute	O
lung	O
injury	O
(	O
ALI	O
)-	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

All	O
three	O
defensins	B-PATH
were	O
also	O
readily	O
expressed	O
in	O
skin	O
samples	O
,	O
while	O
their	O
expression	O
in	O
lymphoid	O
tissues	O
and	O
the	O
kidney	O
was	O
low	O
and	O
inconsistent	O
.	O

We	O
conclude	O
that	O
early	O
respiratory	O
assessment	O
and	O
timely	O
PICU	O
referral	O
is	O
of	O
mainstem	O
importance	O
in	O
the	O
youngest	O
infants	O
with	O
measles	B-PATH
-	O
induced	O
respiratory	O
failure	O
.	O

Plasmodium	O
falciparum	O
malaria	B-PATH
and	O
to	O
some	O
extent	O
malaria	B-PATH
caused	O
by	O
other	O
species	O
of	O
Plasmodium	O
can	O
lead	O
to	O
many	O
complications	O
such	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
cerebral	O
malaria	B-PATH
,	O
acute	O
renal	O
failure	O
,	O
severe	O
anemia	O
,	O
thrombocytopenia	O
,	O
and	O
bleeding	O
complications	O
.	O

About	O
10	O
%	O
of	O
patients	O
with	O
severe	O
malaria	B-PATH
die	O
,	O
usually	O
as	O
a	O
result	O
of	O
multiorgan	O
dysfunction	O
.	O

In	O
this	O
article	O
,	O
we	O
review	O
the	O
different	O
manifestations	O
of	O
severe	O
malaria	B-PATH
as	O
relevant	O
to	O
critical	O
care	O
physicians	O
and	O
discuss	O
the	O
principles	O
of	O
laboratory	O
diagnosis	O
and	O
management	O
.	O

ABSTRACT	O
:	O
Severe	O
respiratory	O
failure	O
(	O
including	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
)	O
caused	O
by	O
2009	O
H1N1	O
influenza	B-PATH
infection	I-PATH
has	O
been	O
reported	O
worldwide	O
.	O

TITLE	O
:	O
Gamma	O
interferon	B-PATH
signaling	I-PATH
in	O
oligodendrocytes	O
is	O
critical	O
for	O
protection	O
from	O
neurotropic	O
coronavirus	O
infection	O
.	O

The	O
associated	O
Monte	O
Carlo	O
simulations	O
have	O
been	O
performed	O
for	O
SARS	O
-	O
CoV	O
E	O
protein	O
and	O
M2	O
protein	O
segment	O
(	O
residues	O
18	O
-	O
60	O
)	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

By	O
combining	O
these	O
data	O
with	O
quantitative	O
analyses	O
on	O
viral	O
RNA	O
,	O
protein	O
synthesis	O
and	O
virion	O
release	B-PATH
,	O
this	O
study	O
generates	O
an	O
integrated	O
molecular	O
and	O
ultrastructural	O
overview	O
of	O
CoV	O
infection	O
.	O

Four	O
scientific	O
search	O
engines	O
using	O
12	O
search	O
sequences	O
identified	O
21	O
mask	O
studies	O
in	O
healthcare	O
settings	O
for	O
the	O
prevention	O
of	O
transmission	O
of	O
respiratory	O
syncytial	O
virus	O
,	O
Bordetella	O
pertussis	B-PATH
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
possible	O
mechanism	O
responsible	O
for	O
the	O
antiviral	O
activity	O
,	O
the	O
induction	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
release	B-PATH
as	O
well	O
as	O
the	O
attachment	O
ability	O
of	O
LAB	O
on	O
the	O
cell	O
lines	O
was	O
investigated	O
.	O

We	O
want	O
to	O
underline	O
,	O
within	O
the	O
current	O
context	O
of	O
severe	O
respiratory	O
distresses	O
due	O
to	O
Influenza	B-PATH
A	I-PATH
pandemic	O
,	O
the	O
necessity	O
to	O
develop	O
a	O
multidisciplinary	O
care	O
network	O
,	O
or	O
to	O
reinforce	O
the	O
existing	O
channels	O
between	O
well	O
-	O
trained	O
medical	O
crews	O
familiar	O
with	O
ECMO	O
'	O
s	O
technics	O
and	O
the	O
ICU	O
that	O
are	O
not	O
.	O

Until	O
recently	O
,	O
intravenous	O
quinine	O
was	O
the	O
standard	O
treatment	O
;	O
however	O
,	O
artemisin	O
derivatives	O
are	O
now	O
regarded	O
as	O
the	O
first	O
-	O
line	O
treatment	O
for	O
multidrug	O
-	O
resistant	O
falciparum	O
malaria	B-PATH
.	O

To	O
investigate	O
the	O
effects	O
of	O
on	O
-	O
site	O
in	O
-	O
service	O
clinical	O
skills	O
training	O
for	O
nurse	O
practitioners	O
on	O
tuberculosis	B-PATH
(	O
TB	O
)	O
treatment	O
outcomes	O
in	O
the	O
same	O
clinics	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
resulting	O
from	O
novel	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H1N1	O
)	O
infection	O
remains	O
uncommon	O
.	O

To	O
describe	O
these	O
characteristics	O
in	O
patients	O
with	O
confirmed	O
,	O
probable	O
,	O
and	O
suspected	O
viral	O
pneumonia	O
caused	O
by	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
admitted	O
to	O
35	O
intensive	O
care	O
units	O
with	O
acute	O
respiratory	O
failure	O
requiring	O
mechanical	O
ventilation	O
in	O
Argentina	O
,	O
between	O
June	O
3	O
and	O
September	O
7	O
.	O

Of	O
these	O
,	O
15	O
were	O
female	O
and	O
16	O
had	O
identifiable	O
risk	O
factors	O
for	O
severe	O
disease	O
,	O
including	O
pregnancy	O
(	O
n	O
=	O
6	O
),	O
type	O
2	O
diabetes	O
mellitus	O
(	O
n	O
=	O
6	O
),	O
obesity	O
(	O
n	O
=	O
4	O
),	O
HIV	B-PATH
infection	I-PATH
(	O
n	O
=	O
3	O
),	O
immunosuppressive	O
therapy	O
(	O
n	O
=	O
3	O
)	O
and	O
active	O
pulmonary	O
tuberculosis	B-PATH
(	O
n	O
=	O
2	O
).	O

The	O
clinical	O
data	O
of	O
75	O
severe	O
influenza	B-PATH
A	I-PATH
H1N1	O
patients	O
were	O
analyzed	O
retrospectively	O
in	O
regard	O
to	O
common	O
features	O
,	O
clinical	O
symptoms	O
,	O
signs	O
,	O
laboratory	O
data	O
and	O
treatments	O
hospitalized	O
in	O
Qinghai	O
Hospital	O
for	O
Infectious	O
Diseases	O
during	O
September	O
4	O
,	O
2009	O
to	O
December	O
31	O
,	O
2009	O
.	O

The	O
first	O
case	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
H1N1	O
was	O
diagnosed	O
on	O
October	O
14	O
,	O
and	O
up	O
to	O
75	O
patients	O
(	O
47	O
.	O
78	O
%)	O
on	O
December	O
31	O
.	O

CONCLUSIONS	O
:	O
In	O
Qinghai	O
Province	O
,	O
cases	O
with	O
influenza	B-PATH
A	I-PATH
H1N1	O
peaked	O
early	O
with	O
relative	O
high	O
incidence	O
of	O
severe	O
cases	O
.	O

ABSTRACT	O
:	O
The	O
recently	O
emerged	O
novel	O
influenza	B-PATH
A	I-PATH
H1N1	O
virus	O
continues	O
to	O
spread	O
globally	O
.	O

The	O
present	O
review	O
highlights	O
the	O
drug	O
design	O
approaches	O
utilized	O
to	O
understand	O
the	O
mechanism	O
of	O
inhibition	O
and	O
discovery	O
of	O
inhibitors	O
against	O
protozoal	O
cysteine	O
protease	O
,	O
falcipain	O
(	O
a	O
cysteine	O
protease	O
of	O
P	O
.	O
falciparum	O
which	O
causes	O
malaria	B-PATH
),	O
and	O
viral	O
cysteine	O
protease	O
,	O
SARS	O
-	O
CoV	O
M	O
(	O
pro	O
)	O
(	O
a	O
cysteine	O
protease	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
corona	O
virus	O
).	O

A	O
large	O
number	O
of	O
cases	O
of	O
malaria	B-PATH
have	O
been	O
reported	O
from	O
the	O
State	O
of	O
Orissa	O
,	O
India	O
.	O

CONCLUSIONS	O
:	O
We	O
report	O
a	O
case	O
of	O
AMAN	O
variant	O
of	O
GBS	O
associated	O
with	O
proven	O
H1N1	O
influenza	B-PATH
A	I-PATH
infection	O
.	O

Three	O
children	O
,	O
aged	O
8	O
,	O
11	O
,	O
and	O
17	O
yrs	O
,	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
hemodynamic	O
compromise	O
related	O
to	O
the	O
2009	O
pH1N1	O
influenza	B-PATH
A	I-PATH
virus	O
documented	O
by	O
polymerase	O
chair	O
reaction	O
.	O

ABSTRACT	O
:	O
The	O
fi	O
rst	O
case	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
detected	O
in	O
Singapore	O
on	O
26	O
May	O
2009	O
,	O
1	O
month	O
after	O
the	O
fi	O
rst	O
cases	O
of	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
reported	O
in	O
California	O
and	O
Texas	O
in	O
the	O
United	O
States	O
.	O

RESULTS	O
:	O
Using	O
surface	O
plasmon	O
resonance	O
biomolecular	O
interaction	O
analysis	O
(	O
SPR	O
/	O
BIA	O
)	O
and	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
of	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
mass	O
spectrometry	O
,	O
we	O
found	O
that	O
only	O
the	O
proteasome	B-PATH
subunit	O
p42	O
from	O
human	O
fetal	O
lung	O
diploid	O
fibroblast	O
(	O
2BS	O
)	O
cells	O
bound	O
to	O
SARS	O
-	O
CoV	O
NP	O
.	O

MHV	O
assembly	O
and	O
release	B-PATH
were	O
,	O
however	O
,	O
not	O
appreciably	O
affected	O
by	O
these	O
compounds	O
.	O

ABSTRACT	O
:	O
Many	O
viruses	O
,	O
including	O
coronaviruses	O
(	O
CoVs	O
),	O
depend	O
on	O
a	O
functional	O
cellular	O
proteasome	B-PATH
for	O
efficient	O
infection	O
in	O
vitro	O
.	O

Many	O
people	O
have	O
experienced	O
risk	O
factors	O
,	O
e	O
.	O
g	O
.:	O
asthma	B-PATH
,	O
sarcoidosis	O
,	O
or	O
chronic	O
bronchitis	O
and	O
other	O
pulmonary	O
illness	O
.	O

TITLE	O
:	O
Severe	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
in	O
cancer	O
patients	O
.	O

TITLE	O
:	O
Right	O
and	O
left	O
heart	O
failure	O
in	O
severe	O
H1N1	O
influenza	B-PATH
A	I-PATH
infection	O
.	O

Patients	O
admitted	O
to	O
the	O
ICU	O
with	O
a	O
diagnosis	O
of	O
severe	O
pneumonia	O
,	O
ARDS	O
,	O
and	O
high	O
suspicion	O
of	O
influenza	B-PATH
A	I-PATH
H1N1	O
.	O

CONCLUSIONS	O
:	O
This	O
case	O
illustrates	O
the	O
serious	O
nature	O
of	O
malaria	B-PATH
in	O
the	O
pregnant	O
patient	O
.	O

As	O
demonstrated	O
by	O
the	O
international	O
response	O
to	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
influenza	B-PATH
A	I-PATH
,	O
rapid	O
genomic	O
sequencing	O
is	O
a	O
crucial	O
tool	O
to	O
understand	O
diseases	O
that	O
occur	O
at	O
the	O
interface	O
of	O
human	O
and	O
animal	O
populations	O
.	O

JHMV	O
infection	O
of	O
enriched	O
oligodendrocyte	O
progenitor	O
cell	O
(	O
OPC	O
)	O
cultures	O
revealed	O
that	O
apoptosis	B-PATH
was	O
associated	O
with	O
elevated	O
expression	O
of	O
cleaved	O
caspase	O
3	O
and	O
muted	O
Bcl	O
-	O
2	O
expression	O
.	O

TITLE	O
:	O
Synthesis	O
,	O
activity	O
,	O
and	O
pharmacokinetic	O
properties	O
of	O
a	O
series	O
of	O
conformationally	O
-	O
restricted	O
thiourea	O
analogs	O
as	O
novel	O
hepatitis	B-PATH
C	I-PATH
virus	O
inhibitors	O
.	O

Cytotoxicity	O
and	O
antiviral	O
activity	O
were	O
evaluated	O
against	O
herpes	O
simplex	O
virus	O
-	O
1	O
(	O
KOS	O
),	O
herpes	O
simplex	O
virus	O
-	O
2	O
(	O
G	O
),	O
vaccinia	O
virus	O
,	O
vesicular	O
stomatitis	O
virus	O
,	O
herpes	O
simplex	O
virus	O
-	O
1	O
TK	O
-	O
KOS	O
ACVr	O
,	O
para	O
influenza	O
-	O
3	O
virus	O
,	O
reovirus	O
-	O
1	O
,	O
Sindbis	O
virus	O
,	O
Coxsackie	O
virus	O
B4	O
,	O
Punta	O
Toro	O
virus	O
,	O
feline	O
corona	O
virus	O
(	O
FIPV	O
),	O
feline	O
herpes	O
virus	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
H1N1	O
subtype	O
,	O
influenza	B-PATH
A	I-PATH
H3N2	O
subtype	O
,	O
and	O
influenza	O
B	O
virus	O
.	O

Concomitantly	O
,	O
a	O
generic	O
and	O
classical	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
was	O
performed	O
to	O
detect	O
all	O
circulating	O
influenza	B-PATH
A	I-PATH
virus	O
strains	O
in	O
the	O
same	O
samples	O
.	O

Among	O
the	O
infections	O
,	O
25	O
(	O
83	O
%)	O
were	O
monoinfections	O
,	O
whereas	O
5	O
(	O
17	O
%)	O
were	O
multiple	O
infections	O
associating	O
influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
virus	O
with	O
coronavirus	O
(	O
CoV	O
),	O
human	O
bocavirus	O
(	O
HBoV	O
),	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
or	O
human	O
rhinoviruses	O
(	O
HRVs	O
).	O

Of	O
the	O
95	O
respiratory	O
samples	O
tested	O
,	O
35	O
(	O
37	O
%)	O
were	O
positive	O
for	O
respiratory	O
viruses	O
other	O
than	O
influenza	B-PATH
A	I-PATH
/	O
H1N1v	O
virus	O
.	O

TITLE	O
:	O
Rhabdomyolysis	O
following	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

These	O
results	O
may	O
have	O
infection	O
control	O
implications	O
for	O
other	O
airborne	O
infections	O
,	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
and	O
tuberculosis	B-PATH
,	O
as	O
well	O
as	O
for	O
pandemic	O
influenza	B-PATH
infection	I-PATH
.	O

Further	O
,	O
the	O
lysosome	B-PATH
-	O
tropic	O
reagents	O
failed	O
to	O
inhibit	O
,	O
whereas	O
the	O
heptad	O
repeat	O
peptide	O
efficiently	O
inhibited	O
viral	O
entry	O
into	O
cells	O
,	O
suggesting	O
that	O
TMPRSS2	O
affects	O
the	O
S	O
protein	O
at	O
the	O
cell	O
surface	O
and	O
induces	O
virus	O
-	O
plasma	O
membrane	O
fusion	O
.	O

Pearson	O
'	O
s	O
χ²	O
tests	O
and	O
logistic	O
regression	O
models	O
were	O
used	O
to	O
analyze	O
associations	O
between	O
seropositivity	O
for	O
coronaviruses	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
and	O
the	O
following	O
:	O
a	O
)	O
history	O
of	O
recurrent	O
mood	O
disorders	O
b	O
)	O
having	O
attempted	O
suicide	O
in	O
the	O
past	O
c	O
)	O
uni	O
-	O
vs	O
.	O
bi	O
-	O
polarity	O
and	O
d	O
)	O
presence	O
of	O
psychotic	O
symptoms	O
during	O
mood	O
episodes	O
.	O

While	O
the	O
ResPlex	O
II	O
and	O
MultiCode	O
-	O
PLx	O
offer	O
a	O
broader	O
virus	O
detection	O
range	O
and	O
greater	O
ease	O
of	O
use	O
,	O
the	O
xTAG	O
PRV	O
showed	O
increased	O
sensitivity	O
to	O
common	O
viral	O
targets	O
represented	O
in	O
the	O
assays	O
,	O
and	O
also	O
had	O
the	O
ability	O
to	O
differentiate	O
human	O
from	O
non	O
-	O
human	O
influenza	B-PATH
A	I-PATH
H1	O
.	O

Malaria	B-PATH
constituted	O
the	O
largest	O
bulk	O
(	O
of	O
which	O
95	O
.	O
9	O
%	O
of	O
the	O
2126	O
reported	O
cases	O
were	O
imported	O
),	O
followed	O
by	O
hepatitis	O
A	O
(	O
57	O
.	O
1	O
%	O
of	O
1053	O
cases	O
imported	O
),	O
typhoid	O
(	O
87	O
.	O
6	O
%	O
of	O
596	O
cases	O
imported	O
),	O
paratyphoid	O
(	O
87	O
.	O
6	O
%	O
of	O
241	O
cases	O
imported	O
),	O
and	O
hepatitis	O
E	O
(	O
68	O
.	O
8	O
%	O
of	O
231	O
cases	O
imported	O
).	O

The	O
RNA	O
synthesis	O
of	O
these	O
two	O
distantly	O
related	O
nidoviruses	O
is	O
catalyzed	O
by	O
an	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
which	O
is	O
the	O
core	O
enzyme	O
of	O
their	O
multiprotein	O
replication	O
and	O
transcription	O
complex	O
(	O
RTC	O
).	O

ABSTRACT	O
:	O
A	O
pandemic	O
(	O
H1N1	O
)	O
influenza	B-PATH
A	I-PATH
virus	O
was	O
identified	O
in	O
2009	O
.	O

Patients	O
who	O
received	O
corticosteroids	O
were	O
significantly	O
older	O
and	O
were	O
more	O
likely	O
to	O
have	O
coexisting	O
asthma	B-PATH
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
),	O
and	O
chronic	O
steroid	O
use	O
.	O

No	O
patients	O
required	O
hospitalization	O
either	O
due	O
to	O
primary	O
influenza	B-PATH
infection	I-PATH
or	O
secondary	O
complications	O
.	O

ABSTRACT	O
:	O
To	O
review	O
the	O
literature	O
on	O
novel	O
swine	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
2009	O
)	O
as	O
a	O
cause	O
of	O
respiratory	O
failure	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
During	O
the	O
2009	O
-	O
2010	O
winter	O
season	O
,	O
the	O
new	O
pandemic	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
virus	O
(	O
S	O
-	O
OIV	O
)	O
was	O
responsible	O
for	O
1	O
,	O
334	O
hospitalized	O
severe	O
infection	O
cases	O
including	O
312	O
(	O
23	O
.	O
4	O
%)	O
deaths	O
in	O
metropolitan	O
France	O
.	O

Infection	O
with	O
novel	O
(	O
swine	O
origin	O
)	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
was	O
confirmed	O
by	O
PCR	O
analysis	O
of	O
blood	O
as	O
well	O
as	O
myocardial	O
tissue	O
.	O

All	O
patients	O
presented	O
with	O
severe	O
cardiac	O
dysfunction	O
(	O
acute	O
heart	O
failure	O
,	O
cardiogenic	O
shock	O
or	O
cardiac	O
arrest	O
due	O
to	O
ventricular	O
fibrillation	O
)	O
as	O
the	O
leading	O
symptom	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

Acute	O
respiratory	O
distress	O
syndrome	O
due	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
developed	O
in	O
one	O
patient	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
may	O
be	O
associated	O
with	O
severe	O
cardiac	O
dysfunction	O
which	O
can	O
even	O
be	O
the	O
leading	O
clinical	O
symptom	O
at	O
presentation	O
.	O

ABSTRACT	O
:	O
Emerging	O
data	O
suggest	O
that	O
pregnancy	O
conveys	O
high	O
risk	O
for	O
severe	O
complications	O
from	O
the	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
2009	O
H1N1	O
)	O
infection	O
.	O

ABSTRACT	O
:	O
Interferon	O
-	O
inducible	O
transmembrane	O
proteins	O
1	O
,	O
2	O
,	O
and	O
3	O
(	O
IFITM1	O
,	O
2	O
,	O
and	O
3	O
)	O
are	O
recently	O
identified	O
viral	O
restriction	O
factors	O
that	O
inhibit	O
infection	O
mediated	O
by	O
the	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
hemagglutinin	O
(	O
HA	O
)	O
protein	O
.	O

The	O
Virochip	O
successfully	O
detected	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
in	O
serum	O
containing	O
6	O
.	O
10	O
×	O
10	O
(	O
2	O
)	O
viral	O
copies	O
per	O
microliter	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
lung	O
lavage	O
fluid	O
containing	O
2	O
.	O
08	O
×	O
10	O
(	O
6	O
)	O
viral	O
copies	O
per	O
microliter	O
.	O

TITLE	O
:	O
Computed	O
tomography	O
findings	O
from	O
patients	O
with	O
ARDS	O
due	O
to	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
-	O
associated	O
pneumonia	O
.	O

ABSTRACT	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
retrospectively	O
evaluate	O
whether	O
computed	O
tomography	O
(	O
CT	O
)	O
findings	O
have	O
prognostic	O
value	O
for	O
the	O
prediction	O
of	O
mortality	O
and	O
severity	O
of	O
the	O
clinical	O
course	O
in	O
patients	O
presenting	O
with	O
early	O
stage	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
due	O
to	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
S	O
-	O
OIV	O
).	O

ABSTRACT	O
:	O
Acute	O
lung	O
injury	O
(	O
ALI	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
virus	O
H5N1	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
supposedly	O
depend	O
on	O
activation	O
of	O
the	O
oxidative	O
-	O
stress	O
machinery	O
that	O
is	O
coupled	O
with	O
innate	O
immunity	O
,	O
resulting	O
in	O
a	O
strong	O
proinflammatory	O
host	O
response	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
establish	O
and	O
validate	O
assays	O
to	O
monitor	O
host	O
immune	O
responses	O
in	O
the	O
hamster	O
including	O
important	O
pro	O
-	O
inflammatory	O
,	O
anti	O
-	O
inflammatory	O
and	O
innate	O
immune	O
responses	O
,	O
as	O
well	O
as	O
markers	O
of	O
apoptosis	B-PATH
,	O
cell	O
proliferation	O
,	O
cell	O
junction	O
integrity	O
and	O
coagulation	O
.	O

ABSTRACT	O
:	O
The	O
open	O
-	O
reading	O
-	O
frame	O
3a	O
of	O
SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
had	O
been	O
demonstrated	O
previously	O
to	O
form	O
a	O
cation	O
-	O
selective	O
channel	O
that	O
may	O
become	O
expressed	O
in	O
the	O
infected	O
cell	O
and	O
is	O
then	O
involved	O
in	O
virus	O
release	B-PATH
.	O

We	O
conducted	O
a	O
prospective	O
observational	O
study	O
of	O
25	O
critically	O
ill	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
at	O
a	O
single	O
-	O
center	O
intensive	O
care	O
unit	O
in	O
Germany	O
between	O
5	O
October	O
2009	O
and	O
4	O
January	O
2010	O
.	O

The	O
severity	O
of	O
pandemic	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
/	O
2009	O
was	O
determined	O
by	O
massive	O
bilateral	O
pneumonia	O
,	O
interstitial	O
(	O
alveolar	O
)	O
pulmonary	O
edema	O
,	O
formation	O
of	O
diffuse	O
bilateral	O
lung	O
fibrosis	O
at	O
the	O
outcome	O
of	O
severe	O
virus	O
pneumonia	O
(	O
acute	O
respiratory	O
distress	O
syndrome	O
)	O
with	O
a	O
decrease	O
in	O
vital	O
and	O
diffusing	O
capacities	O
,	O
thereby	O
generating	O
a	O
need	O
to	O
follow	O
up	O
this	O
patient	O
category	O
and	O
,	O
possibly	O
,	O
to	O
elaborate	O
special	O
rehabilitation	O
programs	O
.	O

A	O
respiratory	O
pathogen	O
was	O
detected	O
in	O
41	O
%	O
of	O
tested	O
patient	O
samples	O
;	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
human	O
rhinovirus	O
were	O
both	O
detected	O
in	O
16	O
%.	O

TITLE	O
:	O
Fulminant	O
myocarditis	O
in	O
an	O
adult	O
with	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
influenza	O
)	O
infection	O
.	O

ABSTRACT	O
:	O
H1N1	O
subtype	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
has	O
clinical	O
presentation	O
ranging	O
from	O
mild	O
flu	O
like	O
illness	O
to	O
severe	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenator	O
rescue	O
and	O
airborne	O
transportation	O
of	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
a	O
Mediterranean	O
underserved	O
area	O
.	O

In	O
contrast	O
to	O
many	O
well	O
-	O
studied	O
enveloped	O
viruses	O
that	O
assemble	O
and	O
bud	O
at	O
the	O
plasma	O
membrane	O
,	O
coronaviruses	O
assemble	O
by	O
budding	B-PATH
into	O
the	O
lumen	O
of	O
the	O
endoplasmic	O
reticulum	O
-	O
Golgi	O
intermediate	O
compartment	O
and	O
are	O
released	O
from	O
the	O
cell	O
by	O
exocytosis	O
.	O

Legionellosis	B-PATH
,	O
foodborne	O
diseases	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
bovine	O
spongiform	O
encephalopathy	O
(	O
BSE	O
),	O
bioterrorism	O
,	O
meningococcal	O
meningitis	O
,	O
tuberculosis	B-PATH
,	O
heat	O
waves	O
,	O
and	O
influenza	O
epidemics	O
were	O
found	O
to	O
be	O
cause	O
for	O
most	O
public	O
health	O
crises	O
.	O

TITLE	O
:	O
Immunogenic	O
characterization	O
and	O
epitope	O
mapping	O
of	O
transmissible	O
gastroenteritis	O
virus	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

ABSTRACT	O
:	O
Increasing	O
number	O
of	O
epidemiological	O
and	O
clinical	O
studies	O
to	O
date	O
showed	O
that	O
the	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
,	O
by	O
its	O
characteristics	O
,	O
significantly	O
differs	O
from	O
infection	O
caused	O
by	O
seasonal	O
influenza	O
.	O

The	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
test	O
for	O
identification	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
was	O
positive	O
in	O
14	O
(	O
77	O
.	O
8	O
%),	O
while	O
pneumonia	O
was	O
verified	O
in	O
30	O
(	O
30	O
.	O
7	O
%)	O
of	O
the	O
patients	O
.	O

Proning	O
in	O
combination	O
with	O
APRV	O
provides	O
improvement	O
of	O
hypoxemia	O
with	O
limitation	O
of	O
end	O
-	O
organ	O
dysfunction	O
and	O
thereby	O
facilitates	O
recovery	O
from	O
severe	O
2009	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

Using	O
various	O
cell	B-PATH
cycle	I-PATH
inhibitors	O
,	O
we	O
have	O
shown	O
that	O
the	O
nuclear	O
entry	O
of	O
9b	O
is	O
independent	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
.	O

ABSTRACT	O
:	O
Most	O
patients	O
infected	O
with	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
/	O
H5N1	O
virus	O
develop	O
severe	O
pneumonia	O
resulting	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
with	O
extrarespiratory	O
disease	O
as	O
an	O
uncommon	O
complication	O
.	O

Rhinovirus	O
was	O
identified	O
in	O
33	O
%	O
of	O
patients	O
,	O
RSV	O
(	O
30	O
.	O
1	O
%),	O
PIV	O
-	O
3	O
(	O
7	O
.	O
8	O
%),	O
hBoV	O
(	O
6	O
.	O
1	O
%),	O
adenovirus	O
(	O
5	O
.	O
7	O
%),	O
hMPV	O
(	O
4	O
.	O
8	O
%),	O
influenza	B-PATH
A	I-PATH
(	O
3	O
.	O
4	O
%),	O
coronavirus	O
NL63	O
(	O
2	O
.	O
1	O
%),	O
and	O
OC43	O
(	O
1	O
.	O
8	O
%).	O

Nevertheless	O
,	O
cells	O
infected	O
with	O
rTGEV	O
-	O
Δ7	O
virus	O
showed	O
an	O
increased	O
cytopathic	O
effect	O
caused	O
by	O
an	O
enhanced	O
apoptosis	B-PATH
mediated	O
by	O
caspase	O
activation	O
.	O

TITLE	O
:	O
Serial	O
histopathological	O
examination	O
of	O
the	O
lungs	O
of	O
mice	O
infected	O
with	O
influenza	B-PATH
A	I-PATH
virus	O
PR8	O
strain	O
.	O

We	O
compared	O
the	O
effects	O
of	O
airway	O
pressure	O
release	B-PATH
ventilation	O
and	O
conventional	O
mechanical	O
ventilation	O
on	O
oxygenation	O
in	O
a	O
porcine	O
model	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
induced	O
by	O
wood	O
smoke	O
inhalation	O
.	O

Before	O
injury	O
,	O
the	O
pigs	O
were	O
randomized	O
to	O
receive	O
conventional	O
mechanical	O
ventilation	O
(	O
n	O
=	O
15	O
)	O
or	O
airway	O
pressure	O
release	B-PATH
ventilation	O
(	O
n	O
=	O
12	O
)	O
for	O
48	O
hrs	O
after	O
smoke	O
inhalation	O
.	O

Their	O
spleens	O
contained	O
infiltrated	O
megakaryocytes	O
with	O
DENV	O
-	O
2	O
antigen	O
-	O
positive	O
red	O
-	O
pulp	O
macrophages	O
,	O
while	O
their	O
livers	O
displayed	O
extensive	O
necrosis	O
,	O
apoptosis	B-PATH
and	O
macro	O
-	O
and	O
micro	O
-	O
steatosis	O
,	O
with	O
DENV	O
-	O
2	O
antigen	O
-	O
positive	O
Kuppfer	O
cells	O
and	O
hepatocytes	O
.	O

ABSTRACT	O
:	O
Legionellosis	B-PATH
is	O
a	O
systemic	O
disease	O
that	O
primarily	O
affects	O
the	O
lungs	O
.	O

TITLE	O
:	O
Health	O
care	O
provider	O
obligations	O
in	O
caring	O
for	O
patients	O
with	O
tuberculosis	B-PATH
.	O

Preliminary	O
comparisons	O
with	O
seasonal	O
influenza	O
suggest	O
that	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
disproportionately	O
affects	O
younger	O
ages	O
and	O
causes	O
generally	O
mild	O
disease	O
.	O

A	O
retrospective	O
study	O
on	O
62	O
severe	O
and	O
critically	O
ill	O
patients	O
with	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
conducted	O
in	O
Shanghai	O
Public	O
Health	O
Clinical	O
Center	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
two	O
severe	O
or	O
critically	O
ill	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
with	O
confirmed	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

TITLE	O
:	O
Comorbid	O
presentation	O
of	O
severe	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
Evans	O
syndrome	O
:	O
a	O
case	O
report	O
.	O

TITLE	O
:	O
Cerebral	O
edema	O
and	O
a	O
transtentorial	O
brain	O
herniation	O
syndrome	O
associated	O
with	O
pandemic	O
swine	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
.	O

ABSTRACT	O
:	O
Acute	O
encephalitis	O
,	O
encephalopathy	O
,	O
and	O
seizures	O
are	O
known	O
rare	O
neurologic	O
sequelae	O
of	O
respiratory	O
tract	O
infection	O
with	O
seasonal	O
influenza	B-PATH
A	I-PATH
and	O
B	O
virus	O
,	O
but	O
the	O
neurological	O
complications	O
of	O
the	O
pandemic	O
2009	O
swine	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
,	O
particularly	O
in	O
adults	O
,	O
are	O
ill	O
-	O
defined	O
.	O

Doctor	O
-	O
diagnoses	O
of	O
asthma	B-PATH
may	O
represent	O
asthma	B-PATH
or	O
wheezing	O
unrelated	O
to	O
asthma	B-PATH
.	O

We	O
describe	O
here	O
a	O
pregnant	O
woman	O
resuscitated	O
from	O
a	O
cardiac	O
arrest	O
due	O
to	O
acute	O
severe	O
asthma	B-PATH
,	O
and	O
an	O
inability	O
to	O
reach	O
a	O
consensus	O
based	O
on	O
published	O
guidelines	O
,	O
with	O
a	O
brief	O
overview	O
of	O
myoclonus	O
,	O
LAS	O
and	O
the	O
role	O
of	O
MRI	O
brain	O
in	O
assisting	O
prognostication	O
.	O

Paradoxically	O
,	O
these	O
failures	O
are	O
not	O
caused	O
by	O
a	O
defect	O
in	O
apoptosis	B-PATH
,	O
but	O
by	O
a	O
presumed	O
proliferative	O
function	O
of	O
this	O
protease	O
.	O

The	O
inhibition	O
of	O
the	O
respiratory	O
complexes	O
III	O
and	O
I	O
and	O
pyruvate	B-PATH
dehydrogenase	I-PATH
might	O
lead	O
to	O
the	O
increased	O
production	O
of	O
free	O
radical	O
resulting	O
in	O
oxidative	O
stress	O
and	O
cerebral	O
energy	O
disturbances	O
thereby	O
leading	O
to	O
mitochondrial	O
swelling	O
and	O
further	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
FHF	O
.	O

The	O
high	O
degree	O
of	O
sequence	O
identity	O
of	O
50	O
-	O
70	O
%	O
between	O
the	O
avian	O
and	O
mammalian	O
(	O
human	O
and	O
mouse	O
)	O
sPLA2	O
orthologs	O
suggests	O
a	O
conservation	O
of	O
important	O
enzymatic	O
functions	O
for	O
these	O
phospholipases	B-PATH
.	O

ABSTRACT	O
:	O
Perturbation	O
of	O
cell	B-PATH
cycle	I-PATH
regulation	O
is	O
a	O
characteristic	O
feature	O
of	O
infection	O
by	O
many	O
DNA	O
and	O
RNA	O
viruses	O
,	O
including	O
Coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
).	O

ABSTRACT	O
:	O
Pandemic	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
was	O
identified	O
as	O
the	O
major	O
febrile	O
respiratory	O
illness	O
worldwide	O
during	O
the	O
year	O
2009	O
.	O

TITLE	O
:	O
[	O
Causes	O
,	O
complications	O
and	O
risk	O
factors	O
of	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)].	O

Three	O
genotypes	O
,	O
A	O
,	O
B	O
and	O
C	O
,	O
of	O
HCoV	O
-	O
HKU1	O
and	O
homologous	B-PATH
recombination	I-PATH
among	O
their	O
genomes	O
,	O
are	O
observed	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
proapoptotic	O
proteins	O
BAX	O
,	O
cytochrome	O
c	O
(	O
CytC	O
),	O
and	O
apoptosis	B-PATH
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
were	O
relocalized	O
toward	O
the	O
mitochondria	O
,	O
cytosol	O
,	O
and	O
nucleus	O
,	O
respectively	O
,	O
after	O
infection	O
by	O
both	O
virus	O
variants	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
of	O
swine	O
origin	O
caused	O
human	O
infection	O
and	O
acute	O
respiratory	O
illness	O
in	O
Mexico	O
during	O
the	O
spring	O
of	O
2009	O
.	O

The	O
burden	O
and	O
character	O
of	O
pandemic	O
influenza	B-PATH
infection	I-PATH
in	O
developing	O
countries	O
are	O
still	O
incompletely	O
understood	O
.	O

CONCLUSIONS	O
:	O
The	O
burden	O
and	O
character	O
of	O
pandemic	O
influenza	B-PATH
infection	I-PATH
in	O
developing	O
countries	O
are	O
still	O
incompletely	O
understood	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
activities	O
of	O
a	O
number	O
of	O
thiazolides	O
[	O
2	O
-	O
hydroxyaroyl	O
-	O
N	O
-(	O
thiazol	O
-	O
2	O
-	O
yl	O
)	O
amides	O
]	O
against	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
genotypes	O
IA	O
and	O
IB	O
,	O
using	O
replicon	O
assays	O
.	O

ABSTRACT	O
:	O
Plasmodium	O
falciparum	O
and	O
to	O
some	O
extent	O
malaria	B-PATH
caused	O
by	O
other	O
species	O
of	O
Plasmodia	O
can	O
quickly	O
lead	O
to	O
cerebral	O
malaria	B-PATH
,	O
acute	O
renal	O
failure	O
,	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Most	O
of	O
the	O
patients	O
admitted	O
to	O
our	O
intensive	O
care	O
unit	O
due	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
associated	O
ARDS	O
were	O
previously	O
healthy	O
young	O
people	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
replication	O
and	O
transcription	O
are	O
processes	O
mediated	O
by	O
a	O
protein	O
complex	O
,	O
with	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
as	O
a	O
main	O
component	O
.	O

TITLE	O
:	O
Thoracic	O
computerized	O
tomographic	O
(	O
CT	O
)	O
findings	O
in	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
infection	O
in	O
Isfahan	O
,	O
Iran	O
.	O

Retrospectively	O
,	O
the	O
archive	O
of	O
all	O
patients	O
with	O
a	O
diagnosis	O
of	O
2009	O
H1N1	O
influenza	B-PATH
A	I-PATH
were	O
reviewed	O
,	O
in	O
Al	O
-	O
Zahra	O
Hospital	O
in	O
Isfahan	O
,	O
central	O
Iran	O
,	O
between	O
September	O
23	O
(	O
rd	O
)	O
2009	O
to	O
February	O
20	O
(	O
th	O
)	O
2010	O
.	O

ABSTRACT	O
:	O
Influenza	O
B	O
virus	O
infections	O
are	O
less	O
common	O
than	O
infections	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
virus	O
in	O
critically	O
ill	O
patients	O
,	O
but	O
similar	O
mortality	O
rates	O
have	O
been	O
observed	O
for	O
both	O
influenza	O
types	O
.	O

Our	O
previous	O
study	O
demonstrated	O
that	O
nsp1	O
induces	O
RNA	O
modification	O
near	O
the	O
5	O
'-	O
end	O
of	O
a	O
reporter	O
mRNA	O
having	O
a	O
short	O
5	O
'	O
untranslated	O
region	O
and	O
RNA	O
cleavage	O
in	O
the	O
encephalomyocarditis	O
virus	O
internal	O
ribosome	B-PATH
entry	O
site	O
(	O
IRES	O
)	O
region	O
of	O
a	O
dicistronic	O
RNA	O
template	O
,	O
but	O
not	O
in	O
those	O
IRES	O
elements	O
from	O
hepatitis	B-PATH
C	I-PATH
or	O
cricket	O
paralysis	O
viruses	O
.	O

ABSTRACT	O
:	O
The	O
appearance	O
of	O
eight	O
new	O
respiratory	O
viruses	O
,	O
including	O
the	O
SARS	O
coronavirus	O
in	O
2003	O
and	O
swine	O
-	O
origin	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
in	O
2009	O
,	O
in	O
the	O
human	O
population	O
in	O
the	O
past	O
nine	O
years	O
has	O
tested	O
the	O
ability	O
of	O
virology	O
laboratories	O
to	O
develop	O
diagnostic	O
tests	O
to	O
identify	O
these	O
viruses	O
.	O

None	O
of	O
the	O
studies	O
established	O
a	O
conclusive	O
relationship	O
between	O
mask	O
/	O
respirator	O
use	O
and	O
protection	O
against	O
influenza	B-PATH
infection	I-PATH
.	O

ABSTRACT	O
:	O
In	O
English	O
literature	O
,	O
there	O
are	O
only	O
2	O
specific	O
series	O
of	O
pandemic	O
H1N1	O
influenza	B-PATH
infection	I-PATH
in	O
children	O
with	O
leukemia	O
.	O

All	O
these	O
children	O
[	O
3	O
acute	O
lymphoblastic	O
leukemia	O
and	O
5	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
(	O
AML	B-PATH
)	O
cases	O
]	O
were	O
receiving	O
chemotherapy	O
during	O
the	O
course	O
of	O
infection	O
,	O
except	O
1	O
who	O
was	O
found	O
to	O
be	O
H1N1	O
positive	O
at	O
the	O
same	O
time	O
that	O
she	O
was	O
diagnosed	O
with	O
AML	B-PATH
.	O

ABSTRACT	O
:	O
The	O
resurgence	O
of	O
the	O
malaria	B-PATH
eradication	O
agenda	O
and	O
the	O
increasing	O
number	O
of	O
severe	O
manifestation	O
reports	O
has	O
contributed	O
to	O
a	O
renewed	O
interested	O
in	O
the	O
Plasmodium	O
vivax	O
infection	O
.	O

HSA	O
is	O
a	O
valuable	O
biomarker	O
of	O
many	O
diseases	O
,	O
including	O
cancer	O
,	O
rheumatoid	B-PATH
arthritis	I-PATH
,	O
ischemia	O
,	O
post	O
-	O
menopausal	O
obesity	O
,	O
severe	O
acute	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
,	O
and	O
diseases	O
that	O
need	O
monitoring	O
of	O
the	O
glycemic	O
control	O
.	O

In	O
contrast	O
,	O
an	O
immunofluorescence	O
assay	O
(	O
IFA	O
)	O
showed	O
that	O
depalmitylated	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SCoV	O
)	O
S	O
proteins	O
still	O
co	O
-	O
localized	O
with	O
the	O
M	O
protein	O
in	O
the	O
budding	B-PATH
site	O
.	O

ABSTRACT	O
:	O
The	O
diagnosis	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
is	O
mainly	O
clinical	O
,	O
particularly	O
during	O
peak	O
or	O
seasonal	O
flu	O
outbreaks	O
.	O

Molecular	O
methods	O
based	O
on	O
nucleic	O
acid	O
amplification	O
techniques	O
(	O
RT	O
-	O
PCR	O
)	O
are	O
the	O
gold	O
standard	O
for	O
the	O
diagnosis	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
.	O

We	O
propose	O
that	O
a	O
possibility	O
of	O
hidden	O
HSV	O
pneumonia	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
patients	O
with	O
prolonged	O
severe	O
pneumonia	O
due	O
to	O
influenza	B-PATH
infection	I-PATH
.	O

Interestingly	O
,	O
the	O
onset	O
of	O
apoptosis	B-PATH
occurred	O
earlier	O
in	O
IBV	O
-	O
infected	O
mammalian	O
cells	O
silenced	O
with	O
short	O
interfering	O
RNA	O
targeting	O
Mcl	O
-	O
1	O
(	O
siMcl	O
-	O
1	O
),	O
and	O
was	O
delayed	O
in	O
cells	O
silenced	O
with	O
siBak	O
.	O

Furthermore	O
,	O
RCoV	O
-	O
AT1	O
inhibited	O
spontaneous	O
PMN	O
apoptosis	B-PATH
,	O
including	O
activation	O
of	O
effector	O
caspase	O
3	O
and	O
initiator	O
caspases	O
8	O
and	O
9	O
.	O

Remarkably	O
,	O
the	O
same	O
protein	O
harboring	O
the	O
sequence	O
GPLG	O
instead	O
of	O
the	O
His	O
(	O
6	O
)	O
tag	O
at	O
its	O
N	O
terminus	O
exhibits	O
a	O
substantially	O
increased	O
,	O
primer	O
-	O
independent	O
RNA	B-PATH
polymerase	I-PATH
activity	O
.	O

In	O
addition	O
,	O
TGEV	O
infection	O
down	O
-	O
regulated	O
Bcl	O
-	O
2	O
,	O
up	O
-	O
regulated	O
Bax	O
expression	O
,	O
promoted	O
translocation	O
of	O
Bax	O
to	O
mitochondria	O
,	O
activated	O
mitochondria	O
-	O
mediated	O
apoptotic	O
pathway	O
,	O
which	O
in	O
turn	O
caused	O
the	O
release	B-PATH
of	O
cytochrome	O
c	O
and	O
the	O
activation	O
of	O
caspase	O
-	O
9	O
.	O

Real	O
-	O
time	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
testing	O
yielded	O
a	O
positive	O
result	O
for	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

Four	O
of	O
the	O
12	O
cases	O
were	O
co	O
-	O
infections	O
,	O
3	O
of	O
them	O
with	O
influenza	B-PATH
A	I-PATH
and	O
1	O
with	O
coronavirus	O
OC43	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
podocarpusflavone	O
A	O
(	O
2	O
)	O
is	O
the	O
strongest	O
noncytotoxic	O
non	O
-	O
nucleotide	O
molecule	O
exhibiting	O
a	O
specific	O
inhibitory	O
activity	O
against	O
the	O
RNA	B-PATH
polymerase	I-PATH
domain	O
of	O
DV	O
-	O
NS5	O
and	O
thus	O
is	O
promising	O
for	O
chemotherapy	O
development	O
against	O
dengue	O
fever	O
.	O

Recent	O
studies	O
in	O
our	O
laboratory	O
and	O
others	O
have	O
revealed	O
a	O
hitherto	O
unknown	O
correlation	O
between	O
chemokine	O
CXCL10	O
/	O
CXCR3	O
,	O
Heme	O
/	O
HO	O
-	O
1	O
and	O
STAT3	O
and	O
cerebral	O
malaria	B-PATH
severity	O
and	O
mortality	O
.	O

We	O
conclude	O
that	O
these	O
factors	O
are	O
mutually	O
regulated	O
and	O
provide	O
new	O
opportunities	O
to	O
develop	O
potential	O
novel	O
therapeutic	O
targets	O
that	O
could	O
be	O
used	O
to	O
supplement	O
traditional	O
prophylactics	O
and	O
treatments	O
for	O
malaria	B-PATH
and	O
improve	O
clinical	O
outcomes	O
while	O
reducing	O
malaria	B-PATH
mortality	O
.	O

As	O
a	O
result	O
,	O
15	O
-	O
16kb	O
nucleotide	O
sequences	O
encoding	O
complete	O
RNA	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
,	O
spike	O
,	O
envelope	O
,	O
membrane	O
,	O
and	O
nucleocapsid	O
proteins	O
plus	O
other	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
were	O
generated	O
.	O

ABSTRACT	O
:	O
Acylguanidines	O
are	O
a	O
new	O
class	O
of	O
antiviral	O
compounds	O
with	O
the	O
unique	O
ability	O
to	O
target	O
both	O
RNA	B-PATH
polymerase	I-PATH
and	O
transmembrane	O
proteins	O
of	O
viruses	O
from	O
different	O
families	O
.	O

Importantly	O
,	O
they	O
inhibit	O
proteins	O
which	O
are	O
not	O
targeted	O
by	O
existing	O
antiviral	O
therapies	O
,	O
for	O
example	O
,	O
Vpu	O
of	O
HIV	O
type	O
1	O
,	O
p7	O
of	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
E	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
and	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
of	O
coxsackievirus	O
B3	O
.	O

During	O
chronic	O
disease	O
,	O
CXCR2	O
signaling	O
on	O
oligodendroglia	O
protects	O
these	O
cells	O
from	O
apoptosis	B-PATH
and	O
restricts	O
the	O
severity	O
of	O
demyelination	O
.	O

The	O
aim	O
was	O
to	O
verify	O
whether	O
being	O
overweight	O
could	O
have	O
played	O
a	O
critical	O
role	O
in	O
cases	O
of	O
mortality	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
in	O
pregnant	O
women	O
.	O

It	O
could	O
not	O
be	O
verified	O
whether	O
being	O
overweight	O
was	O
a	O
factor	O
of	O
higher	O
mortality	O
due	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
amongst	O
pregnant	O
women	O
in	O
the	O
state	O
of	O
Mexico	O
.	O

ABSTRACT	O
:	O
The	O
influenza	B-PATH
A	I-PATH
(	O
H1N1pdm09	O
)	O
[	O
pH1N1	O
]	O
virus	O
resulted	O
in	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
admissions	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
death	O
.	O

TITLE	O
:	O
θ	O
-	O
Defensins	B-PATH
:	O
cyclic	O
peptides	O
with	O
endless	O
potential	O
.	O

θ	O
-	O
Defensins	B-PATH
have	O
multiple	O
arginines	O
and	O
a	O
ladder	O
-	O
like	O
tridisulfide	O
array	O
spanning	O
their	O
two	O
antiparallel	O
β	O
-	O
strands	O
.	O

Ns2	O
cleaves	O
2	O
',	O
5	O
'-	O
oligoadenylate	O
,	O
the	O
product	O
of	O
OAS	O
,	O
to	O
prevent	O
activation	O
of	O
the	O
cellular	O
endoribonuclease	O
RNase	O
L	O
and	O
consequently	O
block	O
viral	O
RNA	B-PATH
degradation	I-PATH
.	O

ABSTRACT	O
:	O
The	O
novel	O
pandemic	O
(	O
pdm	O
)	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
virus	O
caused	O
an	O
epidemic	O
of	O
critical	O
illness	O
,	O
with	O
some	O
patients	O
developing	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

SSYA10	O
-	O
001	O
did	O
not	O
inhibit	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
helicase	O
,	O
other	O
bacterial	O
and	O
viral	O
RNA	O
-	O
dependent	O
RNA	O
polymerases	O
,	O
or	O
reverse	O
transcriptase	O
.	O

TITLE	O
:	O
Use	O
of	O
intravenous	O
peramivir	O
for	O
treatment	O
of	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
.	O

RESULTS	O
:	O
Of	O
17	O
autopsies	O
,	O
13	O
revealed	O
that	O
death	O
could	O
be	O
attributed	O
to	O
P	O
.	O
vivax	O
infection	O
;	O
in	O
the	O
remaining	O
4	O
,	O
acute	O
diseases	O
other	O
than	O
malaria	B-PATH
were	O
found	O
to	O
be	O
the	O
cause	O
of	O
death	O
.	O

ABSTRACT	O
:	O
A	O
30	O
-	O
year	O
-	O
old	O
female	O
experienced	O
severe	O
acute	O
respiratory	O
distress	O
in	O
her	O
apartment	O
assumed	O
to	O
be	O
due	O
to	O
an	O
allergic	O
asthma	B-PATH
.	O

TITLE	O
:	O
Biochemical	O
characterization	O
of	O
a	O
recombinant	O
SARS	O
coronavirus	O
nsp12	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
capable	O
of	O
copying	O
viral	O
RNA	O
templates	O
.	O

ABSTRACT	O
:	O
During	O
2009	O
occurred	O
the	O
emergence	O
and	O
global	O
spread	O
of	O
a	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
.	O

We	O
describe	O
the	O
clinical	O
and	O
epidemiologic	O
features	O
of	O
hospitalized	O
patients	O
who	O
survived	O
and	O
patients	O
who	O
died	O
because	O
of	O
pandemic	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
reported	O
in	O
Santa	O
Fe	O
,	O
Argentina	O
,	O
from	O
May	O
to	O
July	O
2009	O
.	O

A	O
changing	O
epidemiology	O
was	O
demonstrated	O
,	O
with	O
obesity	O
and	O
pregnancy	O
beyond	O
established	O
risk	O
groups	O
for	O
influenza	B-PATH
A	I-PATH
,	O
other	O
clinical	O
syndromes	O
beyond	O
primary	O
viral	O
pneumonia	O
,	O
possible	O
coinfections	O
by	O
other	O
viral	O
beyond	O
bacterial	O
pathogens	O
and	O
a	O
disappointing	O
performance	O
of	O
all	O
available	O
severity	O
assessment	O
tools	O
.	O

TITLE	O
:	O
Plasmodium	O
vivax	O
malaria	B-PATH
admissions	O
and	O
risk	O
of	O
mortality	O
in	O
a	O
tertiary	O
-	O
care	O
children	O
'	O
s	O
hospital	O
in	O
North	O
India	O
.	O

A	O
retrospective	O
chart	O
review	O
of	O
patients	O
admitted	O
with	O
parasitologically	O
confirmed	O
malaria	B-PATH
between	O
January	O
and	O
December	O
2010	O
.	O

CONCLUSIONS	O
:	O
Increased	O
morbidity	O
owing	O
to	O
P	O
.	O
vivax	O
malaria	B-PATH
was	O
observed	O
and	O
risk	O
of	O
mortality	O
was	O
highest	O
in	O
patients	O
with	O
ARDS	O
and	O
MODS	O
.	O

TITLE	O
:	O
Respiratory	O
manifestations	O
of	O
malaria	B-PATH
.	O

The	O
best	O
antimalarial	O
treatment	O
of	O
severe	O
malaria	B-PATH
is	O
IV	O
artesunate	O
.	O

Greater	O
than	O
90	O
%	O
of	O
all	O
deaths	O
from	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
occur	O
in	O
the	O
elderly	O
(>	O
65	O
years	O
of	O
age	O
).	O

PLpro	O
-	O
activated	O
ubiquitin	O
proteasome	B-PATH
pathway	O
via	O
upregulation	O
of	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
E2	O
-	O
25k	O
and	O
proteasome	B-PATH
subunit	O
alpha	O
type	O
5	O
.	O

Newly	O
identified	O
viruses	O
such	O
as	O
pandemic	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
,	O
human	O
metapneumovirus	O
,	O
human	O
bocavirus	O
,	O
and	O
human	O
coronavirus	O
NL63	O
were	O
not	O
detected	O
in	O
our	O
population	O
,	O
except	O
for	O
1	O
human	O
coronavirus	O
NL63	O
.	O

TITLE	O
:	O
[	O
Peculiarities	O
of	O
clinical	O
and	O
X	O
-	O
ray	O
picture	O
of	O
pneumonia	O
in	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)].	O

In	O
order	O
to	O
study	O
the	O
ramifications	O
caused	O
by	O
both	O
infections	O
within	O
the	O
same	O
host	O
we	O
established	O
an	O
experimental	O
mouse	O
model	O
of	O
co	O
-	O
infection	O
between	O
Mycobacterium	O
tuberculosis	B-PATH
and	O
Plasmodium	O
berghei	O
NK65	O
,	O
a	O
recently	O
described	O
model	O
for	O
MA	O
-	O
ARDS	O
.	O

Using	O
the	O
natural	O
routes	O
of	O
infection	O
,	O
we	O
observed	O
that	O
co	O
-	O
infection	O
exacerbated	O
chronic	O
tuberculosis	B-PATH
while	O
rendering	O
mice	O
less	O
refractory	O
to	O
Plasmodium	O
.	O

While	O
9	O
(	O
53	O
%)	O
of	O
17	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
decedents	O
with	O
available	O
data	O
had	O
obesity	O
and	O
7	O
(	O
17	O
%)	O
of	O
40	O
had	O
diabetes	O
,	O
less	O
than	O
4	O
%	O
of	O
surviving	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
case	O
-	O
patients	O
had	O
these	O
pre	O
-	O
existing	O
conditions	O
(	O
p	O
≤	O
0	O
.	O
001	O
).	O

In	O
vitro	O
experiments	O
,	O
the	O
result	O
showed	O
the	O
representative	O
SARS	O
-	O
CoV	O
ssRNAs	O
had	O
powerful	O
immunostimulatory	O
activities	O
to	O
induce	O
considerable	O
level	O
of	O
pro	O
-	O
inflammatory	O
cytokine	O
TNF	O
-	O
a	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
12	O
release	B-PATH
via	O
the	O
TLR7	O
and	O
TLR8	O
,	O
almost	O
2	O
-	O
fold	O
higher	O
than	O
the	O
strong	O
stimulatory	O
ssRNA40	O
that	O
was	O
found	O
previously	O
from	O
other	O
virus	O
.	O

Bortezomib	O
is	O
a	O
proteasome	B-PATH
inhibitor	O
indicated	O
for	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
patients	O
.	O

ABSTRACT	O
:	O
Many	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
receive	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
as	O
a	O
rescue	O
therapy	O
.	O

When	O
patients	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)-	O
related	O
ARDS	O
treated	O
with	O
ECMO	O
were	O
compared	O
with	O
conventionally	O
treated	O
patients	O
,	O
no	O
difference	O
in	O
mortality	O
rates	O
existed	O
.	O

The	O
major	O
clinical	O
symptoms	O
associated	O
with	O
HCoV	O
-	O
HKU1	O
infection	O
were	O
examined	O
statistically	O
and	O
sequence	O
variations	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
spike	O
,	O
and	O
nucleocapsid	O
genes	O
were	O
also	O
analyzed	O
.	O

Cytoadherence	O
of	O
infected	O
red	O
blood	O
cells	O
to	O
the	O
vascular	O
endothelium	O
of	O
different	O
organs	O
and	O
rosetting	O
are	O
unique	O
features	O
of	O
malaria	B-PATH
parasites	O
which	O
are	O
likely	O
to	O
contribute	O
to	O
the	O
vascular	O
damage	O
and	O
the	O
consequent	O
excessive	O
inflammatory	O
/	O
immune	O
response	O
of	O
the	O
host	O
.	O

Viral	O
infections	O
were	O
detected	O
in	O
3	O
of	O
the	O
'	O
well	O
'	O
weeks	O
and	O
17	O
of	O
the	O
'	O
sick	O
'	O
weeks	O
(	O
10	O
rhinovirus	O
,	O
three	O
coronavirus	O
,	O
two	O
influenza	B-PATH
A	I-PATH
,	O
two	O
influenza	O
B	O
,	O
two	O
respiratory	O
syncytial	O
virus	O
,	O
one	O
parainfluenza	O
).	O

We	O
conclude	O
that	O
in	O
children	O
with	O
asthma	B-PATH
,	O
naturally	O
occurring	O
viral	O
infections	O
apparently	O
induce	O
a	O
robust	O
innate	O
immune	O
response	O
including	O
expression	O
of	O
specific	O
chemokines	O
,	O
IFNs	O
,	O
and	O
IFN	O
-	O
responsive	O
genes	O
.	O

To	O
analyze	O
the	O
clinical	O
and	O
laboratory	O
characteristics	O
of	O
patients	O
hospitalized	O
for	O
vivax	O
malaria	B-PATH
in	O
Apartadó	O
.	O

TITLE	O
:	O
Three	O
-	O
dimensional	O
architecture	O
and	O
biogenesis	O
of	O
membrane	O
structures	O
associated	O
with	O
hepatitis	B-PATH
C	I-PATH
virus	O
replication	O
.	O

TITLE	O
:	O
Lessons	O
from	O
the	O
history	O
of	O
quarantine	O
,	O
from	O
plague	O
to	O
influenza	B-PATH
A	I-PATH
.	O
ABSTRACT	O
:	O
In	O
the	O
new	O
millennium	O
,	O
the	O
centuries	O
-	O
old	O
strategy	O
of	O
quarantine	O
is	O
becoming	O
a	O
powerful	O
component	O
of	O
the	O
public	O
health	O
response	O
to	O
emerging	O
and	O
reemerging	O
infectious	O
diseases	O
.	O

We	O
therefore	O
diagnosed	O
her	O
with	O
miliary	O
tuberculosis	B-PATH
complicated	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
disseminated	O
intravascular	O
coagulation	O
(	O
DIC	O
).	O

The	O
majority	O
of	O
persons	O
with	O
asthma	B-PATH
had	O
an	O
uncomplicated	O
course	O
;	O
however	O
,	O
severe	O
disease	O
,	O
including	O
ICU	O
admission	O
and	O
death	O
,	O
occurred	O
in	O
asthma	B-PATH
patients	O
who	O
presented	O
with	O
pneumonia	O
.	O

RESULTS	O
:	O
Among	O
473	O
cases	O
,	O
29	O
%	O
had	O
asthma	B-PATH
.	O

RESULTS	O
:	O
When	O
compared	O
with	O
health	O
outcomes	O
among	O
formula	O
-	O
fed	O
children	O
,	O
the	O
health	O
advantages	O
associated	O
with	O
breastfeeding	O
include	O
a	O
lower	O
risk	O
of	O
acute	O
otitis	O
media	O
,	O
gastroenteritis	O
and	O
diarrhea	O
,	O
severe	O
lower	O
respiratory	O
infections	O
,	O
asthma	B-PATH
,	O
sudden	O
infant	O
death	O
syndrome	O
,	O
obesity	O
and	O
other	O
childhood	O
diseases	O
and	O
conditions	O
.	O

Human	O
AEC	O
appear	O
to	O
protect	O
human	O
PMVEC	O
barrier	O
function	O
under	O
septic	O
conditions	O
in	O
vitro	O
,	O
through	O
release	B-PATH
of	O
a	O
soluble	O
mediator	O
(	O
s	O
),	O
which	O
are	O
at	O
least	O
partly	O
lipid	O
in	O
nature	O
.	O

HBP	O
concentrations	O
are	O
markedly	O
elevated	O
in	O
all	O
critically	O
ill	O
patients	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
infection	O
.	O

It	O
is	O
postulated	O
that	O
excess	O
inflammation	O
and	O
cytokine	O
production	O
in	O
obese	O
patients	O
following	O
severe	O
influenza	B-PATH
infection	I-PATH
leads	O
to	O
viral	O
pneumonitis	O
and	O
/	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

TITLE	O
:	O
Severe	O
imported	O
falciparum	O
malaria	B-PATH
among	O
adults	O
requiring	O
intensive	O
care	O
:	O
a	O
retrospective	O
study	O
at	O
the	O
hospital	O
for	O
tropical	O
diseases	O
,	O
London	O
.	O

Retrospective	O
study	O
of	O
patients	O
with	O
WHO	O
severe	O
falciparum	O
malaria	B-PATH
admitted	O
to	O
ICU	O
at	O
the	O
Hospital	O
for	O
Tropical	O
Diseases	O
,	O
London	O
,	O
UK	O
.	O

TITLE	O
:	O
Complicated	O
falciparum	O
Malaria	B-PATH
in	O
western	O
Maharashtra	O
.	O

Plasmodium	O
falciparum	O
malaria	B-PATH
is	O
a	O
syndrome	O
and	O
a	O
disease	O
of	O
protean	O
clinical	O
manifestations	O
.	O

The	O
most	O
common	O
discharge	O
diagnoses	O
were	O
""""	O
URTI	O
""""	O
with	O
or	O
without	O
LRTI	O
/	O
asthma	B-PATH
(	O
n	O
=	O
58	O
).	O

TITLE	O
:	O
Acute	O
acalculous	O
cholecystitis	O
in	O
malaria	B-PATH
:	O
a	O
review	O
of	O
seven	O
cases	O
from	O
an	O
adult	O
cohort	O
.	O

To	O
our	O
knowledge	O
,	O
only	O
case	O
reports	O
of	O
AAC	O
related	O
to	O
12	O
malaria	B-PATH
adult	O
patients	O
have	O
been	O
published	O
.	O

Sequencing	O
analyses	O
revealed	O
that	O
all	O
the	O
genes	O
from	O
these	O
three	O
viruses	O
were	O
of	O
avian	O
origin	O
,	O
with	O
six	O
internal	O
genes	O
from	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H9N2	O
)	O
viruses	O
.	O

Of	O
these	O
,	O
7	O
risk	O
factors	O
were	O
significantly	O
associated	O
with	O
severe	O
ALRI	O
in	O
a	O
consistent	O
manner	O
across	O
studies	O
,	O
with	O
the	O
following	O
meta	O
-	O
analysis	O
estimates	O
of	O
odds	O
ratios	O
(	O
with	O
95	O
%	O
confidence	O
intervals	O
):	O
low	O
birth	O
weight	O
3	O
.	O
18	O
(	O
1	O
.	O
02	O
-	O
9	O
.	O
90	O
),	O
lack	O
of	O
exclusive	O
breastfeeding	O
2	O
.	O
34	O
(	O
1	O
.	O
42	O
-	O
3	O
.	O
88	O
),	O
crowding	O
-	O
more	O
than	O
7	O
persons	O
per	O
household	O
1	O
.	O
96	O
(	O
1	O
.	O
53	O
-	O
2	O
.	O
52	O
),	O
exposure	O
to	O
indoor	O
air	O
pollution	O
1	O
.	O
57	O
(	O
1	O
.	O
06	O
-	O
2	O
.	O
31	O
),	O
incomplete	O
immunization	O
1	O
.	O
83	O
(	O
1	O
.	O
32	O
-	O
2	O
.	O
52	O
),	O
undernutrition	O
-	O
weight	O
-	O
for	O
-	O
age	O
less	O
than	O
2	O
standard	O
deviations	O
4	O
.	O
47	O
(	O
2	O
.	O
10	O
-	O
9	O
.	O
49	O
),	O
and	O
HIV	B-PATH
infection	I-PATH
4	O
.	O
15	O
(	O
2	O
.	O
57	O
-	O
9	O
.	O
74	O
).	O

In	O
the	O
process	O
,	O
they	O
can	O
pause	O
the	O
elongating	O
ribosome	B-PATH
for	O
regulation	O
.	O

Some	O
patients	O
treated	O
with	O
blinatumomab	O
and	O
other	O
T	O
cell	O
-	O
activating	O
therapies	O
develop	O
cytokine	O
release	B-PATH
syndrome	O
(	O
CRS	O
).	O

ABSTRACT	O
:	O
Severe	O
malaria	B-PATH
causes	O
nearly	O
one	O
million	O
deaths	O
annually	O
in	O
endemic	O
areas	O
and	O
is	O
a	O
public	O
health	O
priority	O
worldwide	O
.	O

The	O
sequestration	O
of	O
cerebral	O
vasculature	O
with	O
parasitized	O
red	O
blood	O
cells	O
is	O
one	O
of	O
the	O
proposed	O
mechanisms	O
for	O
the	O
development	O
of	O
cerebral	O
malaria	B-PATH
.	O

Several	O
events	O
have	O
since	O
stimulated	O
progress	O
in	O
public	O
health	O
emergency	O
planning	O
:	O
the	O
1997	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
outbreak	O
in	O
Hong	O
Kong	O
,	O
China	O
;	O
the	O
2001	O
anthrax	O
attacks	O
in	O
the	O
United	O
States	O
;	O
the	O
2003	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
;	O
and	O
the	O
2003	O
reemergence	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
infection	O
in	O
humans	O
.	O

These	O
results	O
suggested	O
that	O
PHEV	O
induces	O
apoptosis	B-PATH
in	O
PK	O
-	O
15	O
cells	O
via	O
a	O
caspase	O
-	O
dependent	O
pathway	O
.	O

Thrombocytopenia	O
,	O
leukopenia	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
hypotension	O
,	O
mucosal	O
bleeding	O
were	O
seen	O
as	O
frequently	O
as	O
in	O
falciparum	O
and	O
mixed	O
malaria	B-PATH
.	O

TITLE	O
:	O
Plasmodium	O
vivax	O
malaria	B-PATH
presenting	O
as	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
a	O
case	O
report	O
.	O

Patients	O
with	O
severe	O
malaria	B-PATH
reported	O
to	O
the	O
US	O
national	O
malaria	B-PATH
surveillance	O
system	O
during	O
1985	O
-	O
2010	O
were	O
matched	O
,	O
and	O
survival	O
outcomes	O
were	O
compared	O
between	O
patients	O
receiving	O
and	O
not	O
receiving	O
ET	O
.	O

Main	O
ARDS	O
etiologies	O
were	O
bacterial	O
(	O
45	O
%),	O
influenza	B-PATH
A	I-PATH
[	O
H₁N₁	O
]	O
(	O
26	O
%)	O
and	O
post	O
-	O
operative	O
(	O
17	O
%)	O
pneumonias	O
.	O

In	O
this	O
article	O
the	O
case	O
of	O
a	O
38	O
-	O
year	O
old	O
hemodialyzed	O
patient	O
who	O
became	O
ill	O
with	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
(	O
AML	O
)	O
three	O
years	O
after	O
being	O
diagnosed	O
with	O
von	O
Hippel	O
-	O
Lindau	O
disease	O
is	O
presented	O
.	O

TITLE	O
:	O
Severe	O
Measles	B-PATH
Infection	O
:	O
The	O
Spectrum	O
of	O
Disease	O
in	O
36	O
Critically	O
Ill	O
Adult	O
Patients	O
.	O

One	O
patient	O
had	O
developed	O
measles	B-PATH
during	O
childhood	O
.	O

Measles	B-PATH
-	O
associated	O
pneumonitis	O
and	O
its	O
complications	O
,	O
and	O
less	O
commonly	O
postinfectious	O
encephalomyelitis	O
,	O
are	O
the	O
main	O
source	O
of	O
morbidity	O
and	O
mortality	O
.	O

Severe	O
malaria	B-PATH
was	O
defined	O
as	O
per	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
criteria	O
.	O

Accessory	O
protein	O
4a	O
was	O
found	O
to	O
block	O
interferon	O
induction	O
at	O
the	O
level	O
of	O
melanoma	B-PATH
differentiation	O
-	O
associated	O
protein	O
5	O
(	O
MDA5	O
)	O
activation	O
presumably	O
by	O
direct	O
interaction	O
with	O
double	O
-	O
stranded	O
RNA	O
.	O

ABSTRACT	O
:	O
The	O
2009	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pandemic	O
highlighted	O
the	O
importance	O
of	O
quality	O
hospital	O
care	O
of	O
the	O
severely	O
ill	O
,	O
yet	O
there	O
is	O
evidence	O
that	O
the	O
impact	O
of	O
the	O
2009	O
pandemic	O
was	O
highest	O
in	O
low	O
-	O
and	O
middle	O
-	O
income	O
countries	O
with	O
fewer	O
resources	O
.	O

TGEV	O
infection	O
promoted	O
p21	O
accumulation	O
,	O
down	O
-	O
regulated	O
cell	B-PATH
cycle	I-PATH
-	O
regulatory	O
proteins	O
cyclins	O
B1	O
,	O
cdc2	O
,	O
cdk2	O
and	O
PCNA	O
.	O

These	O
experiments	O
show	O
that	O
if	O
S	O
protein	O
on	O
MERS	O
pseudovirions	O
is	O
uncleaved	O
,	O
then	O
viruses	O
enter	O
by	O
endocytosis	B-PATH
in	O
a	O
cathepsin	O
L	O
-	O
dependent	O
manner	O
,	O
but	O
if	O
MERS	O
-	O
CoV	O
S	O
is	O
cleaved	O
,	O
either	O
during	O
virus	O
maturation	O
by	O
serine	O
proteases	O
or	O
on	O
pseudovirions	O
by	O
trypsin	O
in	O
extracellular	O
fluids	O
,	O
then	O
viruses	O
enter	O
at	O
the	O
plasma	O
membrane	O
at	O
neutral	O
pH	O
and	O
cause	O
massive	O
syncytia	O
formation	O
even	O
in	O
cells	O
that	O
express	O
little	O
or	O
no	O
MERS	O
-	O
CoV	O
receptor	O
.	O

Demographic	O
analyses	O
revealed	O
that	O
the	O
school	O
/	O
daycare	O
attendance	O
was	O
the	O
only	O
parameter	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
for	O
influenza	B-PATH
infection	I-PATH
.	O

Samples	O
were	O
tested	O
with	O
multiplexed	O
-	O
PCR	O
,	O
using	O
an	O
automated	O
system	O
for	O
nine	O
respiratory	O
viruses	O
,	O
Chlamydophila	O
pneumoniae	O
,	O
Mycoplasma	O
pneumoniae	O
,	O
and	O
Bordetella	O
pertussis	B-PATH
.	O

TITLE	O
:	O
Extracorporeal	O
membrane	O
oxygenation	O
for	O
refractory	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
severe	O
malaria	B-PATH
.	O

TITLE	O
:	O
Pharmacotherapy	O
of	O
critical	O
asthma	B-PATH
syndrome	O
:	O
current	O
and	O
emerging	O
therapies	O
.	O

Immunomodulation	O
with	O
drugs	O
like	O
omalizumab	O
in	O
IgE	O
-	O
mediated	O
asthma	B-PATH
syndromes	O
is	O
one	O
important	O
approach	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
a	O
major	O
public	O
health	O
problem	O
in	O
the	O
south	O
-	O
east	O
Asian	O
region	O
.	O

There	O
have	O
been	O
case	O
reports	O
of	O
complications	O
like	O
thrombocytopaenia	O
,	O
cerebral	O
malaria	B-PATH
,	O
a	O
disseminated	O
intravascular	O
coagulation	O
,	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
hepatic	O
dysfunction	O
and	O
renal	O
involvement	O
.	O

CONCLUSIONS	O
:	O
Plasmodium	O
vivax	O
is	O
emerging	O
as	O
a	O
cause	O
of	O
severe	O
malaria	B-PATH
.	O

Sequencing	O
of	O
the	O
malaria	B-PATH
parasite	O
DNA	O
from	O
both	O
cases	O
,	O
followed	O
by	O
multiple	O
sequence	O
alignment	O
and	O
phylogenetic	O
tree	O
construction	O
suggested	O
that	O
the	O
causative	O
agent	O
for	O
both	O
malaria	B-PATH
cases	O
was	O
P	O
.	O
ovale	O
curtisi	O
.	O

We	O
recommend	O
that	O
primary	O
care	O
physicians	O
refer	O
patients	O
promptly	O
to	O
an	O
asthma	B-PATH
specialist	O
for	O
consultation	O
to	O
reduce	O
the	O
frequency	O
of	O
acute	O
exacerbations	O
and	O
prevent	O
the	O
development	O
of	O
CAS	O
.	O

Previous	O
studies	O
indicate	O
that	O
TGEV	O
infection	O
induces	O
cell	O
apoptosis	B-PATH
in	O
host	O
cells	O
.	O

However	O
,	O
only	O
TNFR1	O
(-/-)	O
mice	O
were	O
resistant	O
to	O
MHV	O
-	O
3	O
mediated	O
FH	O
,	O
as	O
displayed	O
by	O
a	O
dramatic	O
decrease	O
in	O
tissue	O
necrosis	O
and	O
cell	O
apoptosis	B-PATH
in	O
the	O
infected	O
spleens	O
and	O
livers	O
from	O
TNFR1	O
(-/-)	O
mice	O
,	O
as	O
well	O
as	O
prolonged	O
survival	O
in	O
these	O
mice	O
compared	O
to	O
wild	O
type	O
littermate	O
controls	O
.	O

There	O
are	O
still	O
over	O
2	O
million	O
deaths	O
annually	O
from	O
tuberculosis	B-PATH
,	O
with	O
most	O
of	O
these	O
occurring	O
in	O
the	O
developing	O
world	O
.	O

Respiratory	O
syncytial	O
virus	O
,	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
and	O
pertussis	B-PATH
are	O
other	O
respiratory	O
infectious	O
diseases	O
with	O
special	O
problems	O
of	O
their	O
own	O
,	O
from	O
vaccine	O
development	O
to	O
vaccine	O
coverage	O
.	O

This	O
article	O
describes	O
national	O
trends	O
in	O
seasonal	O
influenza	O
vaccine	O
(	O
IV	O
)	O
coverage	O
in	O
Portugal	O
from	O
1998	O
/	O
99	O
to	O
2010	O
/	O
11	O
,	O
analyzes	O
progress	O
towards	O
meeting	O
WHO	O
2010	O
coverage	O
goals	O
,	O
and	O
addresses	O
the	O
effect	O
of	O
major	O
public	O
health	O
threats	O
of	O
the	O
last	O
12	O
years	O
(	O
SARS	O
in	O
2003	O
/	O
04	O
,	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
in	O
2005	O
/	O
06	O
,	O
and	O
the	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
2009	O
pandemic	O
)	O
on	O
vaccination	O
trends	O
.	O

The	O
genes	O
in	O
the	O
1	O
-	O
Mb	O
windows	O
surrounding	O
each	O
single	O
nucleotide	O
polymorphism	O
with	O
significant	O
effect	O
for	O
the	O
antibody	O
level	O
against	O
IBV	O
were	O
associated	O
with	O
many	O
biological	O
processes	O
or	O
pathways	O
related	O
to	O
immunity	O
,	O
such	O
as	O
the	O
defense	O
response	O
and	O
mTOR	B-PATH
signaling	I-PATH
pathway	I-PATH
.	O

However	O
,	O
new	O
threats	O
such	O
as	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
present	O
continued	O
challenges	O
,	O
reinforcing	O
the	O
need	O
to	O
improve	O
the	O
global	O
capacity	O
to	O
prevent	O
,	O
detect	O
,	O
and	O
respond	O
to	O
public	O
health	O
threats	O
.	O

ABSTRACT	O
:	O
This	O
was	O
a	O
retrospective	O
study	O
done	O
on	O
110	O
patients	O
hospitalized	O
with	O
P	O
.	O
vivax	O
malaria	B-PATH
in	O
three	O
medical	O
college	O
hospitals	O
,	O
one	O
in	O
the	O
union	O
territory	O
of	O
Chandigarh	O
and	O
the	O
other	O
two	O
in	O
Gujarat	O
,	O
that	O
is	O
,	O
Ahmedabad	O
and	O
Surat	O
.	O

WHO	O
guidelines	O
for	O
treatment	O
of	O
P	O
.	O
vivax	O
malaria	B-PATH
need	O
to	O
be	O
reinforced	O
.	O

Coronavirus	O
surveillance	O
studies	O
in	O
different	O
populations	O
of	O
bats	O
have	O
suggested	O
that	O
they	O
are	O
probable	O
reservoirs	O
for	O
this	O
novel	O
virus	O
,	O
and	O
phylogenetic	O
analysis	O
of	O
both	O
the	O
spike	O
(	O
S1	O
)	O
and	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
proteins	O
of	O
MERS	O
-	O
CoV	O
have	O
revealed	O
that	O
it	O
is	O
related	O
to	O
bat	O
viruses	O
.	O

TITLE	O
:	O
TGEV	O
nucleocapsid	O
protein	O
induces	O
cell	B-PATH
cycle	I-PATH
arrest	O
and	O
apoptosis	B-PATH
through	O
activation	O
of	O
p53	O
signaling	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
TGEV	O
N	O
protein	O
might	O
play	O
an	O
important	O
role	O
in	O
TGEV	O
infection	O
-	O
induced	O
p53	O
activation	O
and	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
the	O
S	O
and	O
G2	O
/	O
M	O
phases	O
and	O
apoptosis	B-PATH
occurrence	O
.	O

ABSTRACT	O
:	O
Neuroleptic	O
malignant	O
-	O
like	O
syndrome	O
(	O
NMLS	O
)	O
is	O
a	O
rare	O
but	O
catastrophic	O
complication	O
of	O
drug	O
treatment	O
for	O
Parkinson	B-PATH
'	I-PATH
s	I-PATH
disease	I-PATH
(	O
PD	O
).	O

TITLE	O
:	O
Imported	O
falciparum	O
malaria	B-PATH
among	O
adults	O
requiring	O
intensive	O
care	O
:	O
analysis	O
of	O
the	O
literature	O
.	O

ABSTRACT	O
:	O
Malaria	B-PATH
is	O
the	O
most	O
important	O
imported	O
tropical	O
disease	O
.	O

TITLE	O
:	O
Prevalence	O
and	O
molecular	O
characterization	O
of	O
human	O
metapneumovirus	O
in	O
influenza	B-PATH
a	I-PATH
negative	O
sample	O
in	O
Thailand	O
.	O

A	O
total	O
of	O
1	O
,	O
184	O
nasopharyngeal	O
washes	O
were	O
collected	O
from	O
hospitalized	O
patients	O
and	O
sent	O
to	O
the	O
Department	O
of	O
Microbiology	O
,	O
Siriraj	O
Hospital	O
,	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
detection	O
.	O

TITLE	O
:	O
ARDS	O
associated	O
with	O
pneumonia	O
caused	O
by	O
avian	O
influenza	B-PATH
A	I-PATH
H7N9	O
virus	O
treated	O
with	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

Interestingly	O
,	O
compound	O
4e	O
could	O
inhibit	O
not	O
only	O
HBsAg	O
and	O
HBeAg	O
secretions	O
but	O
also	O
HBV	O
DNA	B-PATH
replication	I-PATH
with	O
SI	O
values	O
of	O
20	O
.	O
3	O
,	O
125	O
.	O
0	O
and	O
104	O
.	O
9	O
.	O

With	O
respect	O
to	O
release	B-PATH
,	O
all	O
possibilities	O
appear	O
to	O
occur	O
.	O

We	O
report	O
the	O
case	O
of	O
complicated	O
P	O
.	O
vivax	O
malaria	B-PATH
in	O
a	O
previously	O
healthy	O
42	O
-	O
year	O
-	O
old	O
Greek	O
female	O
.	O

The	O
most	O
frequently	O
detected	O
pathogens	O
were	O
respiratory	O
syncytial	O
virus	O
(	O
768	O
/	O
2361	O
,	O
32	O
.	O
5	O
%),	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
428	O
/	O
2361	O
,	O
18	O
.	O
1	O
%),	O
enterovirus	O
(	O
138	O
/	O
2361	O
,	O
13	O
.	O
3	O
%),	O
Mycoplasma	O
pneumoniae	O
(	O
267	O
/	O
2361	O
,	O
11	O
.	O
3	O
%)	O
and	O
adenovirus	O
(	O
213	O
/	O
2361	O
,	O
9	O
.	O
0	O
%).	O

ABSTRACT	O
:	O
A	O
63	O
-	O
year	O
-	O
old	O
Caucasian	O
woman	O
developed	O
severe	O
Plasmodium	O
falciparum	O
malaria	B-PATH
when	O
travelling	O
back	O
from	O
Cameroun	O
.	O

TITLE	O
:	O
Importin	O
-	O
α7	O
is	O
required	O
for	O
enhanced	O
influenza	B-PATH
A	I-PATH
virus	O
replication	O
in	O
the	O
alveolar	O
epithelium	O
and	O
severe	O
lung	O
damage	O
in	O
mice	O
.	O

ABSTRACT	O
:	O
Subphenotypes	O
have	O
been	O
identified	O
within	O
heterogeneous	O
diseases	O
such	O
as	O
asthma	B-PATH
and	O
breast	O
cancer	O
,	O
with	O
important	O
therapeutic	O
implications	O
.	O

However	O
,	O
the	O
contribution	O
of	O
the	O
innate	O
immune	O
response	O
to	O
allograft	B-PATH
rejection	I-PATH
in	O
a	O
model	O
of	O
viral	O
-	O
induced	O
neurological	O
disease	O
has	O
not	O
been	O
well	O
defined	O
.	O

A	O
multidisciplinary	O
critical	O
team	O
is	O
needed	O
to	O
individualize	O
the	O
use	O
of	O
ECMO	O
in	O
immunocompromised	O
patients	O
,	O
including	O
those	O
with	O
HIV	B-PATH
infection	I-PATH
.	O

The	O
downstream	O
pseudoknot	O
in	O
the	O
mRNA	O
impairs	O
the	O
closing	O
movement	O
of	O
the	O
30S	O
subunit	O
head	O
,	O
the	O
dissociation	O
of	O
EF	O
-	O
G	O
,	O
and	O
the	O
release	B-PATH
of	O
tRNA	O
from	O
the	O
ribosome	B-PATH
.	O

TITLE	O
:	O
Surfactant	O
protein	O
A	O
genetic	O
variants	O
associate	O
with	O
severe	O
respiratory	O
insufficiency	O
in	O
pandemic	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
can	O
cause	O
severe	O
illness	O
,	O
including	O
pneumonia	O
and	O
acute	O
respiratory	O
disorder	O
syndrome	O
(	O
ARDS	O
),	O
with	O
high	O
rates	O
of	O
intensive	O
care	O
unit	O
admission	O
and	O
death	O
.	O

Molecular	O
docking	O
of	O
compound	O
8a	O
with	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
was	O
performed	O
to	O
understand	O
the	O
binding	O
mode	O
between	O
these	O
inhibitors	O
and	O
the	O
active	O
site	O
of	O
RdRp	O
and	O
to	O
rationalize	O
some	O
SARs	O
.	O

ABSTRACT	O
:	O
It	O
is	O
believed	O
that	O
most	O
of	O
the	O
serious	O
and	O
life	O
threatening	O
complications	O
are	O
caused	O
only	O
by	O
P	O
falciparum	O
infection	O
while	O
P	O
vivax	O
infections	O
are	O
relatively	O
mild	O
and	O
run	O
a	O
benign	O
course	O
and	O
usually	O
not	O
required	O
hospitalisation	O
but	O
in	O
the	O
last	O
few	O
years	O
hospitalisation	O
rate	O
and	O
complications	O
are	O
also	O
increasing	O
in	O
P	O
vivax	O
infection	O
;	O
so	O
we	O
planned	O
this	O
study	O
to	O
evaluate	O
the	O
severity	O
and	O
complicated	O
presentation	O
of	O
P	O
vivax	O
malaria	B-PATH
.	O

TITLE	O
:	O
Pegylated	O
interferon	O
α	O
plus	O
ribavirin	O
for	O
the	O
treatment	O
of	O
chronic	O
hepatitis	B-PATH
C	I-PATH
:	O
a	O
multicentre	O
independent	O
study	O
supported	O
by	O
the	O
Italian	O
Drug	O
Agency	O
.	O

ABSTRACT	O
:	O
Data	O
on	O
the	O
efficacy	O
of	O
Peg	O
-	O
interferon	O
/	O
ribavirin	O
therapy	O
for	O
chronic	O
hepatitis	B-PATH
C	I-PATH
are	O
mostly	O
derived	O
from	O
treatment	O
of	O
selected	O
patients	O
enrolled	O
in	O
clinical	O
trials	O
.	O

However	O
,	O
NSP6	O
inhibited	O
the	O
autophagosome	O
/	O
lysosome	B-PATH
expansion	O
normally	O
seen	O
following	O
starvation	O
.	O

VIDISCA	O
-	O
454	O
enabled	O
the	O
identification	O
of	O
one	O
previously	O
undiagnosed	O
measles	B-PATH
infection	O
.	O

ABSTRACT	O
:	O
Recent	O
experience	O
with	O
pandemic	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
highlighted	O
the	O
importance	O
of	O
global	O
surveillance	O
for	O
severe	O
respiratory	O
disease	O
to	O
support	O
pandemic	O
preparedness	O
and	O
seasonal	O
influenza	O
control	O
.	O

Active	O
,	O
prospective	O
,	O
continuous	O
,	O
hospital	O
-	O
based	O
SARI	O
surveillance	O
is	O
useful	O
in	O
supporting	O
pandemic	O
preparedness	O
for	O
emerging	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
infections	O
and	O
seasonal	O
influenza	O
prevention	O
and	O
control	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
severity	O
proportion	O
and	O
factors	O
associated	O
with	O
severity	O
in	O
cases	O
of	O
vivax	O
and	O
falciparum	O
malaria	B-PATH
.	O

Plasmodium	O
falciparum	O
had	O
significantly	O
higher	O
odds	O
[	O
adjusted	O
odds	O
ratio	O
(	O
95	O
%	O
CI	O
),	O
2	O
.	O
80	O
(	O
2	O
.	O
04	O
-	O
3	O
.	O
83	O
)]	O
of	O
severe	O
malaria	B-PATH
than	O
P	O
.	O
vivax	O
.	O

RESULTS	O
:	O
Of	O
922	O
malaria	B-PATH
cases	O
included	O
in	O
the	O
study	O
,	O
P	O
.	O
vivax	O
was	O
the	O
largest	O
(	O
63	O
.	O
4	O
%,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
60	O
.	O
3	O
-	O
66	O
.	O
5	O
%)	O
infecting	O
species	O
,	O
followed	O
by	O
P	O
.	O
falciparum	O
(	O
34	O
.	O
4	O
%,	O
95	O
%	O
CI	O
31	O
.	O
3	O
-	O
37	O
.	O
5	O
%)	O
and	O
their	O
mixed	O
infection	O
(	O
2	O
.	O
2	O
%,	O
95	O
%	O
CI	O
1	O
.	O
3	O
-	O
3	O
.	O
2	O
%).	O

Nitazoxanide	O
also	O
inhibits	O
the	O
replication	O
of	O
a	O
broad	O
range	O
of	O
other	O
RNA	O
and	O
DNA	O
viruses	O
including	O
respiratory	O
syncytial	O
virus	O
,	O
parainfluenza	O
,	O
coronavirus	O
,	O
rotavirus	O
,	O
norovirus	O
,	O
hepatitis	O
B	O
,	O
hepatitis	B-PATH
C	I-PATH
,	O
dengue	O
,	O
yellow	O
fever	O
,	O
Japanese	O
encephalitis	O
virus	O
and	O
human	O
immunodeficiency	O
virus	O
in	O
cell	O
culture	O
assays	O
.	O

Clinically	O
,	O
heliox	O
can	O
decrease	O
airway	O
resistance	O
in	O
acute	O
asthma	B-PATH
in	O
adults	O
and	O
children	O
and	O
in	O
COPD	O
.	O

Sepsis	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
involve	O
the	O
release	B-PATH
of	O
inflammatory	O
mediators	O
to	O
the	O
systemic	O
circulation	O
,	O
propagating	O
the	O
cellular	O
and	O
molecular	O
response	O
and	O
affecting	O
distal	O
organs	O
,	O
including	O
the	O
brain	O
.	O

TITLE	O
:	O
The	O
endoplasmic	O
reticulum	O
stress	O
sensor	O
IRE1α	O
protects	O
cells	O
from	O
apoptosis	B-PATH
induced	O
by	O
the	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
.	O

Testing	O
before	O
RRP	O
implementation	O
used	O
batched	O
polymerase	O
chain	O
reaction	O
analysis	O
for	O
respiratory	O
syncytial	O
virus	O
and	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
with	O
additional	O
testing	O
for	O
parainfluenza	O
1	O
through	O
3	O
in	O
approximately	O
11	O
%	O
of	O
patients	O
and	O
for	O
human	O
metapneumovirus	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
.	O

The	O
RRP	O
tested	O
for	O
respiratory	O
syncytial	O
virus	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
parainfluenza	O
1	O
through	O
4	O
,	O
human	O
metapneumovirus	O
,	O
adenovirus	O
,	O
rhinovirus	O
/	O
enterovirus	O
,	O
and	O
coronavirus	O
NL62	O
.	O

Among	O
them	O
,	O
twenty	O
-	O
three	O
compounds	O
showed	O
much	O
better	O
anti	O
-	O
HBV	O
activity	O
than	O
caudatin	O
,	O
and	O
eleven	O
compounds	O
significantly	O
inhibited	O
the	O
HBV	O
DNA	B-PATH
replication	I-PATH
with	O
IC50	O
values	O
<	O
10	O
μM	O
.	O
Interestingly	O
,	O
three	O
compounds	O
(	O
22	O
,	O
28	O
,	O
29	O
)	O
exhibited	O
excellent	O
activity	O
against	O
the	O
secretion	O
of	O
HBsAg	O
(	O
IC50	O
=	O
63	O
.	O
02	O
μM	O
,	O
52	O
.	O
81	O
μM	O
,	O
56	O
.	O
08	O
μM	O
),	O
HBeAg	O
(	O
IC50	O
=	O
204	O
.	O
80	O
μM	O
,	O
173	O
.	O
51	O
μM	O
,	O
70	O
.	O
39	O
μM	O
),	O
along	O
with	O
HBV	O
DNA	B-PATH
replication	I-PATH
(	O
IC50	O
=	O
24	O
.	O
55	O
μM	O
,	O
5	O
.	O
69	O
μM	O
,	O
8	O
.	O
23	O
μM	O
)	O
with	O
lower	O
cytotoxicity	O
.	O

We	O
report	O
a	O
31	O
-	O
year	O
old	O
pregnant	O
woman	O
infected	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
and	O
progressed	O
to	O
ARDS	O
.	O

We	O
contrast	O
this	O
to	O
the	O
mechanism	O
employed	O
by	O
the	O
distantly	O
related	O
hepacivirus	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
in	O
which	O
STING	O
is	O
bound	O
and	O
inactivated	O
by	O
the	O
NS4B	O
protein	O
.	O

Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
are	O
promising	O
therapeutic	O
cells	O
for	O
preventing	O
apoptosis	B-PATH
and	O
eliminating	O
cellular	O
injury	O
.	O

The	O
anti	O
-	O
apoptosis	B-PATH
action	O
of	O
BMSCs	O
was	O
reversed	O
by	O
SB216763	O
,	O
a	O
specific	O
inhibitor	O
of	O
GSK	O
-	O
3β	O
that	O
also	O
activates	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
.	O

Specific	O
treatment	O
depends	O
on	O
the	O
exact	O
cause	O
,	O
however	O
croup	O
and	O
acute	O
severe	O
asthma	B-PATH
have	O
been	O
discussed	O
in	O
this	O
article	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
viral	O
gene	O
products	O
are	O
capable	O
of	O
inducing	O
apoptosis	B-PATH
by	O
interfering	O
with	O
various	O
cellular	O
signalling	O
cascades	O
.	O

One	O
third	O
(	O
29	O
.	O
8	O
%)	O
of	O
the	O
participants	O
acquired	O
≥	O
1	O
virus	O
,	O
particularly	O
rhinovirus	O
(	O
14	O
.	O
0	O
%),	O
coronavirus	O
E229	O
(	O
12	O
.	O
4	O
%),	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
virus	O
(	O
6	O
.	O
2	O
%)	O
while	O
in	O
Saudi	O
Arabia	O
.	O

Our	O
approach	O
provides	O
insight	O
into	O
a	O
variety	O
of	O
scenarios	O
,	O
including	O
the	O
transmission	O
of	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
in	O
the	O
Arabian	O
peninsula	O
,	O
measles	B-PATH
in	O
North	O
America	O
,	O
pre	O
-	O
eradication	O
smallpox	O
in	O
Europe	O
,	O
and	O
human	O
monkeypox	O
in	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
.	O

Lung	O
tissues	O
were	O
negative	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
,	O
canine	O
distemper	O
virus	O
,	O
canine	O
parainfluenza	O
virus	O
,	O
canine	O
respiratory	O
coronavirus	O
,	O
and	O
canine	O
adenovirus	O
2	O
.	O

Articles	O
on	O
emerging	O
diseases	O
caused	O
by	O
Ebola	O
virus	O
,	O
Marburg	O
virus	O
,	O
coronaviruses	O
such	O
as	O
SARS	O
and	O
MERS	O
,	O
Nipah	O
virus	O
and	O
noroviruses	O
are	O
followed	O
by	O
reviews	O
of	O
enteroviruses	O
,	O
HIV	B-PATH
infection	I-PATH
,	O
measles	B-PATH
,	O
mumps	O
,	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
influenza	O
,	O
cytomegalovirus	O
(	O
CMV	O
)	O
and	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
).	O

Using	O
siRNA	O
gene	O
silencing	O
,	O
we	O
found	O
that	O
proteins	O
known	O
to	O
be	O
important	O
for	O
late	O
endosomal	O
maturation	O
and	O
endosome	O
-	O
lysosome	B-PATH
fusion	O
profoundly	O
promote	O
infection	O
of	O
cells	O
with	O
mouse	O
hepatitis	O
coronavirus	O
(	O
MHV	O
).	O

Despite	O
release	B-PATH
of	O
ATF3	O
-	O
dependent	O
Nrf2	O
transcriptional	O
inhibition	O
,	O
mice	O
that	O
lacked	O
ATF3	O
expression	O
in	O
resident	O
cells	O
had	O
increased	O
Nrf2	O
protein	O
degradation	O
.	O

There	O
are	O
a	O
number	O
of	O
infectious	O
diseases	O
that	O
are	O
transmitted	O
from	O
person	O
to	O
person	O
via	O
the	O
respiratory	O
route	O
,	O
including	O
influenza	O
,	O
tuberculosis	B-PATH
(	O
TB	O
),	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
,	O
and	O
these	O
infectious	O
agents	O
are	O
associated	O
with	O
considerable	O
morbidity	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
Little	O
attention	O
has	O
been	O
paid	O
to	O
asthma	B-PATH
in	O
'	O
under	O
-	O
fives	O
'	O
in	O
Sub	O
-	O
Saharan	O
Africa	O
.	O

Hypoxemia	O
,	O
severe	O
malnutrition	O
,	O
and	O
being	O
an	O
infant	O
were	O
associated	O
with	O
poor	O
prognosis	O
among	O
children	O
with	O
acute	O
asthma	B-PATH
and	O
pneumonia	O
and	O
need	O
to	O
be	O
addressed	O
in	O
the	O
management	O
protocols	O
.	O

Whereas	O
binding	O
to	O
the	O
host	O
cell	O
receptor	O
is	O
an	O
essential	O
first	O
step	O
in	O
establishing	O
infection	O
,	O
the	O
proteolytic	O
activation	O
step	O
is	O
often	O
critical	O
for	O
the	O
fusion	O
function	O
of	O
spike	O
,	O
as	O
it	O
allows	O
for	O
controlled	O
release	B-PATH
of	O
the	O
fusion	O
peptide	O
into	O
target	O
cellular	O
membranes	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
three	O
pathogens	O
that	O
have	O
caused	O
significant	O
human	O
mortality	O
and	O
raise	O
important	O
public	O
health	O
concerns	O
:	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
coronavirus	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)-	O
coronavirus	O
and	O
avian	O
influenza	B-PATH
A	I-PATH
viruses	O
(	O
H5N1	O
and	O
H7N9	O
).	O

More	O
and	O
larger	O
studies	O
are	O
needed	O
to	O
confirm	O
the	O
role	O
of	O
hCoV	O
,	O
hBoV	O
in	O
causing	O
severe	O
disease	O
when	O
they	O
co	O
-	O
infect	O
with	O
influenza	B-PATH
A	I-PATH
viruses	O
.	O

TITLE	O
:	O
p53	O
degradation	O
by	O
a	O
coronavirus	O
papain	O
-	O
like	O
protease	O
suppresses	O
type	O
I	O
interferon	B-PATH
signaling	I-PATH
.	O

The	O
full	O
-	O
length	O
spike	O
(	O
S	O
),	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
),	O
and	O
nucleocapsid	O
(	O
N	O
)	O
genes	O
were	O
amplified	O
from	O
each	O
respiratory	O
sample	O
collected	O
from	O
65	O
HCoV	O
-	O
OC43	O
-	O
positive	O
patients	O
between	O
2005	O
and	O
2012	O
.	O

The	O
oxygenation	O
response	O
to	O
recruitment	O
maneuvers	O
was	O
associated	O
with	O
better	O
outcome	O
in	O
patients	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
from	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
).	O

TITLE	O
:	O
Pregnancy	O
and	O
severe	O
influenza	B-PATH
infection	I-PATH
in	O
the	O
2013	O
-	O
2014	O
influenza	O
season	O
.	O

TITLE	O
:	O
Severe	O
Falciparum	O
Malaria	B-PATH
-	O
Difference	O
in	O
Mortality	O
among	O
Male	O
and	O
Nonpregnant	O
Females	O
.	O

There	O
are	O
no	O
specific	O
recommendations	O
concerning	O
pulmonary	O
tuberculosis	B-PATH
in	O
ICU	O
but	O
a	O
delay	O
in	O
initiation	O
of	O
anti	O
-	O
tuberculous	O
therapy	O
is	O
a	O
factor	O
of	O
poor	O
prognosis	O
.	O

Avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
and	O
A	O
(	O
H7N9	O
)	O
viruses	O
have	O
continued	O
to	O
circulate	O
widely	O
in	O
some	O
poultry	O
populations	O
and	O
infect	O
humans	O
sporadically	O
.	O

Similar	O
to	O
other	O
members	O
of	O
the	O
genus	O
Enterovirus	O
,	O
the	O
5	O
'	O
UTR	O
of	O
DcEV	O
possessed	O
a	O
putative	O
type	O
I	O
internal	O
ribosome	B-PATH
entry	O
site	O
.	O

Biological	O
plausibility	O
of	O
aerosol	O
transmission	O
is	O
evaluated	O
for	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
coronavirus	O
and	O
norovirus	O
and	O
discussed	O
for	O
Mycobacterium	O
tuberculosis	B-PATH
,	O
influenza	O
,	O
and	O
Ebola	O
virus	O
.	O

In	O
confirmation	O
of	O
the	O
forecast	O
for	O
the	O
period	O
of	O
the	O
Olympic	O
Games	O
in	O
Sochi	O
have	O
been	O
registered	O
about	O
100	O
cases	O
of	O
measles	B-PATH
.	O

For	O
efficient	O
virion	O
assembly	O
,	O
these	O
proteins	O
must	O
be	O
targeted	O
to	O
the	O
budding	B-PATH
site	O
and	O
to	O
interact	O
with	O
each	O
other	O
or	O
the	O
ribonucleoprotein	O
.	O

CONCLUSIONS	O
:	O
A	O
higher	O
risk	O
of	O
death	O
and	O
poor	O
prognosis	O
were	O
found	O
in	O
children	O
with	O
measles	B-PATH
who	O
needed	O
to	O
be	O
treated	O
in	O
PICU	O
,	O
especially	O
for	O
ARDS	O
with	O
pneumothorax	O
.	O

West	O
Nile	O
disease	O
,	O
measles	B-PATH
,	O
pertussis	B-PATH
and	O
tuberculosis	B-PATH
infect	O
South	O
Dakota	O
patients	O
on	O
a	O
yearly	O
basis	O
.	O

ABSTRACT	O
:	O
The	O
novel	O
avian	O
origin	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
has	O
caused	O
severe	O
diseases	O
in	O
humans	O
in	O
eastern	O
China	O
since	O
the	O
spring	O
of	O
2013	O
.	O

Reovirus	O
binds	O
to	O
cell	O
surface	O
glycans	O
,	O
junctional	O
adhesion	O
molecule	O
A	O
(	O
JAM	O
-	O
A	O
),	O
and	O
the	O
Nogo	O
-	O
1	O
receptor	O
(	O
depending	O
on	O
the	O
cell	O
type	O
)	O
and	O
enters	O
cells	O
by	O
receptor	O
-	O
mediated	O
endocytosis	B-PATH
.	O

The	O
ubiquitin	O
-	O
proteasome	B-PATH
,	O
autophagy	O
,	O
and	O
calpain	O
-	O
caspase	O
pathways	O
have	O
all	O
been	O
implicated	O
in	O
early	O
-	O
phase	O
muscle	O
dysfunction	O
.	O

For	O
severe	O
ARDS	O
,	O
airway	O
pressure	O
release	B-PATH
ventilation	O
and	O
neuromuscular	O
blockade	O
were	O
the	O
most	O
popular	O
.	O

The	O
small	O
CoV	O
envelope	O
(	O
E	O
)	O
protein	O
plays	O
roles	O
in	O
assembly	O
,	O
virion	O
release	B-PATH
,	O
and	O
pathogenesis	O
.	O

CNS	O
infection	O
by	O
neurotropic	O
coronavirus	O
with	O
replication	O
confined	O
to	O
the	O
brain	O
and	O
spinal	O
cord	O
induces	O
protective	O
IFN	O
-	O
α	O
/	O
β	O
via	O
Myd88	O
-	O
independent	O
activation	O
of	O
melanoma	B-PATH
differentiation	O
-	O
associated	O
gene	O
5	O
(	O
MDA5	O
).	O

ABSTRACT	O
:	O
Severe	O
infection	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N6	O
)	O
virus	O
in	O
humans	O
was	O
identified	O
first	O
in	O
2014	O
in	O
China	O
.	O

Moreover	O
,	O
our	O
data	O
demonstrated	O
that	O
CQ	O
increased	O
lysosome	B-PATH
-	O
associated	O
membrane	O
protein	O
-	O
1	O
,	O
lysosome	B-PATH
-	O
associated	O
membrane	O
protein	O
-	O
2	O
and	O
light	O
chain	O
-	O
3	O
expressions	O
,	O
suggesting	O
that	O
the	O
mechanism	O
by	O
which	O
CQ	O
rescues	O
PQ	O
-	O
induced	O
cytotoxicity	O
may	O
be	O
through	O
protection	O
of	O
the	O
lysosomal	O
membrane	O
or	O
up	O
-	O
regulation	B-PATH
of	I-PATH
autophagy	I-PATH
.	O

TITLE	O
:	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Efficiently	O
Infects	O
Human	O
Primary	O
T	O
Lymphocytes	O
and	O
Activates	O
the	O
Extrinsic	O
and	O
Intrinsic	O
Apoptosis	B-PATH
Pathways	O
.	O

Overall	O
,	O
our	O
results	O
suggested	O
that	O
the	O
unusual	O
capacity	O
of	O
MERS	O
-	O
CoV	O
to	O
infect	O
T	O
cells	O
and	O
induce	O
apoptosis	B-PATH
might	O
partly	O
contribute	O
to	O
the	O
high	O
pathogenicity	O
of	O
the	O
virus	O
.	O

In	O
parallel	O
,	O
a	O
decrease	O
was	O
seen	O
in	O
multiple	O
pulmonary	O
and	O
systemic	O
markers	O
of	O
inflammation	O
,	O
including	O
epithelial	O
apoptosis	B-PATH
,	O
alveolar	O
-	O
capillary	O
fluid	O
leakage	O
,	O
and	O
proinflammatory	O
cytokines	O
,	O
microRNAs	O
,	O
and	O
chemokines	O
.	O

For	O
the	O
amplification	O
of	O
nucleocapsid	O
(	O
N	O
)	O
and	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
genes	O
,	O
hemi	O
-	O
nested	O
PCR	O
(	O
Invitrogen	O
,	O
ABD	O
)	O
was	O
conducted	O
,	O
followed	O
by	O
sequence	O
analysis	O
of	O
204	O
nucleotide	O
part	O
of	O
N	O
gene	O
.	O

Pv	O
infection	O
is	O
associated	O
with	O
ARDS	O
and	O
other	O
complications	O
such	O
as	O
sepsis	O
and	O
multi	O
-	O
organ	O
dysfunction	O
syndrome	O
;	O
this	O
enhanced	O
severity	O
of	O
Pv	O
infection	O
,	O
if	O
unrecognized	O
,	O
can	O
lead	O
to	O
more	O
deaths	O
in	O
malaria	B-PATH
-	O
endemic	O
areas	O
.	O

TITLE	O
:	O
A	O
Highly	O
Immunogenic	O
and	O
Protective	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
Vaccine	O
Based	O
on	O
a	O
Recombinant	O
Measles	B-PATH
Virus	O
Vaccine	O
Platform	O
.	O

TITLE	O
:	O
Early	O
occurrence	O
of	O
influenza	B-PATH
A	I-PATH
epidemics	O
coincided	O
with	O
changes	O
in	O
occurrence	O
of	O
other	O
respiratory	O
virus	O
infections	O
.	O

Further	O
work	O
has	O
shown	O
that	O
BST	O
-	O
2	O
restricts	O
the	O
release	B-PATH
of	O
many	O
other	O
viruses	O
,	O
including	O
the	O
human	O
coronavirus	O
229E	O
(	O
hCoV	O
-	O
229E	O
),	O
and	O
the	O
genomes	O
of	O
many	O
of	O
these	O
viruses	O
encode	O
BST	O
-	O
2	O
antagonists	O
to	O
overcome	O
BST	O
-	O
2	O
restriction	O
.	O

Bat	O
viruses	O
were	O
5	O
-	O
and	O
6	O
-	O
fold	O
more	O
diversified	O
than	O
HCoV	O
-	O
229E	O
in	O
the	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
and	O
spike	O
genes	O
.	O

The	O
outbreak	O
and	O
spread	O
of	O
these	O
virulent	O
diseases	O
including	O
avian	O
influenza	O
(	O
H1N1	O
),	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
Corona	O
virus	O
),	O
cholera	O
(	O
Vibrio	O
cholera	O
),	O
tuberculosis	B-PATH
(	O
Mycobacterium	O
tuberculosis	B-PATH
),	O
Ebola	O
hemorrhagic	O
fever	O
(	O
Ebola	O
Virus	O
)	O
and	O
AIDS	O
(	O
HIV	O
-	O
1	O
)	O
necessitate	O
urgent	O
attention	O
to	O
develop	O
diagnostic	O
protocols	O
and	O
assays	O
for	O
rapid	O
detection	O
and	O
screening	O
.	O

131	O
genes	O
from	O
apoptosis	B-PATH
cluster	O
(	O
80	O
down	O
-	O
regulated	O
and	O
51	O
up	O
-	O
regulated	O
)	O
along	O
with	O
increase	O
of	O
apoptosis	B-PATH
,	O
p53	O
,	O
p38	O
MAPK	O
,	O
VEGF	O
and	O
chemokines	O
/	O
cytokines	O
signaling	O
pathways	O
were	O
probably	O
involved	O
in	O
apoptosis	B-PATH
process	O
.	O

Up	O
-	O
regulations	O
of	O
both	O
pro	O
-	O
apoptotic	O
(	O
i	O
.	O
e	O
.	O
PDCD5	O
)	O
and	O
anti	O
-	O
apoptotic	O
(	O
i	O
.	O
e	O
.	O
TRAF2	O
)	O
were	O
detected	O
from	O
first	O
hpi	O
and	O
continuing	O
to	O
deregulate	O
during	O
apoptosis	B-PATH
process	O
in	O
the	O
infected	O
cells	O
.	O

ABSTRACT	O
:	O
In	O
March	O
2013	O
,	O
the	O
Chinese	O
Centre	O
for	O
Disease	O
Control	O
and	O
Prevention	O
confirmed	O
the	O
first	O
reported	O
case	O
of	O
human	O
infection	O
with	O
an	O
avian	O
influenza	B-PATH
A	I-PATH
H7N9	O
virus	O
.	O

We	O
review	O
here	O
efforts	O
to	O
develop	O
next	O
-	O
generation	O
vaccines	O
through	O
targeting	O
these	O
key	O
immunomodulatory	O
genes	O
in	O
influenza	O
virus	O
,	O
coronaviruses	O
,	O
respiratory	O
syncytial	O
virus	O
,	O
measles	B-PATH
virus	O
,	O
and	O
mumps	O
virus	O
.	O

This	O
study	O
investigates	O
the	O
subcellular	O
localization	O
and	O
function	O
of	O
PEDV	O
M	O
protein	O
through	O
examination	O
of	O
its	O
effects	O
on	O
cell	O
growth	O
,	O
cell	B-PATH
cycle	I-PATH
progression	O
,	O
and	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
expression	O
.	O

The	O
M	O
protein	O
altered	O
swine	O
intestinal	O
epithelial	O
cell	O
line	O
(	O
IEC	O
)	O
growth	O
and	O
induced	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
the	O
S	O
-	O
phase	O
via	O
the	O
cyclin	O
A	O
pathway	O
.	O

This	O
is	O
the	O
ﬁrst	O
report	O
to	O
demonstrate	O
that	O
the	O
PEDV	O
M	O
protein	O
is	O
localized	O
in	O
the	O
whole	O
cell	O
and	O
induces	O
cell	B-PATH
cycle	I-PATH
arrest	O
at	O
the	O
S	O
-	O
phase	O
.	O

In	O
the	O
present	O
study	O
,	O
two	O
genetic	O
variants	O
of	O
the	O
ST3GAL1	O
gene	O
,	O
which	O
encodes	O
the	O
Siaα2	O
-	O
3Galβ1	O
-	O
receptor	O
to	O
which	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
virus	O
binds	O
for	O
entry	O
into	O
the	O
host	O
cell	O
,	O
were	O
investigated	O
in	O
an	O
admixed	O
Brazilian	O
population	O
.	O

ABSTRACT	O
:	O
We	O
describe	O
the	O
genotypes	O
and	O
allele	O
distribution	O
of	O
interleukin	O
28B	O
(	O
IL28B	O
)	O
rs12979860	O
and	O
rs8099917	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
hepatitis	B-PATH
C	I-PATH
virus	O
(	O
HCV	O
)	O
G1	O
-	O
4	O
infected	O
patients	O
,	O
to	O
assess	O
predictive	O
ability	O
and	O
to	O
determine	O
whether	O
the	O
combined	O
determination	O
of	O
two	O
IL28B	O
SNPs	O
might	O
improve	O
sustained	O
virologic	O
response	O
(	O
SVR	O
)	O
prediction	O
of	O
both	O
in	O
HCV	O
mono	O
-	O
and	O
HIV	O
/	O
HCV	O
co	O
-	O
infected	O
patients	O
.	O

Critical	O
characteristics	O
of	O
ALI	O
are	O
alveolar	O
edema	O
,	O
infiltration	O
of	O
leukocytes	O
(	O
neutrophils	O
and	O
monocytes	O
),	O
release	B-PATH
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
into	O
broncho	O
-	O
alveolar	O
lavage	O
fluid	O
,	O
and	O
activation	O
of	O
integrin	O
receptors	O
.	O

Further	O
,	O
characteristic	O
amino	O
acids	O
were	O
analyzed	O
and	O
phylogenetic	O
analysis	O
were	O
done	O
for	O
key	O
genes	O
of	O
the	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

TITLE	O
:	O
Pathogenicity	O
and	O
tissue	O
tropism	O
of	O
infectious	O
bronchitis	O
virus	O
is	O
associated	O
with	O
elevated	O
apoptosis	B-PATH
and	O
innate	O
immune	O
responses	O
.	O

The	O
vinaceous	O
Amazon	O
parrot	O
(	O
Amazona	O
vinacea	O
)	O
is	O
extinct	O
in	O
several	O
areas	O
,	O
and	O
a	O
project	O
to	O
release	B-PATH
confiscated	O
individuals	O
to	O
their	O
former	O
range	O
is	O
currently	O
underway	O
.	O

TITLE	O
:	O
Mouse	O
Hepatitis	O
Virus	O
Infection	O
Remodels	O
Connexin43	O
-	O
Mediated	O
Gap	B-PATH
Junction	I-PATH
Intercellular	O
Communication	O
In	O
Vitro	O
and	O
In	O
Vivo	O
.	O

ABSTRACT	O
:	O
Asthma	B-PATH
is	O
associated	O
with	O
poorer	O
outcomes	O
in	O
sickle	O
cell	O
disease	O
(	O
SCD	O
).	O

180	O
children	O
aged	O
6	O
-	O
16	O
with	O
diseases	O
of	O
the	O
respiratory	O
organs	O
with	O
BOS	O
and	O
GERD	O
symptoms	O
were	O
examined	O
:	O
85	O
of	O
them	O
--	O
with	O
bronchial	O
asthma	B-PATH
(	O
BA	O
),	O
34	O
--	O
with	O
an	O
acute	O
course	O
of	O
pneumonia	O
,	O
29	O
--	O
with	O
recurrent	O
obstructive	O
bronchitis	O
.	O

Based	O
on	O
400	O
-	O
nt	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRP	O
)	O
sequence	O
analysis	O
,	O
eight	O
belonged	O
to	O
genus	O
Alphacoronavirus	O
and	O
42	O
to	O
Betacoronavirus	O
.	O

Gene	O
transfer	O
of	O
BDNF	O
to	O
primary	O
cultures	O
of	O
mouse	O
neurons	O
prevents	O
the	O
apoptosis	B-PATH
which	O
is	O
triggered	O
by	O
the	O
knockdown	O
of	O
FXN	O
gene	O
expression	O
.	O

CONCLUSIONS	O
:	O
This	O
case	O
underscores	O
the	O
importance	O
of	O
plasma	O
RNA	O
test	O
in	O
conjunction	O
with	O
HIV	O
antibody	O
test	O
for	O
some	O
rare	O
patients	O
with	O
HIV	B-PATH
infection	I-PATH
who	O
present	O
with	O
severe	O
immunodeficiency	O
and	O
opportunistic	O
infections	O
or	O
malignancy	O
.	O

Mixed	O
infections	O
with	O
more	O
than	O
one	O
species	O
of	O
parasite	O
can	O
occur	O
;	O
they	O
commonly	O
involve	O
P	O
.	O
falciparum	O
with	O
the	O
attendant	O
risks	O
of	O
severe	O
malaria	B-PATH
.	O

A	O
diagnosis	O
of	O
malaria	B-PATH
must	O
always	O
be	O
sought	O
in	O
a	O
feverish	O
or	O
sick	O
child	O
or	O
adult	O
who	O
has	O
visited	O
malaria	B-PATH
-	O
endemic	O
areas	O
.	O

Specific	O
country	O
information	O
on	O
malaria	B-PATH
can	O
be	O
found	O
at	O
http	O
://	O
travelhealthpro	O
.	O
org	O
.	O
uk	O
/.	O
P	O
.	O
falciparum	O
infection	O
rarely	O
presents	O
more	O
than	O
six	O
months	O
after	O
exposure	O
but	O
presentation	O
of	O
other	O
species	O
can	O
occur	O
more	O
than	O
a	O
year	O
after	O
exposure	O
.	O

Severe	O
falciparum	O
malaria	B-PATH
,	O
or	O
infections	O
complicated	O
by	O
a	O
relatively	O
high	O
parasite	O
count	O
(	O
more	O
than	O
2	O
%	O
of	O
red	O
blood	O
cells	O
parasitized	O
)	O
should	O
be	O
treated	O
with	O
intravenous	O
therapy	O
until	O
the	O
patient	O
is	O
well	O
enough	O
to	O
continue	O
with	O
oral	O
treatment	O
.	O

The	O
treatment	O
of	O
choice	O
for	O
severe	O
or	O
complicated	O
malaria	B-PATH
in	O
adults	O
and	O
children	O
is	O
intravenous	O
artesunate	O
(	O
Grade	O
1A	O
).	O

Children	O
with	O
uncomplicated	O
malaria	B-PATH
should	O
be	O
treated	O
with	O
an	O
ACT	O
(	O
artemether	O
-	O
lumefantrine	O
or	O
dihydroartemisinin	O
-	O
piperaquine	O
)	O
as	O
first	O
line	O
treatment	O
(	O
Grade	O
1A	O
).	O

At	O
least	O
one	O
respiratory	O
tract	O
pathogen	O
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
in	O
78	O
.	O
6	O
%	O
(	O
n	O
=	O
140	O
)	O
of	O
the	O
patients	O
:	O
influenza	B-PATH
A	I-PATH
33	O
.	O
5	O
%,	O
influenza	O
B	O
16	O
.	O
4	O
%,	O
respiratory	O
syncytial	O
virus	O
9	O
.	O
2	O
%,	O
adenovirus	O
7	O
.	O
8	O
%,	O
rhinovirus	O
7	O
.	O
1	O
%,	O
coronavirus	O
7	O
.	O
1	O
%,	O
human	O
metapneumovirus	O
5	O
.	O
7	O
%,	O
human	O
bocavirus	O
5	O
.	O
7	O
%,	O
parainfluenza	O
virus	O
3	O
.	O
5	O
%,	O
coinfection	O
2	O
.	O
8	O
%.	O

Together	O
,	O
these	O
data	O
reveal	O
a	O
novel	O
antiviral	O
activity	O
of	O
TRIM56	O
against	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
and	O
provide	O
insights	O
into	O
the	O
mechanism	O
by	O
which	O
TRIM56	O
restricts	O
these	O
medically	O
important	O
orthomyxoviruses	O
.	O

Ribosome	B-PATH
profiling	O
is	O
a	O
technique	O
which	O
exploits	O
the	O
capacity	O
of	O
the	O
translating	O
ribosome	B-PATH
to	O
protect	O
around	O
30	O
nucleotides	O
of	O
mRNA	O
from	O
ribonuclease	O
digestion	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
application	O
of	O
ribosome	B-PATH
profiling	O
to	O
an	O
RNA	O
virus	O
.	O

Influenza	B-PATH
A	I-PATH
viruses	O
were	O
detected	O
in	O
co	O
-	O
circulation	O
with	O
influenza	O
B	O
viruses	O
;	O
the	O
latter	O
amounted	O
to	O
34	O
.	O
1	O
%	O
of	O
all	O
influenza	O
detections	O
.	O

Here	O
we	O
report	O
the	O
case	O
of	O
a	O
45	O
year	O
old	O
male	O
who	O
was	O
a	O
victim	O
of	O
severe	O
Plasmodium	O
vivax	O
malaria	B-PATH
culminating	O
into	O
ARDS	O
,	O
prior	O
to	O
the	O
initiation	O
of	O
anti	O
-	O
malarial	O
therapy	O
.	O

An	O
immunosuppressive	O
condition	O
might	O
inhibit	O
air	O
-	O
space	O
pneumonia	O
to	O
become	O
granulomatous	O
inflammation	O
as	O
an	O
initial	O
stage	O
of	O
pulmonary	O
tuberculosis	B-PATH
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
infection	I-PATH
can	O
cause	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
leading	O
to	O
poor	O
disease	O
outcome	O
with	O
high	O
mortality	O
.	O

In	O
this	O
issue	O
of	O
the	O
JCI	O
,	O
Peteranderl	O
and	O
colleagues	O
define	O
a	O
paracrine	O
communication	O
between	O
macrophages	O
and	O
type	O
II	O
alveolar	O
epithelial	O
cells	O
during	O
influenza	B-PATH
infection	I-PATH
where	O
IFNα	O
induces	O
macrophage	O
secretion	O
of	O
TRAIL	O
that	O
causes	O
endocytosis	B-PATH
of	O
Na	O
,	O
K	O
-	O
ATPase	O
by	O
the	O
alveolar	O
epithelium	O
.	O

Mutant	O
recombinant	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
ZF	O
-	O
C	O
(	O
rTGEV	O
-	O
ZF	O
-	O
C	O
)	O
caused	O
decreased	O
cytopathic	O
effect	O
and	O
apoptosis	B-PATH
compared	O
with	O
the	O
wild	O
-	O
type	O
virus	O
and	O
reduced	O
levels	O
of	O
dsRNA	O
accumulation	O
at	O
late	O
times	O
postinfection	O
.	O

Malarial	O
hepatopathy	O
was	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
cerebral	O
malaria	B-PATH
,	O
shock	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
acute	O
kidney	O
injury	O
in	O
both	O
overall	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
and	O
falciparum	O
malaria	B-PATH
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
and	O
hyponatremia	O
and	O
disseminated	O
intravascular	O
coagulation	O
only	O
in	O
overall	O
malaria	B-PATH
(	O
p	O
<	O
0	O
.	O
05	O
).	O

It	O
is	O
an	O
epiphenomenon	O
in	O
severe	O
malaria	B-PATH
and	O
indicative	O
of	O
severe	O
disease	O
.	O

Establishing	O
a	O
particular	O
association	O
with	O
malaria	B-PATH
or	O
mortality	O
would	O
require	O
a	O
larger	O
case	O
-	O
control	O
study	O
of	O
severe	O
malaria	B-PATH
.	O

Furthermore	O
,	O
silencing	O
DJ	O
-	O
1	O
inhibit	O
mitophagy	O
and	O
increase	O
apoptosis	B-PATH
after	O
TGEV	O
infection	O
.	O

TITLE	O
:	O
Human	O
infection	O
with	O
a	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N6	O
)	O
virus	O
in	O
Yunnan	O
province	O
,	O
China	O
.	O

Treatment	O
of	O
the	O
injured	O
lung	O
with	O
rsRAGE	O
significantly	O
suppressed	O
the	O
lung	O
edema	O
,	O
the	O
neutrophils	O
infiltration	O
,	O
the	O
release	B-PATH
of	O
high	O
mobility	O
group	O
box	O
-	O
1	O
(	O
HMGB1	O
),	O
and	O
the	O
expressions	O
of	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
1β	O
and	O
iNOS	O
.	O

Arteriviruses	O
(	O
order	O
Nidovirales	O
)	O
belong	O
to	O
the	O
subset	O
of	O
+	O
RNA	O
viruses	O
that	O
induce	O
double	O
-	O
membrane	O
vesicles	O
(	O
DMVs	O
),	O
similar	O
to	O
the	O
structures	O
induced	O
by	O
e	O
.	O
g	O
.	O
coronaviruses	O
,	O
picornaviruses	O
and	O
hepatitis	B-PATH
C	I-PATH
virus	O
.	O

New	O
and	O
emerging	O
infectious	O
diseases	O
which	O
are	O
both	O
transmissible	O
from	O
patient	O
-	O
to	O
-	O
patient	O
and	O
virulent	O
with	O
a	O
high	O
mortality	O
include	O
novel	O
coronaviruses	O
(	O
SARS	O
-	O
CoV	O
,	O
MERS	O
-	O
CV	O
),	O
hemorrhagic	O
fever	O
viruses	O
(	O
Lassa	O
,	O
Ebola	O
),	O
and	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
viruses	O
,	O
A	O
(	O
H5N1	O
)	O
and	O
A	O
(	O
H7N9	O
).	O

ABSTRACT	O
:	O
Since	O
the	O
beginning	O
of	O
this	O
century	O
,	O
humanity	O
has	O
been	O
facing	O
a	O
new	O
emerging	O
,	O
or	O
re	O
-	O
emerging	O
,	O
virus	O
threat	O
almost	O
every	O
year	O
:	O
West	O
Nile	O
,	O
Influenza	B-PATH
A	I-PATH
,	O
avian	O
flu	O
,	O
dengue	O
,	O
Chikungunya	O
,	O
SARS	O
,	O
MERS	O
,	O
Ebola	O
,	O
and	O
now	O
Zika	O
,	O
the	O
latest	O
newcomer	O
.	O

He	O
was	O
treated	O
for	O
an	O
asthma	B-PATH
exacerbation	O
and	O
sepsis	O
.	O

Heliox	O
might	O
prevent	O
intubation	O
or	O
improve	O
gas	O
flow	O
in	O
mechanically	O
ventilated	O
patients	O
with	O
severe	O
asthma	B-PATH
.	O

Prevention	O
is	O
based	O
on	O
compulsory	O
meningococcal	O
vaccination	O
,	O
vaccination	O
against	O
seasonal	O
influenza	O
and	O
pneumococcal	O
infections	O
for	O
pilgrims	O
at	O
high	O
risk	O
of	O
contracting	O
the	O
infection	O
,	O
and	O
on	O
vaccination	O
against	O
hepatitis	O
A	O
.	O
Updating	O
immunization	O
for	O
diphtheria	O
/	O
tetanus	O
/	O
poliomyelitis	O
/	O
pertussis	B-PATH
and	O
measles	B-PATH
/	O
mumps	O
is	O
also	O
crucial	O
and	O
pilgrims	O
must	O
comply	O
with	O
hygiene	O
precautions	O
.	O

CONCLUSIONS	O
:	O
Prevention	O
is	O
based	O
on	O
compulsory	O
meningococcal	O
vaccination	O
,	O
vaccination	O
against	O
seasonal	O
influenza	O
and	O
pneumococcal	O
infections	O
for	O
pilgrims	O
at	O
high	O
risk	O
of	O
contracting	O
the	O
infection	O
,	O
and	O
on	O
vaccination	O
against	O
hepatitis	O
A	O
.	O
Updating	O
immunization	O
for	O
diphtheria	O
/	O
tetanus	O
/	O
poliomyelitis	O
/	O
pertussis	B-PATH
and	O
measles	B-PATH
/	O
mumps	O
is	O
also	O
crucial	O
and	O
pilgrims	O
must	O
comply	O
with	O
hygiene	O
precautions	O
.	O

Cellular	O
protection	O
against	O
oxidative	O
stress	O
and	O
xenobiotics	O
is	O
mainly	O
conferred	O
by	O
Nrf2	O
,	O
a	O
transcription	O
factor	O
that	O
promotes	O
the	O
expression	O
of	O
genes	O
that	O
regulate	O
oxidative	O
stress	O
,	O
xenobiotic	O
metabolism	O
and	O
excretion	O
,	O
inflammation	O
,	O
apoptosis	B-PATH
,	O
autophagy	O
,	O
and	O
cellular	O
bioenergetics	O
.	O

The	O
molecular	O
mechanism	O
is	O
the	O
degradation	O
of	O
STAT1	O
by	O
PEDV	O
infection	O
in	O
a	O
proteasome	B-PATH
-	O
dependent	O
manner	O
.	O

ABSTRACT	O
:	O
Influenza	B-PATH
infection	I-PATH
in	O
the	O
adult	O
immunocompromised	O
hosts	O
can	O
have	O
severe	O
presentations	O
and	O
rapid	O
progression	O
to	O
lower	O
respiratory	O
tract	O
infection	O
requiring	O
mechanical	O
ventilation	O
,	O
and	O
it	O
even	O
can	O
progress	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

It	O
also	O
covers	O
a	O
new	O
definition	O
of	O
asthma	B-PATH
,	O
the	O
importance	O
of	O
confirming	O
various	O
airflow	O
limitations	O
with	O
spirometry	O
,	O
the	O
epidemiology	O
and	O
the	O
diagnostic	O
flow	O
of	O
asthma	B-PATH
in	O
Korea	O
,	O
the	O
importance	O
and	O
evidence	O
for	O
inhaled	O
corticosteroids	O
(	O
ICS	O
)	O
and	O
ICS	O
/	O
formoterol	O
as	O
a	O
single	O
maintenance	O
and	O
acute	O
therapy	O
in	O
the	O
stepwise	O
management	O
of	O
asthma	B-PATH
,	O
assessment	O
of	O
severity	O
of	O
asthma	B-PATH
and	O
management	O
of	O
exacerbation	O
,	O
and	O
an	O
action	O
plan	O
to	O
cope	O
with	O
exacerbation	O
.	O

RESULTS	O
:	O
Applying	O
the	O
same	O
process	O
used	O
to	O
trace	O
and	O
notify	O
travelers	O
during	O
routine	O
investigations	O
,	O
such	O
as	O
those	O
for	O
tuberculosis	B-PATH
or	O
measles	B-PATH
,	O
CDC	O
was	O
able	O
to	O
notify	O
most	O
travelers	O
of	O
their	O
potential	O
exposure	O
to	O
MERS	O
-	O
CoV	O
during	O
the	O
first	O
few	O
days	O
of	O
each	O
investigation	O
.	O

TITLE	O
:	O
Rapid	O
one	O
-	O
step	O
construction	O
of	O
a	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
-	O
CoV	O
)	O
infectious	O
clone	O
system	O
by	O
homologous	B-PATH
recombination	I-PATH
.	O

Atypical	O
organisms	O
and	O
Bordetella	O
pertussis	B-PATH
were	O
negative	O
in	O
all	O
but	O
one	O
patient	O
.	O

A	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
H5N6	O
virus	O
was	O
isolated	O
from	O
the	O
tracheal	O
aspirate	O
specimen	O
of	O
the	O
patient	O
.	O

Of	O
patients	O
with	O
a	O
confirmed	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
),	O
10	O
(	O
91	O
%)	O
were	O
vaccinated	O
against	O
influenza	O
during	O
the	O
2014	O
-	O
2015	O
season	O
.	O

Phylogenetic	O
analysis	O
seems	O
to	O
suggest	O
no	O
multiple	O
introduction	O
into	O
the	O
two	O
NHs	O
reporting	O
the	O
two	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
outbreaks	O
.	O

TITLE	O
:	O
Synbiotics	O
suppress	O
the	O
release	B-PATH
of	O
lactate	O
dehydrogenase	O
,	O
promote	O
non	O
-	O
specific	O
immunity	O
and	O
integrity	O
of	O
jejunum	O
mucosa	O
in	O
piglets	O
.	O

In	O
Malaysia	O
,	O
Plasmodium	O
knowlesi	O
is	O
the	O
most	O
common	O
cause	O
of	O
severe	O
malaria	B-PATH
,	O
often	O
associated	O
with	O
high	O
parasitaemia	O
.	O

A	O
61	O
years	O
old	O
asplenic	O
man	O
was	O
admitted	O
to	O
a	O
tertiary	O
referral	O
hospital	O
in	O
Sabah	O
,	O
Malaysia	O
,	O
with	O
severe	O
knowlesi	O
malaria	B-PATH
characterized	O
by	O
hyperparasitaemia	O
(	O
7	O
.	O
9	O
%),	O
jaundice	O
,	O
respiratory	O
distress	O
,	O
metabolic	O
acidosis	O
,	O
and	O
acute	O
kidney	O
injury	O
.	O

Although	O
in	O
this	O
case	O
the	O
patient	O
made	O
a	O
rapid	O
recovery	O
,	O
knowlesi	O
malaria	B-PATH
patients	O
with	O
this	O
unusual	O
complication	O
should	O
be	O
closely	O
monitored	O
for	O
potential	O
deterioration	O
.	O

At	O
the	O
time	O
,	O
no	O
connection	O
to	O
patient	O
'	O
s	O
diagnosis	O
of	O
severe	O
asthma	B-PATH
was	O
made	O
.	O

Coronavirus	O
replicase	O
functions	O
include	O
more	O
or	O
less	O
universal	O
activities	O
of	O
plus	O
-	O
stranded	O
RNA	O
viruses	O
,	O
like	O
an	O
RNA	B-PATH
polymerase	I-PATH
(	O
nsp12	O
)	O
and	O
helicase	O
(	O
nsp13	O
),	O
but	O
also	O
a	O
number	O
of	O
rare	O
or	O
even	O
unique	O
domains	O
involved	O
in	O
mRNA	O
capping	O
(	O
nsp14	O
,	O
nsp16	O
)	O
and	O
fidelity	O
control	O
(	O
nsp14	O
).	O

ABSTRACT	O
:	O
Guangzhou	O
reported	O
its	O
first	O
laboratory	O
-	O
confirmed	O
case	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
on	O
January	O
10	O
,	O
2014	O
.	O

TITLE	O
:	O
Cathepsin	O
L	O
Helps	O
to	O
Defend	O
Mice	O
from	O
Infection	O
with	O
Influenza	B-PATH
A	I-PATH
.	O
ABSTRACT	O
:	O
Host	O
-	O
derived	O
proteases	O
can	O
augment	O
or	O
help	O
to	O
clear	O
infections	O
.	O

The	O
most	O
common	O
virus	O
was	O
rhinovirus	O
(	O
38	O
.	O
8	O
%),	O
followed	O
by	O
respiratory	O
syncytial	O
virus	O
,	O
coronavirus	O
,	O
influenza	B-PATH
A	I-PATH
,	O
parainfluenza	O
,	O
adenovirus	O
and	O
metapneumovirus	O
.	O

TITLE	O
:	O
Respiratory	O
microbes	O
present	O
in	O
the	O
nasopharynx	O
of	O
children	O
hospitalised	O
with	O
suspected	O
pulmonary	O
tuberculosis	B-PATH
in	O
Cape	O
Town	O
,	O
South	O
Africa	O
.	O

In	O
contrast	O
,	O
p4a	O
failed	O
to	O
suppress	O
stress	B-PATH
response	I-PATH
pathway	O
activation	O
that	O
is	O
independent	O
of	O
PKR	O
and	O
dsRNA	O
.	O

MERS	O
-	O
CoV	O
p4a	O
represents	O
the	O
first	O
coronavirus	O
stress	B-PATH
response	I-PATH
antagonist	O
described	O
.	O

As	O
necroptosis	O
disrupts	O
cellular	O
membranes	O
and	O
allows	O
the	O
release	B-PATH
of	O
damage	O
-	O
associated	O
molecular	O
patterns	O
(	O
DAMP	O
)	O
and	O
possibly	O
induces	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
it	O
may	O
represent	O
a	O
proinflammatory	O
cell	O
death	O
mechanism	O
that	O
contributes	O
to	O
excessive	O
neuroinflammation	O
and	O
neurodegeneration	O
and	O
eventually	O
to	O
neurological	O
disorders	O
after	O
a	O
coronavirus	O
infection	O
.	O

ABSTRACT	O
:	O
Emerging	O
acute	O
respiratory	O
infectious	O
diseases	O
,	O
such	O
as	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
and	O
the	O
Avian	O
Influenza	B-PATH
A	I-PATH
/	O
H5N1	O
virus	O
are	O
contagious	O
with	O
high	O
morbidity	O
and	O
mortality	O
rates	O
.	O

After	O
adjusting	O
for	O
age	O
,	O
comorbidities	O
,	O
time	O
from	O
onset	O
of	O
illness	O
,	O
and	O
vaccine	O
status	O
,	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
(	O
OR	O
,	O
2	O
.	O
525	O
),	O
coinfection	O
(	O
OR	O
,	O
2	O
.	O
821	O
),	O
and	O
no	O
vaccination	O
(	O
OR	O
,	O
3	O
.	O
086	O
)	O
were	O
independent	O
risk	O
factors	O
for	O
severe	O
disease	O
.	O

TITLE	O
:	O
IL	O
-	O
17	O
protein	O
levels	O
in	O
both	O
induced	O
sputum	O
and	O
plasma	O
are	O
increased	O
in	O
stable	O
but	O
not	O
acute	O
asthma	B-PATH
individuals	O
with	O
obesity	O
.	O

In	O
acute	O
asthma	B-PATH
,	O
IL	O
-	O
17	O
expression	O
,	O
like	O
most	O
other	O
clinical	O
measures	O
,	O
was	O
similar	O
among	O
lean	O
,	O
overweight	O
and	O
obese	O
groups	O
,	O
but	O
was	O
higher	O
in	O
acute	O
versus	O
stable	O
asthma	B-PATH
subjects	O
,	O
with	O
sputum	O
IL	O
-	O
17	O
correlating	O
positively	O
with	O
sputum	O
neutrophils	O
and	O
negatively	O
with	O
FEV	O

ABSTRACT	O
:	O
In	O
October	O
2016	O
,	O
a	O
severe	O
infection	O
with	O
swine	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
virus	O
of	O
the	O
Eurasian	O
avian	O
lineage	O
occurred	O
in	O
a	O
child	O
with	O
a	O
previous	O
history	O
of	O
eczema	O
in	O
the	O
Netherlands	O
,	O
following	O
contact	O
to	O
pigs	O
.	O

Patient	O
-	O
related	O
clinical	O
risk	O
factors	O
were	O
defined	O
as	O
coronary	O
atherosclerotic	O
heart	O
disease	O
,	O
cerebral	O
infarction	O
,	O
diabetes	O
mellitus	O
,	O
cirrhosis	O
,	O
chronic	O
kidney	O
disease	O
,	O
arrhythmia	O
,	O
asthma	B-PATH
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
hypertension	O
,	O
and	O
previous	O
interventional	O
pulmonology	O
treatment	O
.	O

ABSTRACT	O
:	O
Patients	O
with	O
asthma	B-PATH
have	O
a	O
higher	O
incidence	O
of	O
obstructive	O
sleep	O
apnea	O
(	O
OSA	O
).	O

Logistic	O
regression	O
analyses	O
determined	O
that	O
the	O
AHI	O
was	O
significantly	O
associated	O
with	O
the	O
occurrence	O
of	O
severe	O
asthma	B-PATH
exacerbations	O
(	O
odds	O
ratio	O
1	O
.	O
322	O
,	O
95	O
%	O
CI	O
1	O
.	O
148	O
-	O
1	O
.	O
523	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

Since	O
then	O
,	O
several	O
concurrent	O
infections	O
have	O
been	O
reported	O
between	O
the	O
dengue	O
virus	O
(	O
DENV	O
)	O
and	O
the	O
malaria	B-PATH
protozoans	O
,	O
Plasmodium	O
falciparum	O
and	O
Plasmodium	O
vivax	O
.	O

In	O
our	O
patient	O
,	O
the	O
electrocardiographic	O
abnormalities	O
,	O
the	O
rapidly	O
reversible	O
distinctive	O
characteristics	O
of	O
echocardiography	O
,	O
and	O
the	O
modest	O
elevation	O
of	O
serum	O
cardiac	O
biomarkers	O
levels	O
,	O
in	O
combination	O
with	O
the	O
presence	O
of	O
a	O
stress	O
trigger	O
(	O
severe	O
asthma	B-PATH
attack	O
),	O
strongly	O
supported	O
the	O
diagnosis	O
of	O
broken	O
heart	O
syndrome	O
.	O

ABSTRACT	O
:	O
Human	O
infections	O
with	O
highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H5N1	O
)	O
virus	O
are	O
frequently	O
fatal	O
but	O
the	O
mechanisms	O
of	O
disease	O
remain	O
ill	O
-	O
defined	O
.	O

Extensive	O
infection	O
of	O
alveolar	O
epithelial	O
cells	O
caused	O
apoptosis	B-PATH
and	O
leakage	O
of	O
albumin	O
into	O
airways	O
,	O
reflecting	O
loss	O
of	O
epithelial	O
barrier	O
function	O
.	O

TITLE	O
:	O
Prevalence	O
of	O
Diabetes	O
in	O
the	O
2009	O
Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
and	O
the	O
Middle	O
East	O
Respiratory	O
Syndrome	O
Coronavirus	O
:	O
A	O
Systematic	O
Review	O
and	O
Meta	O
-	O
Analysis	O
.	O

Twin	O
nasopharyngeal	O
/	O
oropharyngeal	O
swabs	O
collected	O
from	O
233	O
patients	O
admitted	O
with	O
an	O
acute	O
AECOPD	O
and	O
tested	O
for	O
respiratory	O
viruses	O
including	O
respiratory	O
syncytial	O
virus	O
A	O
and	O
B	O
,	O
parainfluenza	O
were	O
(	O
PIV	O
)	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
,	O
human	O
metapneumovirus	O
(	O
hMPV	O
)	O
A	O
and	O
B	O
,	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
enterovirus	O
,	O
corona	O
NL65	O
,	O
OC43	O
,	O
and	O
229E	O
viruses	O
,	O
adenovirus	O
2	O
and	O
4	O
,	O
rhinovirus	O
,	O
and	O
bocavirus	O
,	O
by	O
duplex	O
real	O
time	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
using	O
CDC	O
approved	O
primers	O
and	O
probes	O
.	O

Coronaviruses	O
(	O
26	O
-	O
34	O
kilobases	O
)	O
have	O
the	O
largest	O
known	O
RNA	O
genomes	O
and	O
their	O
replication	O
presumably	O
requires	O
a	O
processive	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
and	O
enzymatic	O
functions	O
that	O
suppress	O
the	O
consequences	O
of	O
the	O
typically	O
high	O
error	O
rate	O
of	O
viral	O
RdRps	O
.	O

Epigenetic	O
modifications	O
,	O
such	O
as	O
histone	B-PATH
modifications	I-PATH
,	O
DNA	O
methylation	O
,	O
chromatin	O
remodeling	O
,	O
and	O
non	O
-	O
coding	O
RNAs	O
,	O
function	O
as	O
important	O
regulators	O
that	O
remodel	O
host	O
chromatin	O
,	O
altering	O
host	O
expression	O
patterns	O
and	O
networks	O
in	O
a	O
highly	O
flexible	O
manner	O
.	O

It	O
detected	O
one	O
coronavirus	O
229E	O
and	O
eight	O
influenza	B-PATH
A	I-PATH
/	O
H3N2	O
viruses	O
that	O
were	O
missed	O
by	O
the	O
xTAG	O
RVP	O
FAST	O
v2	O
.	O

The	O
role	O
of	O
bacterial	O
infections	O
in	O
severe	O
asthma	B-PATH
in	O
young	O
children	O
is	O
also	O
discussed	O
.	O

Alternative	O
ventilator	O
strategies	O
include	O
high	O
-	O
frequency	O
ventilation	O
and	O
airway	O
pressure	O
release	B-PATH
ventilation	O
.	O

TITLE	O
:	O
Integrated	O
Stress	B-PATH
Response	I-PATH
Mediates	O
Epithelial	O
Injury	O
in	O
Mechanical	O
Ventilation	O
.	O

Influenza	B-PATH
A	I-PATH
/	O
H5	O
,	O
A	O
/	O
H7	O
,	O
or	O
SARS	O
-	O
CoV	O
were	O
not	O
detected	O
.	O

Average	O
yearly	O
incidence	O
rose	O
from	O
300	O
·	O
54	O
per	O
100	O
000	O
in	O
2004	O
to	O
483	O
·	O
63	O
per	O
100	O
000	O
in	O
2013	O
(	O
annual	O
percentage	O
change	O
5	O
·	O
9	O
%);	O
hydatid	O
disease	O
(	O
echinococcosis	O
),	O
hepatitis	B-PATH
C	I-PATH
,	O
and	O
syphilis	O
showed	O
the	O
fastest	O
growth	O
.	O

We	O
found	O
that	O
the	O
accumulation	O
of	O
ROS	O
inhibited	O
the	O
LPS	O
-	O
induced	O
release	B-PATH
of	O
inflammatory	O
cytokines	O
,	O
the	O
upregulation	O
of	O
miR	O
-	O
19	O
and	O
the	O
down	O
-	O
regulation	O
of	O
LPS	O
-	O
induced	O
p47phox	O
expression	O
.	O

Thus	O
,	O
the	O
local	O
expression	O
of	O
proinflammatory	O
cytokines	O
was	O
studied	O
,	O
revealing	O
no	O
correlation	O
in	O
the	O
distribution	O
of	O
cytokine	O
expression	O
with	O
the	O
subregions	O
showing	O
apoptosis	B-PATH
.	O

Infection	O
with	O
YC2014	O
could	O
activate	O
the	O
JAK	B-PATH
-	I-PATH
STAT	I-PATH
signaling	I-PATH
pathway	I-PATH
and	O
the	O
NF	O
-	O
κB	O
pathway	O
more	O
intensively	O
than	O
CV777	O
.	O

Life	O
threatening	O
respiratory	O
involvement	O
is	O
rare	O
with	O
vivax	O
malaria	B-PATH
but	O
common	O
with	O

TITLE	O
:	O
Severe	O
Pediatric	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
Due	O
to	O
Scrub	O
Typhus	O
:	O
Successful	O
Ventilation	O
with	O
Airway	O
Pressure	O
Release	B-PATH
Ventilation	O
Mode	O
after	O
Becoming	O
Refractory	O
to	O
Protective	O
Ventilation	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
MHV	O
N	O
protein	O
inhibited	O
Sendai	O
virus	O
and	O
poly	O
(	O
I	O
:	O
C	O
)-	O
induced	O
IFN	O
-	O
β	O
production	O
by	O
targeting	O
a	O
molecule	O
upstream	O
of	O
retinoic	O
acid	O
-	O
induced	O
gene	O
I	O
(	O
RIG	O
-	O
I	O
)	O
and	O
melanoma	B-PATH
differentiation	O
gene	O
5	O
(	O
MDA5	O
).	O

Ever	O
wheezing	O
(	O
RR	O
:	O
1	O
.	O
6	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
1	O
-	O
2	O
.	O
4	O
),	O
parental	O
asthma	B-PATH
(	O
RR	O
:	O
1	O
.	O
5	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
1	O
-	O
2	O
.	O
2	O
),	O
other	O
allergic	O
diseases	O
in	O
the	O
family	O
(	O
RR	O
:	O
1	O
.	O
8	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
2	O
-	O
2	O
.	O
9	O
)	O
and	O
environmental	O
tobacco	O
smoke	O
(	O
RR	O
:	O
1	O
.	O
6	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
1	O
-	O
3	O
.	O
5	O
)	O
were	O
more	O
common	O
in	O
the	O
severe	O
pneumonia	O
group	O
.	O

ABSTRACT	O
:	O
Individuals	O
with	O
certain	O
communicable	O
diseases	O
may	O
pose	O
risks	O
to	O
the	O
health	O
of	O
the	O
traveling	O
public	O
;	O
there	O
has	O
been	O
documented	O
transmission	O
on	O
commercial	O
aircraft	O
of	O
tuberculosis	B-PATH
(	O
TB	O
),	O
measles	B-PATH
,	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Adenovirus	O
-	O
B	O
,	O
measles	B-PATH
virus	O
,	O
and	O
cytomegalovirus	O
were	O
detected	O
predominantly	O
in	O
tracheal	O
lavage	O
fluid	O
.	O

TITLE	O
:	O
Diagnosis	O
and	O
Management	O
of	O
Asthma	B-PATH
in	O
Adults	O
:	O
A	O
Review	O
.	O

ABSTRACT	O
:	O
Asthma	B-PATH
affects	O
about	O
7	O
.	O
5	O
%	O
of	O
the	O
adult	O
population	O
.	O

The	O
lung	O
tissue	O
of	O
44	O
patients	O
,	O
was	O
divided	O
in	O
the	O
H1N1	O
group	O
(	O
n	O
=	O
15	O
)	O
characterized	O
by	O
severe	O
pulmonary	O
injury	O
due	O
to	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
;	O
the	O
ARDS	O
group	O
(	O
n	O
=	O
13	O
),	O
characterized	O
by	O
patients	O
with	O
DAD	O
due	O
to	O
non	O
-	O
pulmonary	O
causes	O
;	O
and	O
the	O
Control	O
group	O
(	O
n	O
=	O
16	O
),	O
consisting	O
of	O
patients	O
with	O
non	O
-	O
pulmonary	O
causes	O
of	O
death	O
.	O

Such	O
viruses	O
have	O
become	O
a	O
more	O
common	O
cause	O
of	O
severe	O
respiratory	O
-	O
tract	O
infections	O
,	O
especially	O
in	O
children	O
with	O
underlying	O
lung	O
disease	O
such	O
as	O
asthma	B-PATH
.	O

Therefore	O
,	O
IL	O
-	O
17A	O
may	O
play	O
important	O
roles	O
in	O
asthmatic	O
exacerbation	O
,	O
and	O
its	O
high	O
level	O
,	O
in	O
combination	O
with	O
upregulated	O
Th2	O
and	O
other	O
cytokines	O
,	O
may	O
indicate	O
the	O
refractory	O
endotype	O
of	O
asthma	B-PATH
.	O

Then	O
cytokines	O
including	O
lung	O
IL	O
-	O
6	O
,	O
IL	O
-	O
1β	O
,	O
IL	O
-	O
10	O
and	O
plasma	O
HMGB1	O
,	O
apoptosis	B-PATH
of	O
splenic	O
immune	O
cells	O
and	O
Foxp3	O
level	O
on	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
were	O
studied	O
to	O
demonstrate	O
the	O
mechanisms	O
of	O
EP	O
administration	O
on	O
two	O
-	O
hit	O
mice	O
.	O

Conceivably	O
,	O
the	O
participation	O
of	O
the	O
Primary	O
Care	O
and	O
the	O
District	O
and	O
Third	O
Level	O
Hospital	O
professionals	O
defining	O
surveillance	O
,	O
diagnostic	O
tests	O
,	O
referral	O
criteria	O
and	O
clinical	O
management	O
can	O
be	O
considered	O
a	O
useful	O
tool	O
to	O
minimize	O
malaria	B-PATH
morbi	O
-	O
mortality	O
.	O

Drill	O
scenarios	O
presented	O
a	O
patient	O
reporting	O
signs	O
or	O
symptoms	O
and	O
travel	O
history	O
consistent	O
with	O
possible	O
measles	B-PATH
or	O
Middle	O
East	O
Respiratory	O
Syndrome	O
(	O
MERS	O
).	O

In	O
this	O
study	O
,	O
a	O
mouse	O
model	O
of	O
severe	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
infection	O
was	O
established	O
.	O

However	O
,	O
in	O
patients	O
with	O
syndromic	O
CIDs	O
,	O
autosomal	O
recessive	O
mutations	O
in	O
ataxia	O
-	O
telangiectasia	O
mutated	O
(	O
ATM	B-PATH
),	O
autosomal	O
dominant	O
mutations	O
in	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
),	O
and	O
microdeletions	O
in	O
22q11	O
.	O
21	O
were	O
the	O
most	O
commonly	O
affected	O
genomic	O
loci	O
.	O

Studies	O
conducted	O
on	O
mouse	O
models	O
of	O
influenza	B-PATH
A	I-PATH
virus	O
infection	O
show	O
that	O
the	O
test	O
gives	O
positive	O
responses	O
only	O
in	O
the	O
presence	O
of	O
a	O
recent	O
acute	O
viral	O
infection	O
,	O
approximately	O
between	O
day	O
14	O
and	O
day	O
21	O
following	O
the	O
infection	O
,	O
and	O
becomes	O
negative	O
thereafter	O
.	O

We	O
also	O
discuss	O
various	O
cellular	O
processes	O
,	O
such	O
as	O
apoptosis	B-PATH
,	O
innate	O
immunity	O
,	O
ER	O
stress	B-PATH
response	I-PATH
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
and	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
κB	O
)	O
pathway	O
that	O
may	O
be	O
modulated	O
by	O
HCoVs	O
.	O

Additionally	O
,	O
ammonium	O
chloride	O
(	O
NH₄Cl	O
)	O
pretreated	O
HD11	O
cells	O
blocked	O
IBV	O
from	O
entering	O
cells	O
and	O
inhibited	O
IBV	O
-	O
induced	O
apoptosis	B-PATH
.	O

UV	O
-	O
inactivated	O
IBV	O
also	O
lost	O
the	O
ability	O
of	O
apoptosis	B-PATH
induction	O
.	O

RESULTS	O
:	O
During	O
the	O
study	O
period	O
in	O
2015	O
,	O
the	O
index	O
case	O
was	O
a	O
30	O
-	O
year	O
-	O
old	O
Filipino	O
nurse	O
who	O
had	O
a	O
history	O
of	O
unprotected	O
exposure	O
to	O
a	O
MERS	O
-	O
CoV	O
-	O
positive	O
case	O
on	O
May	O
15	O
,	O
2015	O
,	O
and	O
had	O
multiple	O
negative	O
tests	O
for	O
MERS	O
-	O
CoV	O
.	O
Weeks	O
later	O
,	O
she	O
was	O
diagnosed	O
with	O
pulmonary	O
tuberculosis	B-PATH
and	O
MERS	O
-	O
CoV	O
infection	O
.	O

RESULTS	O
:	O
None	O
of	O
the	O
patients	O
had	O
MERS	O
-	O
CoV	O
but	O
influenza	O
viruses	O
were	O
detected	O
in	O
12	O
.	O
7	O
%	O
with	O
high	O
circulation	O
of	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
(	O
47	O
.	O
1	O
%).	O

Chimpanzee	O
adenoviral	O
(	O
ChAd	O
)	O
vectors	O
have	O
been	O
developed	O
as	O
vaccine	O
candidates	O
for	O
multiple	O
infectious	O
diseases	O
and	O
prostate	B-PATH
cancer	I-PATH
.	O

TITLE	O
:	O
VSIG4	O
inhibits	O
proinflammatory	O
macrophage	O
activation	O
by	O
reprogramming	O
mitochondrial	O
pyruvate	B-PATH
metabolism	I-PATH
.	O

Acute	O
kidney	O
injury	O
,	O
liver	O
dysfunction	O
,	O
thrombocytopenia	O
,	O
disseminated	O
intravascular	O
coagulopathy	O
(	O
DIC	O
)	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
are	O
also	O
common	O
in	O
severe	O
malaria	B-PATH
.	O

Here	O
,	O
we	O
systematically	O
describe	O
and	O
compare	O
the	O
distinctive	O
histopathological	O
features	O
of	O
established	O
models	O
of	O
acute	O
pneumonia	O
in	O
mice	O
induced	O
by	O
Streptococcus	O
(	O
S	O
.)	O
pneumoniae	O
,	O
Staphylococcus	O
aureus	O
,	O
Klebsiella	O
pneumoniae	O
,	O
Acinetobacter	O
baumannii	O
,	O
Legionella	O
pneumophila	O
,	O
Escherichia	O
coli	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
coronavirus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
and	O
superinfection	O
of	O
IAV	O
-	O
incuced	O
pneumonia	O
with	O
S	O
.	O
pneumoniae	O
.	O

Involvement	O
of	O
M	O
.	O
cynos	O
and	O
influenza	B-PATH
A	I-PATH
in	O
CIRD	O
was	O
less	O
apparent	O
.	O

Only	O
2	O
.	O
7	O
%	O
of	O
dogs	O
were	O
seropositive	O
for	O
Influenza	B-PATH
A	I-PATH
,	O
and	O
none	O
were	O
positive	O
by	O
PCR	O
.	O

The	O
peroxisome	B-PATH
is	O
the	O
innate	O
antiviral	O
signaling	O
platform	O
for	O
the	O
activation	O
of	O
IRF1	O
-	O
mediated	O
IFN	O
-	O
λ	O
production	O
,	O
and	O
the	O
numbers	O
of	O
peroxisomes	O
were	O
found	O
to	O
be	O
decreased	O
in	O
PEDV	O
-	O
infected	O
cells	O
.	O

Among	O
influenza	O
-	O
positive	O
ILI	O
patients	O
,	O
1431	O
(	O
63	O
%)	O
were	O
influenza	B-PATH
A	I-PATH
[	O
820	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
,	O
611	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)]	O
and	O
847	O
(	O
37	O
%)	O
were	O
influenza	O
B	O
.	O
A	O
majority	O
of	O
SARI	O
and	O
ILI	O
case	O
-	O
patients	O
who	O
tested	O
positive	O
for	O
influenza	O
(	O
72	O
%	O
SARI	O
and	O
59	O
%	O
ILI	O
)	O
were	O
children	O
aged	O
0	O
-	O
4	O
years	O
,	O
as	O
were	O
a	O
majority	O
of	O
those	O
enrolled	O
in	O
surveillance	O
.	O

Influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
continued	O
to	O
circulate	O
in	O
West	O
Africa	O
along	O
with	O
influenza	B-PATH
A	I-PATH
(	O
H3N2	O
)	O
and	O
influenza	O
B	O
during	O
2010	O
-	O
2012	O
.	O

The	O
simulation	O
results	O
seemed	O
to	O
suggest	O
that	O
the	O
close	O
contact	O
route	O
was	O
probably	O
the	O
most	O
significant	O
route	O
(	O
contributes	O
70	O
%,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]:	O
67	O
%-	O
72	O
%)	O
in	O
the	O
in	O
-	O
flight	O
transmission	O
of	O
influenza	B-PATH
A	I-PATH
H1N1	O
transmission	O
;	O
as	O
a	O
result	O
,	O
passengers	O
within	O
2	O
rows	O
of	O
the	O
index	O
case	O
had	O
a	O
significantly	O
higher	O
infection	O
risk	O
than	O
others	O
in	O
the	O
outbreak	O
(	O
relative	O
risk	O
[	O
RR	O
]:	O
13	O
.	O
4	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
5	O
-	O
121	O
.	O
2	O
,	O
P	O
=	O
.	O
019	O
).	O

ABSTRACT	O
:	O
Coronaviruses	O
(	O
CoV	O
)	O
and	O
picornaviruses	O
are	O
plus	O
-	O
strand	O
RNA	O
viruses	O
that	O
use	O
5	O
'	O
cap	O
-	O
dependent	O
and	O
cap	O
-	O
independent	O
strategies	O
,	O
respectively	O
,	O
for	O
viral	B-PATH
mRNA	I-PATH
translation	I-PATH
initiation	O
.	O

TITLE	O
:	O
Accessory	O
proteins	O
8b	O
and	O
8ab	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
suppress	O
the	O
interferon	B-PATH
signaling	I-PATH
pathway	O
by	O
mediating	O
ubiquitin	O
-	O
dependent	O
rapid	O
degradation	O
of	O
interferon	O
regulatory	O
factor	O
3	O
.	O

These	O
results	O
may	O
help	O
understanding	O
the	O
different	O
clinical	O
profiles	O
described	O
in	O
human	O
malaria	B-PATH
hepatopathy	O
.	O

Neutrophils	O
from	O
these	O
patients	O
showed	O
higher	O
capacity	O
to	O
release	B-PATH
MPO	O
-	O
DNA	O
complex	O
in	O
response	O
to	O
interleukin	O
-	O
8	O
or	O
lipopolysaccharide	O
stimulation	O
.	O

TITLE	O
:	O
Loss	O
of	O
Cx43	O
-	O
Mediated	O
Functional	O
Gap	B-PATH
Junction	I-PATH
Communication	O
in	O
Meningeal	O
Fibroblasts	O
Following	O
Mouse	O
Hepatitis	O
Virus	O
Infection	O
.	O

ABSTRACT	O
:	O
Highly	O
pathogenic	O
avian	O
influenza	B-PATH
A	I-PATH
H5N1	O
virus	O
causes	O
pneumonia	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
in	O
humans	O
.	O

RESULTS	O
:	O
In	O
total	O
,	O
188	O
episodes	O
of	O
ARI	O
were	O
reported	O
,	O
being	O
rhinovirus	O
the	O
most	O
frequently	O
detected	O
(	O
n	O
=	O
53	O
),	O
followed	O
by	O
influenza	B-PATH
A	I-PATH
(	O
H3	O
)	O
(	O
n	O
=	O
19	O
)	O
and	O
HBoV	O
(	O
n	O
=	O
14	O
).	O

We	O
present	O
an	O
unusual	O
observation	O
of	O
platypnoea	O
-	O
orthodeoxia	O
syndrome	O
in	O
a	O
young	O
woman	O
with	O
acute	O
atelectasis	O
due	O
to	O
post	O
-	O
tuberculosis	B-PATH
bronchial	O
stricture	O
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
is	O
an	O
inﬂammatory	O
disease	O
characterized	O
by	O
dysfunction	O
of	O
pulmonary	O
epithelial	O
and	O
capillary	O
endothelial	O
cells	O
,	O
infiltration	O
of	O
alveolar	O
macrophages	O
and	O
neutrophils	O
,	O
cell	O
apoptosis	B-PATH
,	O
necroptosis	O
,	O
NETosis	O
,	O
and	O
fibrosis	O
.	O

Nested	O
RT	O
-	O
PCR	O
of	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
(	O
RdRp	O
)	O
gene	O
from	O
rectal	O
swabs	O
was	O
used	O
for	O
CoV	O
detection	O
.	O

A	O
look	O
-	O
back	O
investigation	O
involving	O
two	O
hospitals	O
,	O
multiple	O
blood	O
suppliers	O
,	O
and	O
state	O
and	O
federal	O
public	O
health	O
departments	O
identified	O
the	O
source	O
of	O
malaria	B-PATH
as	O
a	O
unit	O
of	O
RBCs	O
transfused	O
2	O
weeks	O
prior	O
to	O
admission	O
.	O

Her	O
sputum	O
and	O
throat	O
swabs	O
were	O
checked	O
for	O
nucleic	O
acid	O
of	O
influenza	B-PATH
A	I-PATH
and	O
the	O
result	O
was	O
positive	O
for	O
influenza	B-PATH
A	I-PATH
H7N9	O
.	O

Oseltamivir	O
was	O
discontinued	O
because	O
of	O
three	O
consecutive	O
negative	O
results	O
of	O
nucleic	O
acid	O
for	O
influenza	B-PATH
A	I-PATH
H7N9	O
,	O
but	O
anti	O
-	O
Mycoplasma	O
treatment	O
was	O
continued	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
confirmed	O
influenza	B-PATH
A	I-PATH
H7N9	O
infection	O
whose	O
condition	O
worsens	O
again	O
,	O
especially	O
with	O
new	O
infiltration	O
or	O
lung	O
ground	O
-	O
glass	O
infiltration	O
,	O
one	O
should	O
suspect	O
infection	O
by	O
other	O
pathogens	O
such	O
as	O
Mycoplasma	O
pneumoniae	O
.	O

TITLE	O
:	O
Initial	O
performance	O
evaluation	O
of	O
a	O
spotted	O
array	O
Mobile	O
Analysis	O
Platform	O
(	O
MAP	O
)	O
for	O
the	O
detection	O
of	O
influenza	B-PATH
A	I-PATH
/	O
B	O
,	O
RSV	O
,	O
and	O
MERS	O
coronavirus	O
.	O

TITLE	O
:	O
A	O
case	O
of	O
interstitial	O
pneumonia	O
associated	O
with	O
anti	O
-	O
PL	O
-	O
7	O
antibody	O
in	O
a	O
patient	O
with	O
rheumatoid	B-PATH
arthritis	I-PATH
.	O

The	O
conversion	O
of	O
alpha	O
-	O
linolenic	O
acid	O
(	O
ALA	O
)	O
to	O
timodonic	O
(	O
EPA	O
)	O
and	O
cervonic	O
(	O
DHA	O
)	O
acids	O
were	O
lower	O
compared	O
to	O
controls	O
,	O
and	O
together	O
with	O
high	O
levels	O
of	O
myristic	O
,	O
palmitic	O
and	O
palmitoleic	O
acids	O
was	O
associated	O
with	O
the	O
higher	O
proliferation	O
and	O
lower	O
apoptosis	B-PATH
in	O
the	O
primordial	O
,	O
primary	O
and	O
secondary	O
follicles	O
;	O
although	O
the	O
inhibition	O
of	O
the	O
cell	B-PATH
cycle	I-PATH
was	O
observed	O
in	O
relation	O
to	O
the	O
low	O
level	O
of	O
eicosadienoic	O
acid	O
.	O

The	O
high	O
levels	O
of	O
ALA	O
,	O
EPA	O
and	O
DHA	O
and	O
the	O
low	O
levels	O
of	O
myristic	O
,	O
palmitic	O
and	O
palmitoleic	O
acids	O
may	O
have	O
been	O
the	O
effect	O
of	O
flaxseed	O
feeding	O
14	O
days	O
post	O
-	O
weaning	O
and	O
may	O
have	O
had	O
a	O
reverse	O
effect	O
on	O
the	O
proliferation	O
and	O
apoptosis	B-PATH
of	O
ovarian	O
follicles	O
.	O

These	O
data	O
suggest	O
that	O
flaxseed	O
may	O
suppress	O
the	O
follicle	O
development	O
in	O
weanlings	O
via	O
the	O
stimulation	O
of	O
apoptosis	B-PATH
and	O
the	O
inhibition	O
of	O
proliferation	O
via	O
the	O
modulation	O
of	O
the	O
metabolism	O
of	O
selected	O
fatty	O
acids	O
.	O

Furthermore	O
,	O
compared	O
with	O
the	O
sham	O
treatment	O
control	O
,	O
apoptosis	B-PATH
of	O
splenic	O
cells	O
was	O
less	O
pronounced	O
in	O
the	O
splenic	O
white	O
pulp	O
of	O
treated	O
mice	O
,	O
and	O
greater	O
number	O
of	O
proliferating	O
splenic	O
cells	O
,	O
particularly	O
in	O
the	O
red	O
pulp	O
,	O
was	O
observed	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
through	O
p53	O
-	O
dependent	O
pathway	O
causes	O
cell	B-PATH
cycle	I-PATH
arrest	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
.	O

p53	O
protein	O
exists	O
in	O
a	O
wide	O
variety	O
of	O
animal	O
cells	O
,	O
which	O
is	O
involved	O
in	O
cell	B-PATH
cycle	I-PATH
regulation	O
,	O
apoptosis	B-PATH
,	O
cell	O
differentiation	O
and	O
other	O
biological	O
functions	O
.	O

This	O
is	O
the	O
first	O
report	O
to	O
demonstrate	O
that	O
the	O
p53	O
-	O
dependent	O
pathway	O
plays	O
an	O
important	O
role	O
in	O
PEDV	O
induced	O
cell	B-PATH
cycle	I-PATH
arrest	O
and	O
beneficially	O
contributes	O
to	O
viral	O
infection	O
.	O

We	O
selected	O
four	O
recent	O
infectious	O
disease	O
emergencies	O
:	O
outbreaks	O
of	O
avian	O
influenza	B-PATH
A	I-PATH
-	O
H1N1	O
virus	O
(	O
2009	O
)	O
and	O
H7N9	O
virus	O
(	O
2013	O
),	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
(	O
2013	O
),	O
and	O
Ebola	O
virus	O
disease	O
(	O
EVD	O
)	O
(	O
2014	O
to	O
2016	O
).	O

Clinically	O
,	O
such	O
nasal	O
-	O
only	O
inoculation	O
of	O
MHV	O
-	O
1	O
failed	O
to	O
cause	O
pneumonia	O
but	O
significantly	O
reduced	O
mortality	O
and	O
morbidity	O
of	O
lethal	O
pneumonia	O
caused	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
(	O
SARS	O
-	O
CoV	O
)	O
or	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

COPD	O
,	O
HIV	B-PATH
infection	I-PATH
,	O
and	O
hematological	O
malignancy	O
were	O
associated	O
with	O
a	O
lower	O
likelihood	O
of	O
invasive	O
mechanical	O
ventilation	O
on	O
the	O
admission	O
day	O
.	O

ACGs	O
reduced	O
the	O
pulmonary	O
edema	O
and	O
microvascular	O
permeability	O
,	O
demonstrating	O
a	O
dose	O
-	O
dependent	O
down	O
-	O
regulation	O
of	O
LPS	O
-	O
induced	O
TNF	O
-	O
α	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
1β	O
expression	O
in	O
lung	O
tissue	O
and	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
along	O
with	O
reduced	O
apoptosis	B-PATH
.	O

One	O
vaccine	O
candidate	O
is	O
based	O
on	O
live	O
-	O
attenuated	O
measles	B-PATH
virus	O
(	O
MV	O
)	O
vaccine	O
encoding	O
the	O
MERS	O
-	O
CoV	O
spike	O
glycoprotein	O
(	O
MERS	O
-	O
S	O
).	O

TITLE	O
:	O
Epidemiology	O
,	O
drug	O
resistance	O
,	O
and	O
pathophysiology	O
of	O
ABSTRACT	O
:	O
Malaria	B-PATH
,	O
caused	O
by	O
the	O
protozoan	O
parasites	O
of	O
the	O
genus	O
Plasmodium	O
,	O
is	O
a	O
major	O
health	O
problem	O
in	O
many	O
countries	O
of	O
the	O
world	O
.	O

Therefore	O
,	O
in	O
Africa	O
,	O
most	O
malaria	B-PATH
infections	O
are	O
by	O
P	O
.	O
falciparum	O
and	O
the	O
highest	O
burden	O
of	O
P	O
.	O
vivax	O
infection	O
is	O
in	O
Southeast	O
Asia	O
and	O
South	O
America	O
.	O

Tacrolimus	O
was	O
continuously	O
infused	O
to	O
prevent	O
graft	B-PATH
-	I-PATH
versus	I-PATH
-	I-PATH
host	I-PATH
disease	I-PATH
.	O

Samples	O
from	O
749	O
patients	O
with	O
suspected	O
Middle	O
East	O
respiratory	O
coronavirus	O
who	O
presented	O
to	O
Johns	O
Hopkins	O
Aramco	O
Healthcare	O
facilities	O
in	O
the	O
Eastern	O
Province	O
of	O
Saudi	O
Arabia	O
were	O
tested	O
reflexively	O
for	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
2009	O
by	O
the	O
Ministry	O
of	O
Health	O
using	O
the	O
RealTime	O
ready	O
Influenza	B-PATH
A	I-PATH
/	O
H1N1	O
Detection	O
Set	O
for	O
real	O
-	O
time	O
PCR	O
.	O

Additionally	O
,	O
an	O
outbreak	O
of	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
)	O
pdm09	O
may	O
have	O
occurred	O
in	O
Ras	O
Tanura	O
city	O
between	O
April	O
2015	O
and	O
February	O
2016	O
.	O

We	O
investigated	O
the	O
use	O
of	O
alignment	O
-	O
based	O
and	O
alignment	O
-	O
free	O
methods	O
and	O
support	O
vector	O
machine	O
using	O
mononucleotide	O
frequency	O
and	O
dinucleotide	O
bias	O
to	O
predict	O
the	O
hosts	O
of	O
viruses	O
,	O
and	O
applied	O
these	O
approaches	O
to	O
three	O
datasets	O
:	O
rabies	O
virus	O
,	O
coronavirus	O
,	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
.	O

TITLE	O
:	O
TMPRSS11A	O
activates	O
the	O
influenza	B-PATH
A	I-PATH
virus	O
hemagglutinin	O
and	O
the	O
MERS	O
coronavirus	O
spike	O
protein	O
and	O
is	O
insensitive	O
against	O
blockade	O
by	O
HAI	O
-	O
1	O
.	O

The	O
93	O
patients	O
were	O
negative	O
for	O
MERS	O
-	O
CoV	O
RT	O
-	O
PCR	O
,	O
and	O
70	O
(	O
75	O
.	O
2	O
%)	O
patients	O
had	O
documented	O
infection	O
,	O
47	O
(	O
50	O
.	O
5	O
%)	O
viral	O
,	O
22	O
(	O
23	O
.	O
6	O
%)	O
bacterial	O
and	O
one	O
Plasmodium	O
falciparum	O
malaria	B-PATH
.	O

We	O
identified	O
263	O
patients	O
with	O
complicated	O
influenza	B-PATH
infection	I-PATH
who	O
fulfilled	O
ARDS	O
criteria	O
;	O
the	O
mean	O
age	O
was	O
59	O
.	O
8	O
±	O
14	O
.	O
6	O
(	O
years	O
),	O
and	O
66	O
.	O
1	O
%	O
(	O
166	O
/	O
263	O
)	O
were	O
male	O
.	O

The	O
mean	O
tidal	O
volume	O
(	O
V	O
First	O
tidal	O
volume	O
,	O
shortly	O
after	O
intubation	O
,	O
greater	O
than	O
8	O
mL	O
/	O
kg	O
PBW	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
mortality	O
in	O
complicated	O
influenza	B-PATH
infection	I-PATH
with	O
ARDS	O
.	O

Timely	O
recognition	O
of	O
ARDS	O
with	O
strict	O
adherence	O
to	O
protective	O
ventilation	O
strategy	O
of	O
lowering	O
V	O
RESULTS	O
:	O
We	O
identified	O
263	O
patients	O
with	O
complicated	O
influenza	B-PATH
infection	I-PATH
who	O
fulfilled	O
ARDS	O
criteria	O
;	O
the	O
mean	O
age	O
was	O
59	O
.	O
8	O
±	O
14	O
.	O
6	O
(	O
years	O
),	O
and	O
66	O
.	O
1	O
%	O
(	O
166	O
/	O
263	O
)	O
were	O
male	O
.	O

Virus	O
-	O
specific	O
T	O
cells	O
are	O
recruited	O
to	O
the	O
CNS	O
,	O
and	O
control	O
viral	O
replication	O
through	O
release	B-PATH
of	O
antiviral	O
cytokines	O
and	O
cytolytic	O
activity	O
.	O

Based	O
on	O
our	O
published	O
preliminary	O
data	O
,	O
we	O
hypothesized	O
that	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	B-PATH
response	I-PATH
molecule	O
Protein	O
Kinase	O
R	O
-	O
like	O
Endoplasmic	O
Reticulum	O
Kinase	O
(	O
PERK	O
)	O
plays	O
a	O
role	O
in	O
transmitting	O
mechanosensory	O
signals	O
the	O
alveolar	O
epithelium	O
.	O

Between	O
December	O
2016	O
and	O
December	O
2017	O
,	O
6121	O
samples	O
were	O
collected	O
,	O
and	O
submitted	O
to	O
viral	O
culture	O
and	O
genomic	O
quantification	O
,	O
specifically	O
Parainfluenza	O
1	O
-	O
4	O
(	O
PIV1	O
-	O
4	O
),	O
Influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
Respiratory	O
Syncytial	O
Virus	O
(	O
RSV	O
)	O
A	O
and	O
B	O
,	O
Adenovirus	O
,	O
Metapneumovirus	O
,	O
Coronavirus	O
,	O
Rhinovirus	O
,	O
and	O
Enterovirus	O
.	O

It	O
has	O
been	O
utilised	O
as	O
a	O
viral	O
vector	O
to	O
develop	O
many	O
vaccines	O
against	O
cancer	O
and	O
infectious	O
diseases	O
such	O
as	O
malaria	B-PATH
,	O
HIV	O
/	O
AIDS	O
,	O
influenza	O
,	O
and	O
tuberculosis	B-PATH
,	O
MERS	O
-	O
CoV	O
,	O
and	O
Ebola	O
virus	O
infection	O
.	O

Promisingly	O
,	O
the	O
constructs	O
adopted	O
stable	O
α	O
-	O
helical	O
conformations	O
and	O
exhibited	O
relatively	O
broad	O
-	O
spectrum	O
antiviral	O
activities	O
against	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
and	O
influenza	B-PATH
A	I-PATH
viruses	O
(	O
IAVs	O
).	O

TITLE	O
:	O
Upper	O
respiratory	O
infections	O
in	O
a	O
rural	O
area	O
with	O
reduced	O
malaria	B-PATH
transmission	O
in	O
Senegal	O
:	O
a	O
pathogens	O
community	O
study	O
.	O

To	O
determine	O
how	O
coinfection	O
by	O
these	O
two	O
unrelated	O
respiratory	O
viruses	O
affects	O
pathogenesis	O
,	O
we	O
established	O
a	O
mouse	O
model	O
using	O
a	O
minor	O
serogroup	O
rhinovirus	O
(	O
rhinovirus	O
strain	O
1B	O
[	O
RV1B	O
])	O
and	O
mouse	O
-	O
adapted	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
A	O
/	O
Puerto	O
Rico	O
/	O
8	O
/	O
1934	O
[	O
PR8	O
]).	O

ABSTRACT	O
:	O
Influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
causes	O
severe	O
respiratory	O
infections	O
and	O
alveolar	O
epithelial	O
damage	O
resulting	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
We	O
previously	O
demonstrated	O
that	O
transmissible	O
gastroenteritis	O
virus	O
(	O
TGEV	O
)	O
could	O
induce	O
apoptosis	B-PATH
through	O
caspase	O
signaling	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
apoptosis	B-PATH
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
on	O
TGEV	O
-	O
induced	O
apoptotic	O
pathway	O
.	O

Results	O
indicated	O
that	O
AIF	O
translocated	O
from	O
the	O
mitochondria	O
to	O
nucleus	O
during	O
TGEV	O
infection	O
,	O
and	O
the	O
AIF	O
inhibitor	O
,	O
N	O
-	O
phenylmaleimide	O
(	O
NP	O
),	O
significantly	O
attenuated	O
the	O
apoptosis	B-PATH
.	O

However	O
,	O
it	O
was	O
not	O
until	O
acute	O
respiratory	O
failure	O
occurred	O
with	O
subsequent	O
hospitalization	O
in	O
the	O
pediatric	O
intensive	O
care	O
unit	O
that	O
severe	O
anemia	O
and	O
thrombocytopenia	O
were	O
discovered	O
and	O
the	O
diagnosis	O
of	O
acute	B-PATH
myeloid	I-PATH
leukemia	I-PATH
was	O
made	O
.	O

The	O
models	O
are	O
applied	O
to	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
and	O
measles	B-PATH
.	O

Among	O
the	O
133	O
(	O
69	O
.	O
3	O
%)	O
subtyped	O
samples	O
,	O
all	O
influenza	B-PATH
A	I-PATH
were	O
subtype	O
H3	O
(	O
n	O
=	O
57	O
)	O
and	O
all	O
influenza	O
B	O
were	O
B	O
/	O
Victoria	O
(	O
n	O
=	O
76	O
).	O

In	O
infected	O
cells	O
,	O
PEDV	O
-	O
induced	O
apoptosis	B-PATH
is	O
accompanied	O
by	O
nuclear	O
concentration	O
and	O
fragmentation	O
as	O
a	O
result	O
of	O
caspase	O
-	O
3	O
and	O
caspase	O
-	O
8	O
activation	O
and	O
AIFM1	O
and	O
PARP	O
cleavage	O
.	O

Expression	O
of	O
S1	O
proteins	O
of	O
the	O
coronavirus	O
tested	O
in	O
this	O
study	O
could	O
all	O
induce	O
cell	O
apoptosis	B-PATH
suggesting	O
S1	O
maybe	O
is	O
an	O
effective	O
inducer	O
in	O
Coronavirus	O
-	O
induced	O
cell	O
apoptosis	B-PATH
and	O
targeting	O
S1	O
protein	O
expression	O
probably	O
is	O
a	O
promising	O
strategy	O
to	O
inhibit	O
coronavirus	O
infection	O
and	O
thus	O
mediated	O
apoptosis	B-PATH
on	O
host	O
cells	O
.	O

In	O
this	O
review	O
,	O
we	O
compile	O
research	O
findings	O
in	O
the	O
clinic	O
and	O
in	O
animal	O
models	O
that	O
elaborate	O
on	O
the	O
unique	O
features	O
of	O
H1N1	O
influenza	B-PATH
A	I-PATH
viral	O
pathogenesis	O
during	O
pregnancy	O
,	O
the	O
crosstalk	O
between	O
innate	O
immune	O
signaling	O
and	O
hormonal	O
regulation	O
during	O
pregnancy	O
,	O
and	O
the	O
role	O
of	O
pregnancy	O
hormones	O
in	O
modulating	O
cellular	O
responses	O
to	O
influenza	B-PATH
A	I-PATH
viral	O
infection	O
at	O
mid	O
-	O
gestation	O
.	O

ABSTRACT	O
:	O
An	O
association	O
between	O
increased	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
events	O
and	O
influenza	B-PATH
A	I-PATH
H1N1	O
(	O
H1N1	O
)	O
was	O
noted	O
in	O
the	O
first	O
10	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

A	O
6	O
-	O
month	O
-	O
old	O
non	O
-	O
vaccinated	O
boy	O
with	O
B	O
.	O
pertussis	B-PATH
infection	O
who	O
developed	O
ARDS	O
was	O
treated	O
by	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
).	O

Nine	O
(	O
10	O
%)	O
tested	O
positive	O
for	O
adenovirus	O
,	O
four	O
(	O
4	O
.	O
5	O
%)	O
tested	O
positive	O
for	O
respiratory	O
syncytial	O
virus	O
type	O
A	O
,	O
and	O
one	O
(	O
1	O
%)	O
tested	O
positive	O
for	O
influenza	B-PATH
A	I-PATH
virus	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
/	O
PCR	O
.	O

TITLE	O
:	O
Airway	O
pressure	O
release	B-PATH
ventilation	O
in	O
children	O
.	O

TITLE	O
:	O
Hemolytic	O
uremic	O
syndrome	O
associated	O
with	O
Bordetella	O
pertussis	B-PATH
infection	O
in	O
a	O
2	O
-	O
month	O
-	O
old	O
infant	O
carrying	O
a	O
pathogenic	O
variant	O
in	O
complement	O
factor	O
H	O
.	O
ABSTRACT	O
:	O
Hemolytic	O
uremic	O
syndrome	O
(	O
HUS	O
)	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
infectious	O
agents	O
.	O

A	O
2	O
-	O
month	O
-	O
old	O
preterm	O
male	O
was	O
admitted	O
for	O
severe	O
Bordetella	O
pertussis	B-PATH
infection	O
.	O

There	O
comprised	O
9	O
rhinoviruses	O
(	O
36	O
%),	O
4	O
influenza	B-PATH
A	I-PATH
viruses	O
(	O
16	O
%),	O
3	O
HPIV	O
(	O
12	O
%),	O
3	O
HCoV	O
(	O
12	O
%),	O
2	O
adenoviruses	O
(	O
8	O
%),	O
1	O
human	O
HBoV	O
(	O
4	O
%),	O
1	O
hMPV	O
(	O
4	O
%),	O
and	O
1	O
RSV	O
(	O
4	O
%).	O

ABSTRACT	O
:	O
Human	O
infection	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
is	O
easy	O
to	O
induce	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
and	O
traditional	O
mechanical	O
ventilation	O
cannot	O
correct	O
hypoxemia	O
,	O
so	O
patients	O
may	O
die	O
from	O
multiple	O
organ	O
failure	O
(	O
MOF	O
)	O
caused	O
by	O
persistent	O
hypoxia	O
.	O

in	O
late	O
endosome	O
/	O
lysosome	B-PATH
.	O

Our	O
review	O
will	O
focus	O
on	O
the	O
mechanisms	O
responsible	O
for	O
endothelial	O
dysfunction	O
during	O
influenza	B-PATH
infection	I-PATH
leading	O
to	O
cardiovascular	O
collapse	O
and	O
death	O
.	O

Although	O
respiratory	O
infection	O
is	O
a	O
major	O
cause	O
of	O
AE	O
-	O
IPF	O
,	O
no	O
reports	O
have	O
indicated	O
pertussis	B-PATH
infection	O
as	O
a	O
cause	O
.	O

Pertussis	B-PATH
infection	O
should	O
be	O
assayed	O
in	O
AE	O
-	O
IPF	O
patients	O
.	O

During	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
and	O
influenza	B-PATH
A	I-PATH
/	O
H1N1	O
pandemic	O
outbreaks	O
in	O
2003	O
and	O
2009	O
,	O
respectively	O
,	O
customs	O
officers	O
had	O
a	O
fundamental	O
front	O
-	O
line	O
input	O
in	O
the	O
establishment	O
of	O
the	O
recommended	O
at	O
that	O
time	O
border	O
measures	O
.	O

The	O
most	O
common	O
respiratory	O
virus	O
was	O
influenza	B-PATH
A	I-PATH
,	O
followed	O
by	O
non	O
-	O
MERS	O
human	O
coronaviruses	O
,	O
rhinoviruses	O
,	O
and	O
influenza	O
B	O
.	O
Together	O
,	O
we	O
found	O
that	O
it	O
was	O
not	O
MERS	O
-	O
CoV	O
but	O
other	O
respiratory	O
viruses	O
that	O
caused	O
acute	O
respiratory	O
symptoms	O
among	O
pilgrims	O
.	O

TITLE	O
:	O
Management	O
of	O
cytokine	O
release	B-PATH
syndrome	O
and	O
neurotoxicity	O
in	O
chimeric	O
antigen	O
receptor	O
(	O
CAR	O
)	O
T	O
cell	O
therapy	O
.	O

In	O
particular	O
,	O
compound	O
II	O
-	O
1	O
displayed	O
the	O
most	O
potent	O
activity	O
against	O
HBV	O
DNA	B-PATH
replication	I-PATH
(	O
IC	O

Of	O
the	O
254	O
cases	O
detected	O
with	O
only	O
one	O
virus	O
,	O
62	O
were	O
influenza	B-PATH
A	I-PATH
,	O
18	O
were	O
influenza	O
B	O
,	O
65	O
were	O
rhinovirus	O
,	O
35	O
were	O
respiratory	O
syncytial	O
virus	O
,	O
25	O
were	O
metapneumovirus	O
,	O
20	O
were	O
parainfluenza	O
,	O
17	O
were	O
coronavirus	O
,	O
7	O
were	O
bocavirus	O
,	O
and	O
5	O
were	O
adenovirus	O
.	O

Acquisition	O
rates	O
of	O
rhinovirus	O
/	O
enterovirus	O
,	O
coronavirus	O
229E	O
and	O
influenza	B-PATH
A	I-PATH
virus	O
were	O
respectively	O
38	O
.	O
6	O
%,	O
19	O
.	O
8	O
%	O
and	O
2	O
.	O
0	O
%.	O

TITLE	O
:	O
Mouse	O
NC	O
/	O
Jic	O
strain	O
provides	O
novel	O
insights	O
into	O
host	O
genetic	O
factors	O
for	O
malaria	B-PATH
research	O
.	O

These	O
complications	O
are	O
mainly	O
caused	O
by	O
P	O
.	O
falciparum	O
infection	O
and	O
are	O
major	O
causes	O
of	O
death	O
associated	O
with	O
malaria	B-PATH
.	O

We	O
found	O
that	O
mice	O
of	O
the	O
NC	O
/	O
Jic	O
strain	O
infected	O
with	O
rodent	O
malarial	O
parasites	O
exhibit	O
distinctive	O
disease	O
-	O
related	O
complications	O
such	O
as	O
cerebral	O
malaria	B-PATH
and	O
nephrotic	O
syndrome	O
,	O
in	O
addition	O
to	O
a	O
rapid	O
increase	O
in	O
parasitemia	O
.	O

Here	O
,	O
we	O
focus	O
on	O
the	O
analysis	O
of	O
host	O
genetic	O
factors	O
that	O
affect	O
malarial	O
pathogenesis	O
and	O
describe	O
the	O
characteristic	O
features	O
,	O
utility	O
,	O
and	O
future	O
prospects	O
for	O
exploitation	O
of	O
the	O
NC	O
/	O
Jic	O
strain	O
as	O
a	O
novel	O
mouse	O
model	O
for	O
malaria	B-PATH
research	O
.	O

Many	O
of	O
these	O
genes	O
were	O
correlated	O
to	O
the	O
basic	O
metabolism	O
,	O
such	O
as	O
the	O
peroxisome	B-PATH
proliferator	O
-	O
activated	O
receptor	O
(	O
PPAR	O
)	O
signaling	O
pathway	O
which	O
plays	O
a	O
critical	O
role	O
in	O
digestion	O
.	O

Patients	O
with	O
asthma	B-PATH
or	O
allergies	O
are	O
apparently	O
more	O
at	O
risk	O
for	O
severe	O
symptoms	O
.	O

Canine	O
adenovirus	O
,	O
canine	O
distemper	O
virus	O
,	O
canine	O
parainfluenza	O
virus	O
,	O
coronavirus	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
H3N2	O
and	O
H3N8	O
),	O
Bordetella	O
bronchiseptica	O
,	O
M	O
.	O
canis	O
,	O
M	O
.	O
cynos	O
and	O
Streptococcus	O
equi	O
subsp	O
.	O

Our	O
previous	O
study	O
demonstrated	O
that	O
the	O
vasoactive	O
intestinal	O
peptide	O
(	O
VIP	O
)	O
is	O
mediated	O
by	O
lentivirus	O
attenuates	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
ARDS	O
in	O
a	O
murine	O
model	O
,	O
and	O
VIP	O
inhibits	O
the	O
release	B-PATH
of	O
interleukin	O
-	O
17A	O
(	O
IL	O
-	O
17A	O
)	O
from	O
activation	O
macrophages	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
SARS	O
-	O
CoV	O
open	O
reading	O
frame	O
3a	O
(	O
ORF3a	O
)	O
accessory	O
protein	O
activates	O
the	O
NLRP3	O
inflammasome	O
by	O
promoting	O
TNF	O
receptor	O
-	O
associated	O
factor	O
3	O
(	O
TRAF3	O
)-	O
mediated	O
ubiquitination	O
of	O
apoptosis	B-PATH
-	O
associated	O
speck	O
-	O
like	O
protein	O
containing	O
a	O
caspase	O
recruitment	O
domain	O
(	O
ASC	O
).	O

We	O
present	O
the	O
case	O
of	O
a	O
patient	O
who	O
presented	O
with	O
symptoms	O
consistent	O
with	O
viral	B-PATH
myocarditis	I-PATH
but	O
ultimately	O
was	O
found	O
to	O
have	O
severe	O
coronary	O
artery	O
disease	O
(	O
CAD	O
).	O

ABSTRACT	O
:	O
Avian	O
Influenza	B-PATH
A	I-PATH
(	O
H5N6	O
)	O
Virus	O
causes	O
severe	O
influenza	O
disease	O
in	O
humans	O
and	O
is	O
manifested	O
by	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
multi	O
-	O
organ	O
failure	O
,	O
and	O
high	O
mortality	O
rates	O
.	O

A	O
laboratory	O
-	O
confirmed	O
case	O
of	O
human	O
infection	O
with	O
avian	O
influenza	B-PATH
A	I-PATH
(	O
H7N9	O
)	O
virus	O
was	O
treated	O
in	O
our	O
hospital	O
.	O

The	O
CoV	O
envelope	O
(	O
E	O
)	O
protein	O
is	O
a	O
small	O
,	O
integral	O
membrane	O
protein	O
involved	O
in	O
several	O
aspects	O
of	O
the	O
virus	O
'	O
life	O
cycle	O
,	O
such	O
as	O
assembly	O
,	O
budding	B-PATH
,	O
envelope	O
formation	O
,	O
and	O
pathogenesis	O
.	O

Elderly	O
(>	O
50	O
years	O
)	O
had	O
the	O
lowest	O
rates	O
of	O
influenza	B-PATH
A	I-PATH
(	O
13	O
.	O
9	O
%)	O
and	O
B	O
(	O
4	O
.	O
2	O
%),	O
while	O
presenting	O
the	O
highest	O
rates	O
of	O
RSV	O
(	O
3	O
.	O
4	O
%)	O
and	O
HMPV	O
(	O
3	O
.	O
3	O
%).	O

TITLE	O
:	O
SARS	O
-	O
Coronavirus	O
Open	O
Reading	O
Frame	O
-	O
8b	O
triggers	O
intracellular	O
stress	O
pathways	O
and	O
activates	O
NLRP3	O
inflammasomes	B-PATH
.	O

The	O
apoptosis	B-PATH
of	O
ST	O
cells	O
induced	O
by	O
PDCoV	O
infection	O
was	O
studied	O
in	O
this	O
research	O
.	O

TITLE	O
:	O
A	O
30	O
-	O
year	O
retrospective	O
study	O
on	O
causes	O
of	O
death	O
in	O
childhood	O
-	O
onset	O
systemic	B-PATH
lupus	I-PATH
erythematosus	I-PATH
in	O
a	O
tertiary	O
care	O
centre	O
in	O
Southern	O
Thailand	O
.	O

TITLE	O
:	O
Severe	O
Guillain	O
-	O
Barré	O
syndrome	O
associated	O
with	O
chronic	O
active	O
hepatitis	B-PATH
C	I-PATH
and	O
mixed	O
cryoglobulinemia	O
:	O
a	O
case	O
report	O
.	O

Chronic	O
hepatitis	B-PATH
C	I-PATH
was	O
further	O
complicated	O
by	O
type	O
3	O
MC	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
448	O
patients	O
with	O
confirmed	O
viral	O
pneumonia	O
were	O
included	O
,	O
of	O
those	O
,	O
216	O
(	O
48	O
.	O
2	O
%)	O
were	O
caused	O
by	O
influenza	B-PATH
A	I-PATH
(	O
non	O
H1N1	O
)/	O
influenza	O
B	O
,	O
150	O
(	O
33	O
.	O
5	O
%)	O
by	O
H1N1	O
,	O
and	O
82	O
(	O
18	O
.	O
3	O
%)	O
by	O
MERS	O
-	O
CoV	O
.	O
The	O
majority	O
of	O
patients	O
presented	O
with	O
fever	O
(	O
82	O
%),	O
shortness	O
of	O
breath	O
(	O
64	O
%),	O
and	O
flu	O
-	O
like	O
symptoms	O
(	O
54	O
.	O
9	O
%),	O
particularly	O
in	O
MERS	O
-	O
CoV	O
infected	O
cases	O
(	O
92	O
%).	O

TITLE	O
:	O
Tuberculosis	B-PATH
-	O
induced	O
acute	O
respiratory	O
distress	O
syndrome	O
treated	O
with	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

Furthermore	O
,	O
HY	O
inhibited	O
IBV	O
-	O
induced	O
apoptosis	B-PATH
in	O
CEK	O
cells	O
,	O
and	O
significantly	O
reduced	O
the	O
mRNA	O
expression	O
levels	O
of	O
Fas	O
,	O
FasL	O
,	O
JNK	O
,	O
Bax	O
,	O
Caspase	O
3	O
,	O
and	O
Caspase	O
8	O
,	O
and	O
significantly	O
increased	O
Bcl	O
-	O
2	O
mRNA	O
expression	O
level	O
in	O
CEK	O
cells	O
.	O

TITLE	O
:	O
Peripheral	O
immune	O
cell	O
markers	O
in	O
children	O
with	O
recurrent	O
respiratory	O
infections	O
in	O
the	O
absence	O
of	O
primary	B-PATH
immunodeficiency	I-PATH
.	O

Influenza	B-PATH
A	I-PATH
virus	O
infection	O
was	O
found	O
in	O
83	O
.	O
1	O
%	O
of	O
the	O
patients	O
.	O

Ranking	O
the	O
preferred	O
modality	O
of	O
treatments	O
for	O
refractory	O
ARDS	O
from	O
most	O
to	O
least	O
preferable	O
is	O
as	O
follows	O
:	O
airway	O
pressure	O
release	B-PATH
ventilation	O
,	O
bilevel	O
ventilation	O
,	O
paralysis	O
,	O
prone	O
positioning	O
,	O
inhaled	O
nitric	O
oxide	O
,	O
epoprostenol	O
,	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
,	O
corticosteroids	O
,	O
surfactant	O
.	O

Ten	O
pathogens	O
were	O
tested	O
by	O
a	O
combination	O
of	O
five	O
duplex	O
RT	O
-	O
PCRs	O
or	O
PCRs	O
:	O
influenza	B-PATH
A	I-PATH
and	O
B	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
),	O
metapneumovirus	O
(	O
MPV	O
),	O
rhinovirus	O
/	O
enterovirus	O
(	O
RV	O
/	O
EV	O
)),	O
coronavirus	O
(	O
HKU1	O
,	O
NL63	O
,	O
229E	O
and	O
OC43	O
),	O
parainfluenza	O
virus	O
(	O
1	O
-	O
4	O
),	O
adenovirus	O
and	O
bocavirus	O
(	O
Respiratory	O
Multi	O
-	O
Well	O
System	O
MWS	O
r	O
-	O
gene	O
®,	O
BioMérieux	O
,	O
Marcy	O
l	O
'	O
Étoile	O
,	O
France	O
).	O

As	O
a	O
respiratory	O
disease	O
,	O
influenza	B-PATH
A	I-PATH
virus	O
(	O
IAV	O
)	O
infection	O
can	O
lead	O
to	O
hepatitis	O
,	O
but	O
the	O
mechanism	O
remains	O
unclear	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
prospectively	O
evaluate	O
the	O
clinical	O
efficacy	O
of	O
high	O
-	O
titre	O
immune	O
plasma	O
compared	O
with	O
standard	O
low	O
-	O
titre	O
plasma	O
to	O
improve	O
outcomes	O
in	O
patients	O
with	O
severe	O
influenza	B-PATH
A	I-PATH
infection	O
.	O

Pre	O
-	O
exanthem	O
transmission	O
of	O
measles	B-PATH
from	O
airport	O
staff	O
to	O
HCWs	O
with	O
secondary	O
vaccine	O
failure	O
poses	O
a	O
grave	O
challenge	O
to	O
hospital	O
infection	O
control	O
.	O

We	O
demonstrate	O
that	O
EGFR	O
is	O
important	O
during	O
influenza	B-PATH
infection	I-PATH
,	O
but	O
the	O
role	O
it	O
plays	O
changes	O
for	O
lethal	O
versus	O
non	O
-	O
lethal	O
infections	O
.	O

There	O
is	O
no	O
evidence	O
on	O
use	O
of	O
'	O
airway	O
pressure	O
release	B-PATH
ventilation	O
'	O
mode	O
in	O
children	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
complicated	O
by	O
pneumothorax	O
.	O

We	O
suggest	O
that	O
'	O
airway	O
pressure	O
release	B-PATH
ventilation	O
'	O
mode	O
may	O
be	O
used	O
successfully	O
in	O
patients	O
with	O
'	O
acute	O
respiratory	O
distress	O
syndrome	O
'	O
complicated	O
by	O
pneumothorax	O
if	O
intensive	O
and	O
close	O
monitoring	O
is	O
done	O
.	O

ABSTRACT	O
:	O
Clathrin	O
-	O
mediated	O
endocytosis	B-PATH
is	O
a	O
mechanism	O
used	O
for	O
the	O
invasion	O
of	O
cells	O
by	O
a	O
variety	O
of	O
viruses	O
.	O

TITLE	O
:	O
Influenza	B-PATH
A	I-PATH
H1N1	O
virus	O
infection	O
among	O
pregnant	O
women	O
in	O
a	O
tertiary	O
hospital	O
in	O
Belgrade	O
,	O
Serbia	O
.	O

All	O
tested	O
samples	O
which	O
were	O
originally	O
found	O
negative	O
for	O
influenza	B-PATH
A	I-PATH
H1N1	O
virus	O
were	O
also	O
found	O
to	O
be	O
negative	O
for	O
MERS	O
-	O
CoV	O
.	O
These	O
results	O
suggest	O
that	O
circulation	O
of	O
MERS	O
-	O
CoV	O
was	O
uncommon	O
among	O
patients	O
with	O
acute	O
respiratory	O
symptoms	O
in	O
Western	O
Saudi	O
Arabia	O
between	O
2010	O
and	O
2012	O
.	O

RESULTS	O
:	O
All	O
tested	O
samples	O
which	O
were	O
originally	O
found	O
negative	O
for	O
influenza	B-PATH
A	I-PATH
H1N1	O
virus	O
were	O
also	O
found	O
to	O
be	O
negative	O
for	O
MERS	O
-	O
CoV	O
.	O

We	O
diagnosed	O
the	O
patient	O
with	O
RS	O
induced	O
by	O
influenza	B-PATH
A	I-PATH
and	O
use	O
of	O
ibuprofen	O
.	O

RESULTS	O
:	O
There	O
were	O
4	O
,	O
365	O
,	O
578	O
ED	O
visits	O
with	O
RTIs	O
of	O
which	O
321	O
,	O
719	O
(	O
7	O
.	O
4	O
%)	O
were	O
admitted	O
to	O
hospital	O
;	O
817	O
,	O
141	O
ED	O
visits	O
for	O
COPD	O
of	O
which	O
260	O
,	O
665	O
(	O
31	O
.	O
9	O
%)	O
were	O
admitted	O
and	O
649	O
,	O
666	O
ED	O
visits	O
with	O
asthma	B-PATH
of	O
which	O
68	O
,	O
626	O
(	O
10	O
.	O
6	O
%)	O
were	O
admitted	O
.	O

Ruscogenin	O
(	O
RUS	O
)	O
has	O
been	O
found	O
to	O
exert	O
significant	O
protective	O
effect	O
on	O
ALI	O
induced	O
by	O
lipopolysaccharides	O
(	O
LPS	O
),	O
but	O
there	O
is	O
little	O
information	O
about	O
its	O
role	O
in	O
LPS	O
-	O
induced	O
pulmonary	O
endothelial	O
cell	O
apoptosis	B-PATH
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
RUS	O
plays	O
a	O
protective	O
role	O
against	O
LPS	O
-	O
induced	O
endothelial	O
cell	O
apoptosis	B-PATH
via	O
regulating	O
TLR4	O
signaling	O
,	O
and	O
may	O
be	O
a	O
promising	O
agent	O
in	O
the	O
management	O
of	O
ALI	O
.	O

Griffithsin	O
(	O
GRFT	O
)	O
is	O
high	O
-	O
mannose	O
oligosaccharide	O
binding	O
lectin	O
that	O
has	O
shown	O
in	O
vivo	O
broad	O
-	O
spectrum	O
activity	O
against	O
viruses	O
including	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
,	O
human	O
immunodeficiency	O
virus	O
1	O
,	O
hepatitis	B-PATH
C	I-PATH
virus	O
,	O
and	O
Japanese	O
encephalitis	O
virus	O
.	O

Our	O
results	O
showed	O
that	O
the	O
IBV	O
EIC	O
contributed	O
to	O
the	O
induction	O
of	O
ER	O
stress	B-PATH
response	I-PATH
,	O
as	O
up	O
-	O
regulation	O
of	O
ER	O
stress	O
-	O
related	O
genes	O
was	O
markedly	O
reduced	O
in	O
cells	O
infected	O
with	O
the	O
EIC	O
-	O
defective	O
mutants	O
.	O

SADS	O
-	O
CoV	O
-	O
infected	O
cells	O
showed	O
evidence	O
of	O
apoptosis	B-PATH

Non	O
-	O
tuberculous	O
mycobacteria	O
were	O
not	O
isolated	O
,	O
whereas	O
infection	O
with	O
Bcc	O
and	O
Mycobacterium	O
tuberculosis	B-PATH
was	O
observed	O
,	O
which	O
could	O
probably	O
have	O
a	O
role	O
in	O
CF	O
morbidity	O
.	O

Two	O
percentage	O
were	O
Influenza	B-PATH
A	I-PATH
positive	O
and	O
1	O
%	O
positive	O
for	O
influenza	O
B	O
.	O
Mixed	O
viral	O
infection	O
was	O
observed	O
in	O
7	O
%.	O

ABSTRACT	O
:	O
To	O
describe	O
a	O
pediatric	O
case	O
of	O
cytokine	O
release	B-PATH
syndrome	O
secondary	O
to	O
chimeric	O
antigen	O
receptor	O
-	O
modified	O
T	O
cells	O
associated	O
with	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

In	O
this	O
review	O
,	O
we	O
analyzed	O
a	O
total	O
of	O
10	O
literatures	O
on	O
the	O
sampling	O
methods	O
of	O
upper	O
respiratory	O
tract	O
related	O
to	O
infectious	O
diseases	O
such	O
as	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
),	O
middle	O
east	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
),	O
and	O
influenza	B-PATH
A	I-PATH
(	O
H1N1	O
),	O
which	O
were	O
spread	O
worldwide	O
in	O
past	O
years	O
.	O

TITLE	O
:	O
The	O
potential	O
chemical	O
structure	O
of	O
anti	O
-	O
SARS	O
-	O
CoV	O
-	O
2	O
RNA	O
-	O
dependent	O
RNA	B-PATH
polymerase	I-PATH
.	O

When	O
COVI	O
-	O
19	O
infect	O
the	O
upper	O
and	O
lower	O
respiratory	O
tract	O
it	O
can	O
cause	O
mild	O
or	O
highly	O
acute	O
respiratory	O
syndrome	O
with	O
consequent	O
release	B-PATH
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
interleukin	O
(	O
IL	O
)-	O
1β	O
and	O
IL	O
-	O
6	O
.	O

Thus	O
,	O
in	O
light	O
of	O
the	O
strong	O
effect	O
of	O
GA	O
on	O
viral	O
infection	O
,	O
even	O
after	O
the	O
infection	O
begins	O
,	O
it	O
may	O
potentially	O
be	O
used	O
to	O
treat	O
acute	O
infections	O
(	O
e	O
.	O
g	O
.	O
Coronavirus	O
,	O
EBOV	O
,	O
ZIKV	O
,	O
IAV	O
and	O
measles	B-PATH
),	O
and	O
also	O
topically	O
for	O
the	O
successful	O
treatment	O
of	O
active	O
lesions	O
(	O
e	O
.	O
g	O
.	O
HSV	O
-	O
1	O
,	O
HSV	O
-	O
2	O
and	O
varicella	O
-	O
zoster	O
virus	O
(	O
VZV	O
)).	O

Currently	O
,	O
there	O
are	O
still	O
approximately	O
three	O
thousand	O
malaria	B-PATH
cases	O
imported	O
into	O
China	O
every	O
year	O
.	O

In	O
this	O
article	O
we	O
describe	O
cerebral	O
malaria	B-PATH
caused	O
by	O
the	O
Plasmodium	O
falciparum	O
in	O
a	O
45	O
-	O
year	O
-	O
old	O
Polish	O
patient	O
,	O
who	O
traveled	O
to	O
Cameroon	O
without	O
any	O
malaria	B-PATH
prophylaxis	O
.	O

The	O
cerebral	O
malaria	B-PATH
can	O
occur	O
also	O
in	O
adult	O
healthy	O
individuals	O
.	O

(	O
4	O
)	O
The	O
surgical	O
medical	O
workers	O
who	O
process	O
colorectal	B-PATH
cancer	I-PATH
patients	O
with	O
COVID	O
-	O
19	O
must	O
be	O
protected	O
by	O
three	O
-	O
level	O
.	O

The	O
Royal	O
College	O
of	O
Pathologists	O
has	O
responded	O
to	O
this	O
concern	O
with	O
the	O
release	B-PATH
of	O
guidelines	O
on	O
autopsy	O
practice	O
relating	O
to	O
COVID	O
-	O
19	O
.	O

Proteases	O
of	O
the	O
renin	B-PATH
-	I-PATH
angiotensin	I-PATH
system	I-PATH
serve	O
as	O
receptors	O
needed	O
for	O
entry	O
into	O
target	O
cells	O
;	O
this	O
article	O
describes	O
the	O
current	O
knowledge	O
on	O
the	O
involvement	O
of	O
this	O
system	O
in	O
HCoV	O
pathogenesis	O
.	O

Other	O
viral	O
infections	O
were	O
identified	O
in	O
49	O
%	O
of	O
the	O
patients	O
,	O
with	O
most	O
common	O
pathogens	O
being	O
influenza	B-PATH
A	I-PATH
and	O
B	O
viruses	O
,	O
rhinovirus	O
,	O
metapneumovirus	O
and	O
common	O
coronaviruses	O
,	O
notably	O
HKU1	O
and	O
NL63	O
.	O

